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Abstract
Hexachlorobutadiene (HCBD), a by-product for the synthesis of perchloroethylene 
and trichloroethylene and a prominent environmental pollutant, is one of the most 
nephrotoxic chlorinated hydrocarbons in rodents. Its organ-specific toxicity is based 
on a bioactivation mechanism that includes hepatic conjugation to produce penta- 
chlorobutadienyl-glutathione followed by conversion to (penta-chlorobutadienyl)- 
cysteine and subsequent enzymatic degradation to toxic metabolites by the enzyme 
GTK/p-lyase.
28-day old male W/A rats received HCBD at 25mg /kg, ip (low dose) or lOOmg/kg , 
ip (high dose). Other groups received probenecid, an organic anion transport 
inhibitor, (0.5mmol/kg, 1 ml/kg, i.p) before and after HCBD injection. Post mortem 
light microscopic examination of the kidney showed substantial renal tubular necrosis 
in HCBD treated rats compare to those which received HCBD plus probenecid and 
control groups. After 4 to 7 days of exposure, renal tubular damage was decreased, 
and regeneration in the damaged areas of the kidney was observed. Concentrations of 
blood urea nitrogen in HCBD treated rats were elevated in the short-term exposure 
groups. GTK/p-lyase specific activity was lower than control in all the HCBD treated 
groups. In the HCBD treated groups, apoptotic cell death was demonstrated after 2-3 
days using a TUNEL assay and regeneration was demonstrated by immuno-staining 
for the antigen PCNA.
Light microscopic examination of H&E stained brain sections showed extended 
damage in the choroid plexus of the lateral and third ventricles in rats which had 
received lOOmg /kg dose of HCBD. In groups treated with 25mg /kg of HCBD there 
was minor damage (minor hemorrhage in the lateral ventricles with pyknotic and 
mitotic figures in coroidal cells). Brain GTK specific activity in the high dose treated 
groups was lower than control.
Further experiments in which rats were allowed to recover fi*om HCBD treatment 
before further challenge with HCBD, indicated that the kidney and possibly choroid 
plexus remained resistant to HCBD toxicity for up to 3 weeks. This period of
resistance appeared to coincide with a prolonged reduction of GTK /p-lyase activity 
in these tissues compared to control. The results of this work clearly show that the 
toxicity of HCBD towards GTK /p-lyase containing cells and subsequent replacement 
of the damaged cells with cells resistant to HCBD toxicity, is not restricted to the 
kidney in the young male rat. The choroid plexus of the CNS (a tissue related 
developmentally to the kidney proximal tubule) is also a target for site-specific 
toxicity following exposure to HCBD.
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CHAPTER 1: INTRODUCTION 
1.1. Pharmacokinetics of Xenobiotics
Pharmacokinetics is defined as the movement of drugs or xenobiotics within the body, 
and the effects of the various endogenous processes on their fate. These processes include 
the absorption, distribution, biotransformation and elimination of the drugs and chemicals 
and their metabolite(s).
1.1.1. Absorption of drugs and chemicals
Absorption is defined as the entrance of the drugs into the general blood circulation. 
When a drug is administered via different routes, absorption must occur before the drug 
gains access to the different compartments of the body and shows its effects. One of the 
most important factors that determines the efficiency of absorption is the chemical 
structure of drugs. In general, because of the lipophilic nature of the biological 
membranes, lipophilic chemicals are absorbed more easily and faster than hydrophilic 
chemicals. Therefore, drugs in their un-ionised forms are more readily absorbed than their 
ionised forms. The molecular weight of the drug or chemical also affects the absorptive 
process.
1.1.1.1. Gastrointestinal absorption
The gastrointestinal (GI) tract has a variable pH, especially between the stomach and the 
duodenum. Weakly acidic drugs are absorbed more readily via the stomach than weakly 
basic drugs, because weak acids remain un-ionised in the strongly acidic medium of 
stomach. However, most absorption is in the small intestine. Factors, which affect the 
gastrointestinal absorption of drugs, are; digestive processes which can alter the pH of the 
GI tract, binding of the drug with gastric contents, pH of the environment, pKa of the drug 
and peristaltic movements of GI tract.
1.1.1.2. Absorption via parenteral routes
Drugs and chemicals may be injected by different routes, e.g, intramuscular (i.m), 
intravenous (i.v), intradermal (i.d), subcutaneous (s.c), intraperitoneal (i.p). Following 
intravenous injection there is no absorptive process and drugs enter directly into the blood
circulation. In other cases, drugs have to undergo an absorptive mechanism from the site 
of injection into the general blood circulation. Particle size and lipophilicity of drugs are 
important factors that affect absorption.
The mechanisms by which drugs can cross biological membranes include;
a. Passive diffusion
Lipophilic and low molecular weight chemicals can readily cross biological membranes. 
This process does not need energy because drugs are transported down the gradient of 
concentration.
b. Facilitated diffusion
In this mechanism, carriers transport drugs from one side of the biological membranes to 
the other. The main factors that affect the rate of transfer are the level of carriers and the 
concentration of drug. In this process, as long as the carriers are not saturated, the speed 
of transfer depends directly on the concentration of drug.
c. Active transport
Unlike passive diffusion, in active transport drugs can be transported up a gradient of 
concentration. The mechanism therefore requires energy, which is derived from ATP.
1.1.2. Distribution of drugs
When drugs and chemicals entered the general blood circulation, they are transported by 
the bloodstream to their main site(s) of action. One of the most important factors that 
affect distribution in the body is protein binding. In the bloodstream, the binding of drugs 
and chemicals to protein is controlled by their affinity for the plasma proteins in 
particular.
Under normal circumstances, protein-bound drugs cannot leave the bloodstream, but the 
free drug can. If the system is in equilibrium, as free drug leaves the bloodstream, more 
free drug will be released from the protein to maintain the equilibrium. The greater the 
affinity of drug for the plasma proteins, the less free drug will leave the bloodstream and 
enter the tissues.
In addition to protein binding, the blood-brain barrier plays an important role in the 
distribution of drugs to the CNS. The structure of the capillaries of cerebral circulation is 
different from those in the rest of the body. The endothelium of most blood capillaries has 
small pores between the cells. These pores allow materials to cross to and from the tissues 
and the blood. However, the endothelial cells of cerebral capillaries are different. The 
cells are closer to each other and in addition the connective tissue of the CNS creates a 
further barrier between the capillaries and the brain tissue. So this barrier prevents 
entrance of many molecules from the blood into the brain. Only substances that are very 
lipophilic or are actively transported across this barrier can enter from the bloodstream 
into the CNS.
1.1.3. Xenobiotic metabolism
Humans are exposed daily to a wide variety of natural and/or man made, foreign 
compounds called xenobiotics; substances absorbed across the lungs or skin or, more 
commonly, ingested either unintentionally as compounds present in food and drink or 
intentionally as drugs. Exposure to environmental xenobiotics may be unavoidable, when 
they are present as components of air, water and food. Some xenobiotics are not harmful, 
but many can cause biological responses. Often this will result from converting of the 
absorbed substances to an active metabolite.
1.1.3.1. Why are xenobiotics metabolised?
Direct renal excretion can play an important role in terminating the biological activity of 
drugs and chemicals, particularly those that have a small molecular size or possess polar 
characteristic (such as functional groups) that are fully ionised at physiological pH. Most 
drugs however remain un-ionised or only partially ionised at physiological pH. Also they 
are often strongly bound to plasma proteins and are thus not readily filtered at the 
glomerulus. In addition the lipophilic nature of renal tubular membranes facilitates the re­
absorption of lipophilic compounds following glomerular filtration. Consequently, most 
drugs and chemicals would have a long half-life if  termination of their activity depended 
only on renal excretion.
An alternative process that may lead to the termination or alteration of biological activity 
is the metabolism or biotransformation of xenobiotics. The routes by which xenobioics 
may be metabolised are many and include chemical reactions that usually decrease lipid
solubility and inherent toxicity, thus enhancing the elimination of potentially harmful 
substances from the body (Testa and Jenner, 1978). The metabolic products are often less 
active than parent drug and chemicals and may even be inactive. However some 
metabolites may have enhanced activity or toxicity, including mutagenicity, teratogenicity 
and carcinogenicity.
Although every tissue has some ability to metabolise drugs, the liver is the principal organ 
of drug metabolism. Other tissues that display considerable activity include the 
gastrointestinal tract, the lungs, the skin and the kidneys.
Biotransformation of drugs occurs between the process of their absorption into the general 
circulation and excretion from the body. Generally, all biotransformation reactions are 
carried out by one of two major steps, phase I (functionalisation reactions) and phase II 
(conjugation reactions).
1.1.3.2. Phase I metabolism
Phase I metabolism usually converts the parent drug to a more polar metabolite by 
introducing or unmasking a functional group (-0H, -NH2, -SH). These metabolites are 
often inactive, but in some instances the parent drug activity is only partly modified. The 
phase I reactions are thought to act as a preparation of the drug or xenobiotic for the phase 
II reactions. Reactions of phase I metabolism include, oxidation (mainly cytochrome P450 
dependent enzymes), reduction, hydrolysis, hydration as well as other rare reactions such 
as, dethioacetylation and isomerization (Gibson and Skett, 1994).
I.I.3.2.I. Oxidation
Oxidation is performed by the microsomal mixed-function oxidase (cytochrome P450) 
system found in the endoplasmic reticulum of many cells, notably those of liver, kidney, 
lungs and intestine. Many different functionalisation reactions such as aromatic and 
aliphatic hydroxylation, epoxidation, N-, O- and S-dealkylation, N- and S-oxidation, 
phosphothionate oxidation, alcohol oxidation and dehalogenation can occur (Guengerich, 
1990). A number of other enzymes in body, not related to the mixed function-oxidase, 
can also oxidise xenobiotics. These enzymes include; alcohol dehydrogenase, aldehyde 
dehydrogenase, xanthine oxidase, amine oxidase, aromatase and alkyl- hydrazine oxidase 
(Jakoby and Ziegler, 1990).
S-oxidation:
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1.1.3.2.2. Reduction
A number of reductive reactions can be catalysed by hepatic microsomes (George and 
Farrell, 1991). These reactions require NADPH but are generally inhibited by oxygen. 
Compounds undergoing reduction by hepatic microsomes include; azo and nitro 
compounds, epoxides, heterocyclic ring compounds and halogenated hydrocarbons. Azo 
and nitro reductions can also be catalysed by cytochrome P450.
Azo reduction:
Nitro reduction:
H2N
H2N
“ \ 0 / - N  =  N SO2 NHg
N H ,
~ \0/ -  N H2 + H2N - (0 )- SO2 NH2
Eqn. 1.2. Azo reduction of prontosil
Eqn. 1.3. Nitro reduction of nitrobenzene
1.1.3.2.3. Hydrolysis
Enzymes such as esterases can hydrolyse esters, amides, hydrazides and carbamates 
perform these reactions.
Ester hydrolysis:
NHz
+ H O - E C H j z - NE C z H j z
COOH 
CO O- [OH zlz-NECgHslz
Eqn. 1.4. Hydrolysis of procaine
Amide hydrolysis:
CO-NH-NH2 COOH
 1 0  + H2N - N H 2
N
Eqn. 1.5. Hydrolysis of isoniazid
1.1.3.2.4. Hydration
Hydration can be regarded as a specialised form of hydrolysis, where water is added to 
compounds without causing the compound to dissociate. Epoxides are particularly prone 
to hydration by the enzyme, epoxide hydratase, yielding the dihydrodiol. The 
precarcinogenic polycyclic hydrocarbon epoxides in particular undergo this reaction 
(Oesch, 1979, reviewed by Walker et «/., 1986). If the phase I reactions convert the parent 
drug or chemical to a sufficiently polar metabolite, this may be readily eliminated from
the body via glomerular filtration or other routes. However, some phase I metabolites are 
not excreted easily and rapidly, and undergo a further reaction, phase II metabolism, in 
which an endogenous substrate is conjugated with the functional groups to form a highly 
polar metabolite.
Epoxide hydration:
HoO OK).OK).
H OH
Eqn. 1.6. Hydration of benzo[a]pyrene-4,5-epoxide
1.1.3.3. Phase II metabolism
Phase II reactions involve enzymatic conjugation of the functionalised drug or xenobiotic 
from phase I metabolism to various polar endogenous groups, resulting in further 
decreased lipid solubility to aid biliary or renal excretion. Conjugation reactions include; 
glucuronidation, sulfation, méthylation, acétylation, amino acid conjugation, glutathione 
conjugation, fatty acid conjugation and condensation.
In general conjugates are polar molecules and excreted easily. Previously, it was believed 
that conjugation reactions are the “true detoxification” reactions for xenobiotics. 
However, this concept has been modified since a number of conjugation reactions (e.g„ 
conjugation of haloalkenes with glutathione and also acylation of isoniazid) lead to the 
formation of reactive metabolites that display toxic effects toward certain organs. With 
the exception of glutathione conjugation, the conjugating groups is introduced via an 
electophilic activated donor. These donors can then react with nucleophilic centers in 
xenobiotic substrates, such as oxygen in hydroxyl group and nitrogen in amines.
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Fig 1.1. Schematic representation of phase I and phase II metabolism.
1). Drugs may undergo only phase II reactions but not phase I.
2). Drugs may undergo phase I metabolism with alteration in activity or be converted to 
inactive metabolites, then undergo a conjugation reaction before elimination.
3). Some drugs may be eliminated unchanged
1.1.3.3.1. Glucuronidation
Glucuronidation is the major route of sugar conjugation (conjugation with a-D-glucuronic 
acid) and is the most widespread drug conjugation reaction probably due to the relative 
abundance of the cofactor for reaction (Kreomer and Klotz, 1992). UDP-glucuronic acid 
is a component of intermediary metabolism and involved in glycogen synthesis. It is 
found in all tissues of the body. Glucuronic acid conjugation is one of the most important 
pathways for metabolism of many xenobiotics and endogenous compounds, and occurs 
with alcohols, phenols, hydroxylamines, carboxylic acids, amines, sulfonamides and 
thiols.
Glucose-1- ®  + UTP
Glycogen
UDP-glucose + PPi
UDP-glucose
dehydrogenase
^ N A D '"
NADH + H*
UDP-glucoronic acid
Eqn. 1.7. Synthesis of UDP-glucoronic acid (UDPGA)
There are three kinds of glucuronidation, O- glucuronidation, N- glucuronidation and S- 
glucuronidation. O- glucuronides are formed from phenols, alcohols and amines (mainly 
aromatic), amides and sulfonamides. N- glucuronides may be formed spontaneously, i.e. 
without the presence of enzyme. Thiol groups can react with UDPGA in the presence of 
UDP-glucuronosyl transferase to yield S- glucuronides.
0-glucoronidation:
CO-0 - Glucoronic acid 
UDPGA ^  OH
COOH
Eqn. 1.8. The 0-glucoronidation of salicylic acid
N-glucoronidation:
H2N-^ i  )  )~  ' HHz  GliK)uronic -HN SO2 - NH - GJucuronic
Eqn. 1.9. The N-glucuronidation of sulfonamides
1.1.3.3.2. Sulfation
Sulfation is the transfer of a sulfate group from 3’-phosphoadenosine 5’ phosphosulfate 
(PAPS) to a substrate and is catalysed by a family of cytosolic enzymes, the 
sulfotransferases. This reaction affects many different physiological processes, including 
1) deactivation and bioactivation of xenobiotics, 2) inactivation of hormones and 
chatecholamines, 3) structure and function of macromolecules, 4) elimination of end 
products of catabolism (Klaassen and Boles, 1997). Theoretically, factors that might 
influence sulfate conjugation are availability of PAPS, availability of inorganic sulfate, 
rate of PAPS synthesis and activity of sulfotransferases (Hjelle et al,. 1985). PAPS is 
synthesised from ATP and inorganic sulfate.
9  ATP-sulfurylase
SO 4  + A T P -----------------------^  Adenosine-5'-phosphosulfate (APS) + PPi
APS + ATP APS-kinase ^  3'-phosphoadenosine-5'-phosphosulfate + ADP
O—S — O— P----- O
OH
0 = p - •o-
Eqn. 1.10. The formation of PAPS
The body’s reserve of free sulfate are limited. The serum sulfate concentration in human 
is about 0.3 mM. Administration of sulfotransferases substrates such as paracetamol, can 
cause a substantial transient drop in serum sulfate.
Sulfate conjugation:
N H - COCH 3
PAPS
OH
SO3H
I
N - COCH 3
OH
Eqn. 1.11. The conjugation of paracetamol
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1.1.3.3.3. Méthylation
Méthylation reactions are mainly involved with endogenous compound metabolism but 
some drugs may be methylated by non-specific methyltransferases, found in lungs 
(Weinshilboum, 1984). The co-factor S-adenosylmethionine (SAM) is required to form 
methyl conjugates. SAM is a donor of methyl groups in intermediary metabolism. It is 
produced from L-methionine and ATP by the enzyme, L-methionine adenosyltransferase. 
The sulfur atom in SAM is a positively charged sulfonium ion.
N-methylation:
SAM
CH
CH3CH3
Eqn. 1.12. The N-methylation of desmethylimipramine
I.I.3.3.4. Acétylation
The acétylation reaction is a common metabolic route for aromatic amines and requires 
co-factor, acetyl-coA. Acétylation mainly takes place in the liver (Kupfer cells) and in the 
reticuloendothelial cells of the spleen, lung and gut. Acétylation is an important step in 
both metabolic activation and deactivation of arylamines (Hein et al, 1992). In human, 
the acétylation of arylamine substrates is catalysed by either monomorphic N- 
acetyltransferase (NATl) or polymorphic N-acetyltransferase (NAT2) (Minchin et al, 
1992). Human capacity to acetylate arylamines is subject to a genetic polymorphism. 
Individuals are segregated into rapid, intermediate and slow acetylator phenotypes. There 
is a relationship between slow acetylators and urinary bladder cancer, and also between 
rapid acetylators and colorectal cancer (Hein, 1988).
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N-acetylation:
NHNH acetyl-CoA CoA-SH
SO 2 -NH;
Eqn. 1.13. Acétylation of sulfanilamide
1.1.3.3.5. Amino acid conjugation
Exogenous carboxylic acids can form CoA derivatives with acetate in the body and then 
can react with endogenous amines such as amino acids to form conjugates. Amino acid 
conjugation is a special form of N-acetylation. The usual amino acids involved are 
glycine, glutamine, arginine and taurine (Gibson and Skett, 1994). Apparently, there is a 
relationship between species differences and amino acid conjugation, e.g. glycin in 
mammals, glutamine in man, ornithine in birds, taurine in carnivores and aspartic acid in 
plants (Climie and Hutson, 1979).
Amino acid conjugation:
CO-S-CoA:00H ’0-AMP coASH AMPPPiATP
Benzoic acid
Glycine
CoASH
C0-N H -C H 2-C 00H
HIppuric acid
Eqn. 1.14. The conjugation of benzoic acid
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I.I.3.3.6. Glutathione conjugation
The tripeptide glutathione (GSH, y-L-glutamyl-L-cysteinylglycine) is recognized as a 
protective compound within the body for the removal of potentially toxic electrophilic 
compounds and plays an important role in the biotransformation and elimination of 
xenobiotics and in the defence of the cell against oxidative stress and chemical oxidants, 
including free radicals, that occur in biological systems. Glutathione is a thiol containing 
tripeptide found in high concentrations (1-lOmM) in most tissues.
Many of the reactions of GSH are due to the presence of the reactive sulfhydryl group. 
The cloud of electrons surrounding the nucleus of the sulfur atom is highly polarisable, so 
makes the sulfhydryl group a good nucleophile for reaction with electrophilic compounds. 
GSH conjugation is a common detoxification pathway, used in removal of reactive 
intermediates such as nitroalkenes, haloalkenes, alkenes or aromatic halo- and nitro­
compounds, but in some circumstances this pathway may also give rise to the formation 
of a molecule which is equally or more reactive than the parent compound. GSH is 
particularly abundant in the kidney and is synthesised in the proximal tubules. 
Conjugation with GSH may occur either non-enzymatically with highly reactive 
electrophilic substances such as dichloroacetylene or enzymaticaly by a number of 
glutathione -S-transferases, soluble proteins present in a number of tissues such as liver, 
kidney, lung and brain. In general G-S-transferases catalyse attack of the nucleophilic 
thiol of GSH at the electrophilic centre of compounds possessing a lipophilic structure. In 
the case of haloalkenes, depending on structure of substance, substitution or addition 
products, or both may be formed (Elfarra, 1993).
Further to phase I and phase II metabolism, a third phase of metabolism has been 
proposed, whereby the conjugate formed in phase II is metabolised by gut microflora after 
having been excreted in bile. Alternatively GSH conjugates may be reabsorbed and 
metabolised to the cysteine conjugate and mercapturic acid before excretion in the urine.
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Glutathione conjugation:
R  ?
Cl 0=0^
I \
Cl
Cl Cl
Hexachlorobutadiene 
1?
C -NHCH2-COOH 
HS-CHz-in o
Cl
Glutathione Cl 9^
S-transferase  \  I 
 ^
Cl C =C ,^
Cl ^  -CH2-ÇH o
NH-C-CH2-CH-COOH
o
II
C -NHCH2-COOH
NH,
NH-C-CH2-CH-COOH
rliHz {Pentachlorobutadienyi)-giutathloneiNn
Glutathione
Eqn. 1.15. Glutathione conjugation of Hexachlorobutadiene
I.I.3.3.6.I. Glutathione S-transferases
Glutathione S-transferases (GST), catalyse the conjugation of GSH with a very broad 
range of electrophilic chemical compounds, which are often cytotoxic, mutagenic and 
carcinogenic. These enzymes have been found in all aerobic organisms and also occur in 
high concentrations in mammalian tissues. Glutathione S-transferase activity is present in 
cytosolic, microsomal and mitochondrial compartments of the liver. The cytosolic 
transferases are a family of homo- and heterodimeric proteins found in many organs. The 
microsomal transferase is unrelated in protein structure to the cytosolic transferases, and 
the functional enzyme may be a homotrimer or homotetramer (Boyer et al, 1986; Coles 
and Ketterer, 1990). Microsomal glutathione S-transferase activity is high in the liver, 
although low activities are found in extrahepatic sites.
There are eight GST gene families which encoding cytosolic enzymes; the Alpha family, 
including GSTAl, GSTA2 (Strange and Fryer, 1999), GSTA3 and GSTA4 (Board, 1998); 
the Mu family, including GSTMl, GSTM2, GSTM3, GSTM4 and GSTM5 (Xu et a l, 
1998); the Theta family, including GSTTl and GSTT2 (Coggan et a l, 1998); the Pi 
family, including GSTPl with different allels such as GSTP1*A and GSTP1*B (Ali- 
Osman a l, 1997); the Zeta family, including GSTZl (Dixon et a l, 2000); the Kappa 
(Pemble et a l, 1996); the Sigma (Stevens et al., 1998 and Hong et al., 2000) and finally 
the Omega classes Rouimi et a l, (2001) which has been recently reported for the first 
time in pig tissues.
14
The family of human enzymes is divided into four main classes; a , p, n, 0. GSTa, is a 
marker for hepatocellular damage (Vaubourdolle et al., 1995). GSTs are responsible for 
part of the glutathione peroxidase activity and have an important function in intracellular 
binding and transport of a wide variety of both endogenous and exogenous compounds. 
(Mannervik, 1985). They have different catalytic activities and pattern of tissue 
distribution and therefore, may be a contributing factor in tissue-specific susceptibility to 
carcinogenesis (Jaitovitch-Groisman et al., 2000). Also GSTs have an important role in 
anticancer drug resistance ( Tew, 1994; Beaumont et al., 1998 and Sargent et a l, 1999).
Transcription of GST genes is under the control of hormones and some physiological 
factors. Removal of endocrine glands leads to alteration in the amounts of different forms 
of GSTs in various organs. One of the particular example is effects of androgens on the 
regulation of class Pi GST in mouse liver. Castration of adult males reduces the enzyme 
concentration to the juvenile levels, and administration of testostrone enhances the 
concentration up to adult levels (Hatayama et al, 1986).
I.I.3.3.6.2. Gamma-glutamyltransferase (y-gt)
y-glutamyltransferase is a serine hydrolase that catalyses the transfer of the D or L- 
glutamyl group from y-glutamyl di- and tripeptides, glutathione or glutathione S- 
conjugates to acceptor amino acids or dipeptides (Stole et al, 1990).
y-glutamyltransferase, a membrane-bound enzyme, is highly selective for D- or L- 
glutamyl moieties, y-gt activity is present in the bile duct, intestinal microvilli, brush- 
border membrane of the Si and S3 segments of the renal proximal tubules and in the renal 
vasculature and basal-lateral membranes. The kidney has the highest y-gt activity 
(Goldbarg et al, 1960), and in general, high enzyme activity is localised in cells which 
exhibit a secretory or absorptive function. Some studies have also shown the y- 
glutamyltransferase activity in the CNS choroid plexus of some experimental animals 
such as rat, mice and rabbit (Lisy et al, 1979 and Shine and Haber, 1981). In a study 
Bault and Mitro, (1994) have evaluated the distribution and activity of y-gt in different 
vascular compartments of the CNS, in the choroid plexus in lateral ventricles and in 
microvessels of the surrounding periventricular brain structure, in several common 
laboratory animals such as hamster, gerbil, guinea pig, rat and mouse by enzyme-
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histochemistry. Their findings show that; a) There is species differences in localisation of 
the enzyme b) In the gerbil, a positive y-gt reaction was seen in vessels of the choroid 
plexus and in microvessels of the periventricular brain tissue, but the choroid plexus 
epithelium was negative for the enzyme, c) In the guinea pig, the vessels of choroid 
plexus were negative for y-gt, but a positive reaction was seen in surface epithelial cells of 
choroid plexus as well as in microvessels of the periventricular brain tissue, d) In both the 
rat and mouse, the vessels of the choroid plexus were y-gt negative. In contrast a positive 
y-gt reaction was seen in the epithelial cells of choroid plexus and in microvessels of the 
periventricular brain tissue, e) Localisation of y-gt in choroid plexus is the same in guinea 
pig, rat and mouse.
In general, y-glutamyltranspeptidases from different mammalian sources exhibit marked 
similar catalytic behaviour and substrate specificity. These enzymes can catalyse three 
type of reaction:
Hydrolysis:
y-Glu -  X + H2O glutamate + HX
Transpeptidation :
y-Glu - X + acceptor -> y-glu -  acceptor + HX
Autotranspeptidation :
y-Glu - X + y-Glu - X -> y-glu - y-glu - X + HX
X = Cys -  Gly in GSH. The hydrolytic reaction exhibits a broad optimum between pH 6 -8 , 
whereas maximum transpeptidation is seen between pH 8-9 (McIntyre and Curthoy, 1979).
The ontogeny of y-glutamyl transpeptidase has been studied in several species. Fetal 
liver, lung, intestine and brain possess much greater activity than the corresponding adult 
tissues. Rat kidney transpeptidase during development shows that fetal and neonatal 
kidneys possess very little enzyme; adult levels are reached when the rats are about 7 
weeks old (Tate and Meister, 1975; Tate, 1980).
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Urinary y-gt originates from the kidney, while y-gt present in serum comes from the liver, 
so y-gt activity is elevated in all kinds of liver diseases. In general, y-gt is the most 
sensitive enzymatic indicator of hepatobiliary diseases available at present. High levels of 
y-gt are also seen in patients with both primary and secondary liver cancer and also in 
heavy drinkers or patients with alcoholic cirrhosis.
1.1.3.3.6.3. Aminopeptidase M (dipeptidase)
This enzyme catalysis the cleavages of amino acids from dipeptide, cysteinylglycine, to 
produces cysteine conjugate. Aminopeptidase M activity is high in liver, kidney and 
intestinal epithelium and is located on the lumenal surface of microvillus membrane (Tsao 
and Curthoys, 1980). The enzyme is a homodimeric, zinc containing protein with a 
subunit Mr of 130,000.
1.1.3.3.6.4. Cysteine conjugate P-lyase
The lyases are a group of pyridoxal phosphate-dependent enzymes, which catalyse the 
cleavage of C-S, C-N and C-C bonds. Some of these are capable of catalysing the 
cleavage of cysteine S-conjugates by p-elimination. The products of p-elimination are 
thiol-containing compounds and aminoacrylate, which rapidly is hydrolysed to pyruvate 
and ammonia (Fig 1.2). The thiol products may subsequently be methylated by S- 
methyltransferases producing stable and non-toxic methylthio-derivatives (Jacoby et al, 
1984). The cysteine conjugate P-lyases are discussed in more detail later.
1.1.4. Excretion of xenobiotics:
In general when a substance undergoes metabolism, it is converted to polar metabolite(s) 
that are excreted from the body. The main route of drug elimination is via the kidney in 
urine. The kidney receives a very large blood supply (25 percent of cardiac output). 
About 130 ml of plasma water is filtered each minute (190L/day) through the glomerular 
membrane. Of this only about 1.8 L is excreted as urine, the remainder being reabsorbed 
via the renal tubules. Only free drugs in the plasma (not drugs that are bound to plasma 
proteins) can be filtered (Pratt and Taylor, 1990). Drugs with high lipid solubility will be 
reabsorbed easily from the lumen of tubules. Polar compounds and ions will be unable to 
diffuse back and therefore will be excreted, unless reabsorbed by a carrier transport 
system. A drug may be excreted by liver cells into the bile and thus pass into the intestine.
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Chemicals are secreted into the bile by four mechanisms, which are specific for anions, 
bile acids, cations and neutral organic compounds, respectively (Pratt and Taylor, 1990). 
Several findings indicate the presence of three distinct and independent carrier-mediated 
active transport processes:
(i)- Secretion into bile against a high concentration gradient
(ii)- If the drug concentration in plasma is raised progressively, a limiting rate of 
drug secretion is reached, which can not be exceeded
(iii)- Various members of the same class (anion, bile acid, cation, nonionised 
molecule) compete, one depressing the biliary excretion of another, but there is no 
competition between members of different classes
1.2. Mercapturic acid synthesis
Biosynthesis of glutathione-S-conjugates provides a cellular defense against strong 
electrophiles such as haloalkenes, epoxides, alkenes, nitroalkenes and aromatic nitro-and 
halo-compounds. As mentioned above, further to phase I and II metabolism, a third phase 
of metabolism has been proposed, whereby some electrophilic compounds formed during 
phase II metabolism, react with the nucleophilic sulphur atom present in the cysteine 
moiety of GSH, and (usually) produce non-toxic conjugates. The resultant GSH- 
conjugate can be further metabolised to form cysteine conjugates and or N-acetyl-L- 
cysteine conjugates (mercapturic acid) which can be excreted in urine or bile. This 
metabolic pathway is also referred to as the mercapturic acid pathway (Fig 1.2).
The initial step in the formation of mercapturic acids via GSH conjugation involves the 
hydrolytic transfer of the y-glutamyl group of conjugate onto an appropriate acceptor (Fig 
1.2). This step is catalysed by the enzyme y-glutamyltransferase (y-gt), which is the only 
known enzyme that can cleave GSH and glutathione-S- conjugates (Anders and Dekant, 
1998). y-gt was first identified in kidney tissue, which possesses the highest level of y- 
glutamyltransferase activity, followed by the pancreas, which has approximately 2 0 % of 
the renal activity. In the kidney, y-gt is present in the brush-border membrane of the 
proximal tubules and in the renal vasculature and basolateral membranes of the P3 region. 
In rat liver, y-gt is localized in the bile-duct epithelium and in the bile canaliculi. No 
activity has been observed in sinusoidal cells. In contrast, in guinea pigs, sinusoidal cells
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express high y-gt activity and bile canaliculi contain only low y-gt activity, indicating 
possible species differences in the disposition of glutathione-S-conjugates (Hinchman and 
Ballatori, 1990). Some y-gt activity is present in the cytosolic fractions, but the major 
activity is membrane bound, y-gt is a heterodimeric glycoprotein with subunit molecular 
masses of 22kDa and 46 to 51 kDa.
The second step in the formation of mercapturic acid is the removal of glycine. Only two 
enzymes (which remove the glycine from the cysteinylglycine-S-conjugate) have been 
purified, namely cysteinylglycine dipeptidase (CGD, EC 3.4.13.6) and aminopeptidase M 
(APM, EC 3.4.11.2). CGD is more active than APM, but both exhibit their greatest 
activity in kidney, followed by the liver. Relatively low activities have been observed in 
the intestine.
The third step in the formation of mercapturic acid is by N-acetylation of the thioether of 
cysteine. Mercapturic acids are N-acetyl conjugates and are end products of a pathway, 
which involves the detoxification of potentially harmful electrophilic compounds 
(nephrotoxic and cytotoxic cysteine-S-conjugates). This step is catalyzed by the cysteine 
conjugate N-acetyltransferases (NATs, EC 2.3.1.8) which exhibit their greatest activity in 
liver and kidney. NATs require acetyl CoA as a co-factor. NATs are located in the 
endoplasmic reticulum of several tissues with the enzyme active site facing the 
cytoplasmic surface (James and Needham, 1973).
N-acetylcysteine-S-conjugates or mercapturic acids are not substrates for cysteine 
conjugate p-lyases, which require a free amino group for enzymatic activity. N- 
acetylation is a reversible reaction, the reverse reaction being catalysed by renal 
deacetylases, leading to the reformation of cysteine-S- conjugates.
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Fig 1.2: Mercapturic acid synthesis (Adopted from Chasseud 1976)
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1.3. Bioactivation: role of GSH conjugates
It was previously believed that, GSH conjugation was a protective mechanism leading to 
mercapturic acid synthesis, however this is not always the case. GSH conjugation has 
been the focus of much attention since its role in the bioactivation of some xenobiotics to 
toxic substances has become apparent (van Bladeren, 1988).
1.3.1. Reactive direct acting GSH conjugates
Some GSH-conjugates also known as sulphur half-mustards, may undergo internal 
displacement of the second halogen atom, giving rise to the formation of extremely 
reactive electrophilic episulfonium derivatives. It is believed that these strong 
electrophiles may be involved in the formation of DNA-adducts and play an important 
role in the mutagenicity and nephrotoxicity of 1 ,2 -dihaloalkanes, e.g.
1 , 2 - dihaloalkane 2 - haloethylglutathione
1.3.2. GSH conjugates in which GSH reversibly binds and acts as a transport 
molecule
Some GSH conjugates may induce toxicity by transfering electrophiles to distant 
nucleophilic centres of essential biomacromolecules. Bruggeman et al, (1986) 
investigated the reaction between equimolar amounts of GSH and allyl isothiocyanates 
and demonstrated that at equilibrium, 15-20% of the isothiocyanate remained 
unconjugated. Furthermore, they noted that by changing the concentration of the reactants 
and adjusting the pH, the position of equilibrium could be altered.
S
I I
R - N = C = S + GSH -------^  R - N H - C - S G
Benzyl /allyl isothiocyanate
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1. 3.3. GSH conjugates which require further bioactivation
Many GSH conjugates are not usually excreted without further metabolism, instead they 
are metabolised to cysteine conjugates, which are finally N-acetylated and excreted as 
mercapturates in urine. The thioethers of cysteine also serve as substrates for the enzyme 
cysteine conjugate p-lyase, which are present in the proximal tubule of the kidney. These 
compounds contain electronegative and /or unsaturated substituents and are enzymatically 
cleaved to form pyruvate, ammonia and reactive sulphur containing fragments which are 
selectively toxic to the P3 segment of kidney proximal tubule (Lock and Ishmael, 1979). 
The major factors which determine the toxic potential of haloalkyl derived GSH 
conjugates of halogenated alkenes are firstly their suitability as substrates for p-lyases and 
secondly the reactivity of the thiols which they produce.
1. 3. 4. Fate of cysteine conjugates
Cysteine-S- conjugates may undergo cysteine conjugate p-lyase-dependent P-elimination 
reactions that produce a-haloenethiolates or a-haloalkylthiolates, transamination 
reactions that produce a-keto acids, N-acetyltransferase-catalysed N-acetylation that 
produce mercapturates, or flavoprotein- or cytochrome P450 - dependent sulfoxidation 
that produces sulfoxides and /or sulphones (Anders and Dekant, 1998) (Fig 1.3).
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Fig: 1.3: Fate of cysteine S-conjugates {Anders and Dekant, 1998)
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1.3.5. Interorgan transport of GSH conjugates and their metabolites
In general, enzymes involved in the metabolism of GSH-derived conjugates of 
haloalkenes are present in several tissues. The very selective toxicity to the S3 segment of 
the proximal tubule of kidney caused by certain of these compounds can be explained by 
the distribution and relatively high activity of activating enzymes in cells along this part 
of the nephron. Because P-lyase activity is only present intracellularly, nephrotoxic S- 
conjugates, which require p-lyase-mediated bioactivation, have to be transported into the 
renal cells. The S- conjugates can enter into the renal cells from plasma via the basolateral 
membrane or from the tubular lumen via the brush border membrane (Commandeur et al, 
1991). About 70% of the plasma clearance of GSH is via the kidney. Glomerular filtration 
is responsible for 25% of the renal clearance of GSH and the rest of circulating GSH is 
removed by non-filtration mechanisms, which involve transport across the basolateral 
membranes.
It is generally accepted that GSH conjugation predominantly occurs in the liver, most of 
the conjugates passing across the canalicular membrane into the bile and being degraded 
to their appropriate cysteine S- conjugates by enzymes such as y-gt and dipeptidases. 
Some GSH conjugates are delivered to the small intestine intact and will subsequently be 
metabolised to cysteine S- conjugates by y-gt and CGD/APM. From the small intestine or 
bile duct, cysteine S-conjugates are absorbed into the blood and transported to the liver 
via the hepatic portal vein (Fig 1.4). Some cysteine S-conjugates are converted to 
mercapturic acids by N-acetyltransferase in the liver (Green and Elce, 1975). The 
mercapturic acids together with the remaining cysteine conjugates and the GSH 
conjugates (which passed directly from liver into the plasma) are transported via the blood 
to kidney which is the primary organ for handling of plasma GSH and cysteine 
conjugates. Once in the kidney, these metabolites are filtered into the tubular lumen or 
pass into the peri-tubular circulation. The GSH conjugates may then be converted to 
cysteine S-conjugates by y-gt and CGD present in the renal brush border (Elfarra and 
Anders, 1984). From the peri-tubular circulation or tubular lumen, cysteine S-conjugates 
pass into the tubular cells where they undergo one of five possible fates as discussed 
below.
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(i) They may be secreted into the plasma and transported to the liver via the renal hepatic 
circulation and subsequently N-acetylated to mercapturates and excreted in the urine.
(ii) Cysteine S-conjugates may be N-acetylated by N-acetyltransferase in the tubular 
lumen cells giving rise to their corresponding mercapturic acids.
(iii) Cysteine S-conjugates may undergo bioactivation by the kidney enzyme, cysteine 
conjugate P-lyase.
(iv) Regeneration of cysteine conjugates from mercapturic acids by the enzyme, 
deacetyiase (Suzuki and Tateishi,1981).
(v) Some cysteine S-conjugates are direct-acting nephrotoxins which can form 
episulphonium ions non-enzymatically(from sulphur mustards) and therefore do not 
require further metabolism.
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Fig.1.4: Interorgan transport of GSH conjugates and their metabolites {Commander, 1991)
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1.3.6. The thiomethyl shunt
In 1988, van Bladeren discovered that GSH conjugates play an important role in the 
metabolism of xenobiotics, since then much research has focused on this area. Cysteine 
S-conjugates are converted to mercapturic acids by N-acetylation and prepared for 
excretion, however, the mercapturic acids and cysteine conjugates may be shunted away 
from the direction of detoxification by the enzymes, deacetyiase and cysteine conjugate 
p- lyase, with the formation of toxic thiols (Jacoby et al, 1984). The microsomal enzyme 
thiol S-methyltransferase further metabolises the newly generated thiol by converting it 
to a methyl thiol group, which is less water soluble. This pathway (Weisiger and Jacoby, 
1979) has become known as the thiomethyl shunt (Fig, 1-5).
Although the enzymes of detoxication convert xenobiotics to water-soluble metabolites 
and prepare them to be eliminated from body, it is unusual that a major system of 
detoxication such as mercapturic acid synthsis, can be shunted away from this task. The 
shunt pathway takes a generally pharmacologically inactive product and processes it to 
form a member of a toxic group of compounds, a reactive thiol, that is then methylated to 
a less-water soluble derivative. It is clear, however, that the shunt pathway does have the 
potential for toxicity (Jacoby et al, 1984).
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1.4. Toxicity of halogenated alkenes
The first report on the toxicity of cysteine S-conjugates derived from haloalkenes such as 
S-(l,2-dichlorovinyl)-L-cysteine (DC VC) was in 1957 (McKinney et al,). DC VC 
produced aplastic anemia and biochemical alterations in the bone marrow, lymph nodes 
and thymus in cattle, which is a unique observation. In all other species studied, DC VC 
was nephrotoxic, not hematotoxic (McKinney et al, 1957 and Lock et al, 1996). These 
findings indicate that calves have the ability to deacetylate mercapturic acids and that P- 
lyase metabolism of DCVC is necessary for bone marrow and renal injury to occur. 
Subsequently, many halogenated alkenes, have been shown to produce nephrotoxic 
effects in experimental animals. Mice, rats, guinea pigs and dogs displayed toxic 
alterations and necrosis of the renal tubular epithelium 24 hrs after administration of 
DCVC. This was confirmed by an increase in BUN concentration and urinary glucose 
excretion. Several other cysteine S-conjugates such as PCBD, CTFEC and TFEC caused 
identical toxicity to that of DCVC.
Hayden and Stevens, (1989) studied the toxicity of the ^"^C-labeled, ^^S-labeled and 
unlabeled nephrotoxic cysteine S-conjugates such as DCVC, S-(2-chloro-1,1,2- 
triflouroethyl)-L-cysteine (CTFEC), TFEC, PCBC and S-(l, 1,2,3,3,3-hexafiuoropropyl)- 
L-cysteine. Their toxicity was also examined in isolated rat renal mitochondria. Inhibition 
of respiration, covalent binding to macromolecules, metabolism by mitochondria, 
metabolism by purified cysteine conjugate p-lyase and octanol/water partition coefficients 
were studied. All of the conjugates inhibit mitochondrial - state 3 respiration. Binding of 
the ^^S- label to macromolecules was observed after exposure to each of the ^^S-labeled 
conjugates.
Further to experimentation on animals, many cell lines have also been used in order to 
assess the potential toxicity of halogenated alkenes and their conjugates. One such cell 
line is the pig renal epithelial cell line, LLC-PKi, which is sensitive to the toxicity of 
dichlorovinyl glutathione (DCVG) and other, halogenated cysteine conjugates (Stevens et 
al, 1986a).
Proximal tubules of the kidney are sensitive to the toxicity of S-conjugates because of: a) 
the high level of y-gt, dipeptidase, P-lyase and deacetyiase. b) the ability of the kidney to
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accumulate amino acid derivatives, c) high renal blood flow. Halogenated hydrocarbons 
are potentially toxic to man due to occupational and environmental exposure. Mutti et al, 
(1992) found several renal disturbances such as diffuse structural and functional changes 
within the kidney (possibly resulting fi*om generalised membrane disturbances) increased 
glomerular permeability to plasma proteins and increased shedding of epithelial 
membrane component fi*om tubular cells with a different location along the nephron, in 
perchloroethylene-exposed workers. Henschler et al, (1995), investigated the effects of 
occupational exposure to high doses of trichloroethylene and discovered that, there was an 
increased incidence of renal cell tumours amongst these subjects. The addition of DCVG 
to isolated kidney cells led to the identification of GSH conjugates in the cells and uptake 
occurred via a sodium coupled transport system.
Cellular transport is an important factor in the cysteine conjugate induced nephrotoxicity. 
DCVC induced nephrotoxicity in vivo, is blocked by probenecid, an inhibitor of the 
basolateral membrane anion transport system. Lock et al, (1985) reported that 
mercapturates were also transported via the probenecid transporter mechanism.
The cysteine conjugate toxicity is blocked by inhibitors of the organic anion transport 
system. It may therefore be concluded that in order for nephrotoxicity to occur, cysteine 
conjugates must be transported into the renal tubular cells where they are subsequently 
metabolised by cysteine conjugate P-lyase. Aminooxyacetic acid (AOAA) is an inhibitor 
of pyridoxal phosphate-dependent enzymes such as cysteine conjugate p-lyase, and 
research has shown that AOAA reduces the toxicity of the homocysteine analogue of 
DCVC, S-(l,2-dichlorovinyl)-L-homocysteine, (DCVHC) (Lash and Anders, 1989). 
DCVHC is a more potent nephrotoxin in rats than DCVC.
1.4.1. Role of S-oxidase in nephrotoxicity
Recently, a NADPH-dependent cysteine conjugate S-oxidase (S-oxidase) activity, present 
in rat hepatic microsomes, has been characterized (Sausen and Elfarra, 1990). The S- 
oxidase activity, (which appeared to be associated with flavin-dependent 
monooxygenases and catalyzed the sulfoxidation of S-benzyl-L-cysteine) was inhibited 
by DCVC. This result suggested that DCVC may act as a substrate for the S-oxidase 
(Sausen and Elfarra, 1991). One of the metabolites of DCVC is DCVC-sulfoxide
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(DCVCO), which produces greater nephrotoxicity than DCVC in rats. When administered 
in equimolar doses (Lash et al, 1994), DCVCO can react directly as a Michael acceptor 
with cellular nucleophiles, forming covalent adducts, or it may be further metabolised by 
p-lyase to form pyruvate, ammonia and 1, 2-dichlorovinyl sulphonic acid. AOAA does 
not affect S-oxidase activity and does not provide protection for rats against DCVCO- 
induced nephrotoxicity (Lash et al, 1994). DCVC is more cytotoxic than DCVCO in 
proximal tubular cells, (because of the much greater P-lyase activity in proximal tubular 
cells compared to distal tubular cells) but DCVCO shows greater cytotoxicity than DCVC 
in distal tubular cells. Although distal tubular cells possess p-lyase activity which is 
inhibited by AOAA, it does not protect these cells from DC VC-induced toxicity, which 
suggests that cytotoxicity in these cells is not dependent on bioactivation by P-lyase and 
support the role of S-oxidase in the bioactivation and nephrotoxicity of DCVC (Lash et 
al, 1994). Werner et al, (1995) showed that in man the mercapturic acid of HCBD (N- 
AcPCBC), but not its GSH and cysteine conjugates, was a substrate for monooxygenase 
activity. By using selective inhibitors of cytochrome P450 and FMO, it was observed that 
only the cytochrome P450, specifically members of cytochrome P450 3A family, could 
catalyse the oxidation of mercapturic acids.
1.4.2. Mechanisms of cysteine conjugate toxicity
Early this century, it was noted that cattle fed soybean meal, contaminated with 
trichloroethylene, developed aplastic anemia (McKinney et a l, 1957). More than 40 years 
later, the toxic metabolite of the trichloroethylene was shown to be the DCVC which 
formed from GSH S-conjugate and is nephrotoxic to all experimental animals. Early work 
of Schultze and co-workers lead to the important finding that, metabolism of DCVC 
involves a C-S-lyase (Anderson and Schultze, 1965) and metabolism of ^^S-labeled 
DCVC results in incorporation of a labeled sulfur fragment into protein and DNA.
DCVC is a substrate for the cysteine S-conjugate p-lyase that produces thiol containing 
product, ( 1 ,2 -dichloro- 1 -mercaptoethylene), which is highly unstable. It has been shown 
that the most probable breakdown product of 1 ,2 -dichloro- 1 -mercaptoethylene is a 
thioketene arising by elimination of HCl.
There are two major mechanisms of toxicity of cysteine S-conjugates:
31
(i). Formation of a reactive thiol that produces thionoacyl fluorides and thioketenes.
(ii). Formation of direct-acting nephrotoxins such as 1,2-dibromoethane, 1,2- 
dichloroethane and 1 -bromo-2 -chloroethane
Thioketenes are known to be thioacylating agents that react rapidly with nitrogen 
nucleophiles (Adiwidjaja et al, 1991). Amino and /or hydroxyl groups of proteins and 
lipoproteins are susceptible to thioacylation (Dekant et al, 1994). a-Fluoroethanethiols, 
are produced by cysteine S-conjugate p-lyase from fluorinated ethanes. Unlike the 
unsaturated thiol-containing fragment generated in the P-lyase reaction from DCVC 
(Fig. 1.6), the saturated fragment released from the fluoroalkyl cysteine S-conjugate (a- 
fluoroethanethiol) is a stable metabolite and mimics the cysteine S-conjugate p-lyase 
reaction. The a-fluoroethanethiol, rapidly eliminates HF to yield the thioacyl fluoride. 
Thioacyl fluorides, like thioketenes, are strong thioacylating agents (Anders et al, 1993).
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Fig 1.6: Cysteine S-conjugate p-lyase catalysed conversion of S-(haloalkenyl)-L-cysteine 
conjugates to halothioalkene followed by spontaneous conversion to thioketenes. X=H (DCVC).
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1.4.2.1. Formation of reactive thiols
As with many enzymatic reactions, the exact chemical nature of the toxic product of P- 
lyase cleavage of cysteine conjugates is not known in all cases. P-lyase metabolism of S- 
haloalkyl conjugates (e.g CTFEC and S-haloalkenyl conjugates e.g DCVC), produces 
unstable thiols which further rearrange chemically producing reactive intermediates which 
can bind to macromolecules resulting in nephrotoxicity. As mentioned above, thionoacyl 
fluorides and thioketenes are both potent acylating agents. Amino groups and hydroxyl 
groups of proteins and lipoproteins are susceptible to thioacylation. Such covalent 
attachment is associated with nephrotoxicity and mutagenicity.
In 1987, Dekant et al, studied the in vitro bioactivation of CTFEC and found that initially 
an unstable nucleophilic thiol (2 -chloro-l, 1 , 2 -trifluoroethane thiol (thiolate)) was formed 
which then lost hydrogen fluoride giving rise to an acylating intermediate, 
chlorofluorothinoacyl fluoride, which is subsequently hydrolysed to chlorofluoroacetic 
acid, inorganic fluoride and hydrogen sulphide (Fig 1.7)
The stable thiol, in particular, may be methylated by thiol methyltransferase and excreted 
in the urine as methylthioethers. Thiolmethyltransferases are present in various tissues, 
including the liver and kidney, and two enzymatic systems are involved in thiol 
méthylation; thiolmethyltransferase (TMT; EC 2.1.1.9) and thiolpurinemethyltransferases 
(TPMT; EC 2.1.1.67). TMT is a microsomal enzyme involved in the S-methylation of 
aliphatic sulphydryl compounds, and TPMT is a cytosolic enzyme involved in the S- 
methylation of aromatic and heterocyclic sulphydryl compounds. S-Adenosyl-L- 
methionine (SAM) is the methyl donor for these two enzymes. (Morel et a l, 1999).
For p-elimination to be catalysed by mammalian cysteine S-conjugate p-lyases, the 
cysteine S-conjugate must contain a sulfur at the oxidation state of a sulfoxide S(0)R or 
the SR portion must be a good leaving group (i.e., be activated usually by a halogen, 
double bound or an aromatic group). This requirement may be due to the fact that most 
mammalian cysteine S-conjugate p-lyases studied so far are PLP-containing enzymes that 
appear to be coerced into catalysing the p-elimination reaction only by virtue of the strong 
electron-withdrawing properties of the SR [or S(0)R] portion of the conjugate. These p- 
elimination reactions inactivate mammalian cysteine conjugate p-lyases by releasing
34
aminoacrylate following elimination of the SH-containing fragment. Aminoacrylate is 
spontaneously hydrolysed to pyruvate and ammonia, but in some cases the generated 
aminoacrylate can cause enzyme inactivation by alkylating a nearby residue or, more 
likely, by attacking the cofactor (Cooper, 1998).
S-conjugates apparently destroy the renal epithelial cells by a combination of covalent 
binding to macromolecules, depletion of non-protein thiols and lipid peroxidation. Within 
kidney cells, mitochondria are damaged through perturbation of Ca^^ homeostasis, 
modification of membrane proteins and changes in the pyridine nucleotide redox balance 
(Hayden and Stevens, 1990). The fluoroalkene derived cysteine conjugates, which do not 
contain bromine, are toxic both in vivo and in vitro, but those fluoroalkene derived 
cysteine conjugates, which contain bromine, are toxic and mutagenic. Finkelstein et al, 
(1994) suggested a bioactivation pathway via which the formation of glyoxylate during 
metabolism of bromine containing fluoroalkene derived cysteine conjugate can occur. The 
properties of a-thiolactones still remain uncharacterised, however, p-propiolactones 
analogues are both mutagenic and carcinogenic. It has been suggested that a-thiolactones 
may play a role in the mutagenicity seen with bromine containing cysteine conjugates 
(Finkelstein a/., 1994).
There are a number of other enzymes that catalyse a P-elimination reaction with S- 
substituted cysteines to produce pyruvate, ammonia and RSH such as:
(i). p-Cystathionase, which catalysis an important step in the pathway leading to 
formation of methionine in microorganisms and plants. This enzyme catalyses the 
conversion of cystathionine [R= CH2CH2CH(NH2)COOH] to pyruvate, ammonia 
and homocysteine.
(ii). y- Cystathionase, can catalyses a p-elimination if presented with an 
appropriate substrate such as cystine [R= SCH2CH(NH2)COOH], djienkolic acid 
and lanthionine.
(iii). Alliinase, an enzyme present in onion and garlic that catalyses a P- 
elimination reaction with an alkoxide analogues of cysteine 
[RS(0)CH2CH(NH2)C00H) to yield pyruvate, ammonia and a sulfenic acid, 
RS(0)H.
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1.4.2.2. Formation of direct acting nephrotoxins
Some halogenated alkanes are metabolised to form direct-acting nephrotoxins. These 
compounds are transformed by GSH S-transferase into the S-(2-haloethyl) glutathione S- 
conjugates which in turn forms electrophilic episulphonium ions or sulphur half-mustards. 
Examples of these haloalkanes, are 1,2-dibromoethane, 1,2-dichloroethane and 1-bromo- 
2-chloroethane, which are toxic and carcinogenic (Fig 1.8). The formation of the sulphur 
half-mustard is GSH dependent. GSH conjugation of 1,2-dibromoethane results in the 
formation of S- [2-(N^-guanyl)-ethyl]-L-glutathione, which can form DNA adducts in 
vivo (Ozawa and Guengerich, 1983).
Another cysteine S-conjugate, which forms a direct acting nephrotoxin, is S-2- 
chloroethyl-DL-cysteine (CEC) (Elfarra et al., 1985). CEC at doses greater than 50mg/ 
kg causes renal dysfunction, accompanied by histopathological changes in the kidney. 
CEC is not a substrate for cysteine conjugate p-lyase. Evidently, toxicity of CEC is 
dependent on the internal displacement of the chlorine atom by the sulphur atom forming 
electrophilic episulphonium ions. Rat hepatocytes treated with CEC showed rapid 
depletion of intracellular GSH, which is due to the intracellular reaction between 
episulphonium ion and GSH, resulting in the formation of S-[(2-DL-cysteinyl) ethyl]- 
glutathione. CEC can accumulate in toxic concentrations in renal tissue as a result of 
renal tubular cell active transport (Elfarra et al, 1985).
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1.4.3. Molecular mechanisms of mutagenicity and cytotoxicity of haloalkene- 
S-conjugates
Glutathione and cysteine conjugates of haloalkenes are toxic to renal proximal tubules. 
Those conjugates, which are derived from chlorinated alkenes, are also mutagenic but 
those, which are derived from fluorinated alkenes, are not (Green and Odum, 1985). On 
the other hand, the cysteine conjugates of PCBC, DCVC and TCVC produce genotoxic 
effects in mammalian cells, but CTFEC does not. Vamvakas et al, (1989) suggested that 
the differences between the genotoxic effects of chloro- and fluoro- alkene conjugates 
were due to the differences in the stability of their reactive acylating intermediates. The 
reactive intermediate of fluoroalkenes is a thionoacyl fluoride and that of chloroalkenes is 
a thioketene. Carbon-fluorine bonds in thionoacyl fluorides have low bond energies, 
therefore it would be expected that they have a short half-life and may be unable to react 
with DNA.
1.4.3.1. Carcinogenicity and mutagenicity
Some studies have shown that the GSH and cysteine conjugates of halogenated 
hydrocarbons are mutagens. Administration of 1,2-dibromoethane and l,2-dibromo-3- 
chloropropane caused stomach tumours with many métastasés in both rats and mice 
(Weisburger, 1997), whereas HCBD increased the incidence of renal tumours, adenomas 
and adenocarcinomas. Another mutagen is DCVC (Battacharya and Shultzc, 1972 & 1973 
and Commandeur et al, 1991) and p-lyase cleavage produces a reactive intermediate, 
which binds to DNA resulting in structural modifications and alterations in gene 
expression.
It has been demonstrated that the mutagenicity of chloroalkenes is dependent on both p- 
lyase and y-glutamyl transpeptidase. GSH conjugates of chloroalkenes induce 
unscheduled DNA synthesis in LLC-PKi cells, however, this occurs at concentrations, 
which do not give rise to cytotoxicity (Vamvakas et al., 1989). The cysteine conjugate of 
HCBD exhibits genotoxicity by forming DNA-DNA cross links. Experiments involving 
HCBD have shown that following in vivo metabolism, binding of metabolites to DNA 
was more common in kidney than in liver and almost is exclusive to mitochondrial DNA. 
p-lyase-mediated metabolism of DCVC produces reactive intermediates which have been 
shown to interact directly with DNA. DCVC is also mutagen in Salmonella typhimurium.
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In LLC-PKi cells, DCVC induces DNA repair (Vamvakas et ah, 1989) and in vivo 
produces single strand breaks in rat kidney DNA. More recently it has been shown that 
DCVC forms adducts with the nucleotides adenine, guanine and cytosine (Vamvakas and 
Koster, 1993).
1.4.3.2. Direct cytotoxicity
In addition to mutagenic effects, chloroalkyl-derived cysteine conjugates also induce 
cytotoxicity. Chen et ah, (1990), used DCVC and showed that it kills renal epithelial 
cells by a combination of covalent binding, depletion of non-protein thiols and lipid 
peroxidation. They also found that the phenolic antioxidants, N, N’-diphenyl-p-phenylene 
diamine (DPPD), butylated hydroxyanisole, butylated hydroxytoluene, propyl galate, 
butylated hydroxyquinone and iron chelator deferoxamine, significantly inhibited the 
cytotoxicity of DCVC. Among these, DPPD was most potent. PCBC and DCVC 
markedly reduce cellular respiration and ATP levels in freshly isolated proximal tubular 
cells and DCVC and DCVHC inhibit oxygen consumption in isolated kidney cells. Since 
oxygen consumption in proximal tubular cells is mainly due to mitochondrial respiration, 
it is believed that both compounds target the mitochondria (Anders et al, 1987). DCVC 
is a potent inhibitor of the state 3- respiration in intact mitochondria and AOAA provides 
protection against this (Elfarra et al, 1984 and 1985). DCVC also inhibits the 
mitochondrial membrane potential together with the inhibition of succinate-linked state 3 
- respiration (Lash and Anders, 1987). Binding studies using labelled-CTFEC, DCVC, 
HFPC, PCBC and TFEC have confirmed that cysteine conjugates bind to mitochondrial 
macromolecules and cause cell death. This mechanism can be explained by alterations in 
intracellular Ca^  ^homeostasis.
I.4.3.3. Disturbance of intracellular calcium homeostasis
Alteration in intracellular calcium levels, play an important role in the cysteine conjugate 
induced cell death. Vamvakas et al, (1990) showed that DCVC and DCVHC increase 
intracellular [Ca^^]. With DCVC distribution of Ca^^ is low in mitochondrial regions but 
with DCVHC, distribution of Ca^  ^is high in mitochondrial regions, so DCVC is more 
toxic than DCVHC on mitochondria. DNA structure and function may also be disturbed 
by increased intracellular calcium concentrations. Since this activates endonucleases 
which may catalyse the formation of DNA strand breaks by the induction of poly (ADP-
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ribosyl)ation of nuclear proteins. DCVC induced cytotoxicity (Vamvakas et al, 1992) can 
be blocked by:
(i ) Chelation of cytosol Ca^ "^  by Quin-2.
(ii ) Inhibition of DNA fragmentation by aurin tricarboxylic acid.
(iii) Decrease poly (ADP-ribosyl) transferase activity by 3-aminobenzamide
1.4.3.4. Induction of poly (ADP-ribosyl)ation
Chromatin structure plays an important role in the initiation of DNA repair, DNA 
replication and modulation of gene expression. Change in chromatin structure may allow 
certain enzymes or proteins to bind to the DNA. McLaren et al, (1994) showed that 
DCVC can induce poly (ADP-ribosyl)ation after administration to male rats in vivo. 
Among the different type of DNA damage, DNA double-strand breaks are the most potent 
inducers of poly (ADP-ribosyl)ation. DCVC also increases intracellular Ca^^ 
concentration in LLC-PKi cells, this results in activation of calcium dependent 
endonucleases and in an increased formation of DNA double-strand breaks followed by 
increased poly (ADP-ribosyl)ation of nuclear proteins which leads to cytotoxicity 
(Vamvakas et al, 1990 and 1992). It is generally believed that large increases in the 
formation of nuclear poly (ADP-ribosyl) conjugates may lead to depletion of cellular 
NAD"*" levels. NAD"*" being the substrate for poly (ADP-ribosyl)transferase. In turn, this 
will lead to a depletion of the ATP pool and cause cell death.
1.5. Cysteine conjugate |3-lyase
As mentioned above, the lyases are a group of enzymes, which catalyse the cleavage of C- 
S, C-N and C-C bonds. Some of these are capable of catalysing the cleavage of cysteine 
S-conjugates by p-elimination. These enzymes have been found in several mammalian 
tissues with the greatest specific activity being found in the kidney followed by the liver. 
They have also been detected in heart, muscle, brain, testes, pancreas, lung, parasitic 
helminths and the intestinal bacteria (Bowsher and Henry, 1985; Larsen, 1985; Stevens et 
al, 1986b; Tateishi et al, 1978; Adcock et al, 1999).
41
1.5.1. Cysteine conjugate P-lyase of the intestinal bacteria
Several Cysteine conjugate P-lyase enzymes have been isolated and characterised in three 
species of gastrointestinal bacteria, namely Fusobacterium necrophorum (Larsen and 
Larson, 1983), Eubacterium limosum (Larsen and Stevens, 1986), and Fusobacterium 
varium (Tomisawa et al, 1984). In addition, p-lyase enzyme activity has been detected in 
27 of 43 intestinal bacteria tested (Larsen, 1985). The P-lyases from F. necrophorum and 
F.varium have molecular weight of 228 kDa and 70 kDa and require PLP as co-factor. P- 
lyase from F. necrophorum was purified about 50-fold and was shown to catalyse the C-S 
cleavage of propachlor (2-S-cysteinyl)-N-isopropylanilide), 1 ,2 -dihydro-l-hydroxy-2 - 
cysteinylnaphthalene and S-(2-benzothiazolyl)cysteine. p-lyase from F. varium was 
shown to be most active with aromatic cysteine conjugates (e.g. phenyl-, benzyl-, p- 
bromophenyl-) although some activity was noted with alkyl cysteine S-conjugates.
The P-lyase from E. limosum was purified about 540-fold and has the highest activity of 
the cysteine S-conjugate p-lyases studied in enteric bacteria. It has a M.W of 75kDa and 
is composed of two subunits. The enzyme is active with the cysteine conjugate of 
propachlor, trans-9-hydroxy-10- [S(L-cysteinyl)]-9, 10-dihydrophenanthrene, S- 
(benzothiazolyl)-L-cysteine, and DCVC. Activity does not require added PLP and in 
contrast with F. nevrophorum and F. varium, possesses P-cystathionase activity.
Clearly, cysteine S-conjugate P-lyases in the different enteric bacteria have very varied 
physical and catalytic properties. Some studies have reported that gut bacteria are 
important in catalysing the metabolism of xenobiotics and the broad specificity of these 
enzymes suggest that the gut flora may be important for in vivo introduction of sulfur into 
some xenobiotics (Larsen and Stevens, 1986). For example, propachlor does not appear 
to be a substrate for the mammalian cysteine S-conjugate p-lyase, and germ-free rats do 
not convert propachlor to 2-mercapto-N-isopropyl acetanilide (Bakke et a l, 1980). 
Simple S-alkyl- and S-aryl-L- cysteine conjugates are generally substrates of the bacterial 
cysteine conjugate P-lyases. Of the mammalian enzymes, none displays lyase activity 
toward simple S-alkyl cysteines although the human liver enzyme is very active with a 
number of S-aryl cysteines.
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1.5.2. Cysteine conjugate p-lyase in parasitic helminths
Adcock et al, (1999) have shown for the first time cysteine conjugate p-lyase activity in 
three species of parasitic helminth such as; cestodes (Moniezia expansa), digeneans 
(Fasciola hepatica) and nematodes (Necator americanus, Heligmosomoides polygyrus). 
They used DCVC, S-(2-benzothiazolyl)-L-cysteine (BTC) and S-(p-bromophenyl)-L- 
cysteine (BPC) as substrate, p-lyase activity towards DCVC was detected in H. 
polygyros, M. expansa and N. americanus but was absent from F. hepatica. BPC was a 
substrate in H. polygyrus only and BTC was inactive in all cases. Addition of PLP did 
not significantly increase the P-lyase specific activity towards DCVC in any of the 
helminth species tested. Each species was screened for y-gt and transaminase activity 
towards L-aspartate, L-alanine, L-albizziin and L-phenylalanine as well. 
Aminotransferase activity toward L-aspartate and L-alanine was detected in all four 
helminth species. These authors also could purify the p-lyase within the cytosolic fraction 
of tissue from M. expansa. This enzyme has a MW of 27Kda and co-purified with 
transaminase activity towards L-aspartate. The substrate profile for M. expansa P-lyase is 
different from that of mammalian p-lyase (Adcock et al, 2000).
1.5.3. Mammalian cysteine S-conjugate p-lyases
It is now known that in mammals, cysteine conjugate P-lyase is a subsidiary activity of 
members of the amino acid transaminase enzymes including kynureninase, and 
kynurenine aminotransferase / glutamine transaminase K (Fig 1.9).
1.5.3.1. Human liver cysteine S-conjugate P-lyase/ Kynurenine 
aminotransferase
Tomisawa et al, (1986) purified a cysteine S-conjugate-lyase from post mortem human 
liver by about 880-fold. The enzyme has a M.W of 8 8 kDa and optimum pH of 8.5. 
Buckberry et al, (1992) proposed that the biochemical role of human hepatic p-lyase was 
as a kynurenine aminotransferase (Fig 1.9c) but conclusive proof was not obtained. Two 
isoforms of p-lyase have been found in human liver with isoelectric points of 8.0 and 5.0.
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1.5.3.2. Human kidney cysteine S-conjugate p-lyase
Human p-lyase activity has been found in cytosol, mitochondria and microsomes with the 
greatest activity being in the cytosol. Human renal cytosolic p-lyase has M.W of about 
45kDa and is a PLP-dependent enzyme, which co-purifies with GTK and is inhibited by 
AOAA (Lash et al, 1990). Conversion of cysteine S-conjugate to pyruvate, reactive 
mercaptan and ammonia via the elimination reaction results in the regeneration of PLP (in 
Schiff ‘s-base linkage to an active site lysine residue) thus after one turnover through the 
p-elimination pathway, the enzyme is capable of productively binding another equivalent 
of cysteine conjugation, however, if  transamination occurs the cysteine conjugate and co­
factors are converted to the corresponding a-keto acid and pyridoxamine 5’-phosphate 
(PMP). The PMP form of the enzyme cannot productively bind the cysteine conjugate 
substrate and the P-lyase reaction ceases. In order that the enzyme regenerates the active 
PLP form, an a-keto acid acceptor (e.g. phenylpyruvate, a-keto-y-methiol-butyrate) must 
be present, in which case rat renal p-lyase activity is increased by up to 30 times (Stevens 
et al, 1986b) and for human renal cytosolic, about 1.3-fold greater (Lash et al, 1990). 
Addition of a-keto acid stimulates P-lyase activity by being transaminated into amino 
acids. Buckberry et al, (1990), have reported that there are two human renal cytosolic P- 
lyase enzymes, which have identical isoelectric points but different M.W. Physico­
chemical and biochemical properties of both are identical with GTK.
44
a) NHzI
R-S-CHg-CH-COOH
C y s te in e  S -c o n ju g a te
O
I I
R-SH + CH 3 -C-COOH + NH3
Thiol P y ru n a te  A m m o n ia
CO OH
K ynuren in e
k y n u re n in a s e
HoO H
+ NH2
A nthran i l ic  ac id
+  C H 3 - Ç H - C O O H  
NH2
A lan ine
C) o  C O O H
I w "  H
K ynuren in e
K A T
^C O O H
K ynuren ic  ac id
d)
COOH 
H - C - NHo
I
CH2
I
CH2
CONHo
G lu tam in e  t r a n s a m i n a s e
OII
R-C-COOH
NHg
R-CH-COOH
COOH
C=0
I,
CH2 
I  ^
CH2
I
CONH2
Fig. 1.9: The different reactions catalysed by; a) p-lyase, b) Kynureninase, c) Kynurenine 
Aminotransferases (KAT), d) Glutamine Transaminase K (GTK) (From, Harries HM, 1997). 
Reactions a) and b) are performed in the liver, and reactions a, c and d, are performed in the 
kidney
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1.5.3.3. Rat liver cysteine S-conjugate P-lyase/ Kynureninase
Rat liver P-lyase, was first isolated by Tateishi et al, (1978), and catalyses the cleavage of 
the thioether linkage in cysteine conjugates of aromatic compounds such as 2,4- 
dinitrobenzene and p-bromobenzene. It has been purified about 500-fold from rat liver 
cytosol and is a PLP-containing enzyme identical to kynureninase (Fig 1.9b). The enzyme 
has a M.W of about lOOkDa and is composed of two identical subunits (Mr 55kDa). 
Kynureninase is the enzyme by which kynurenine (a metabolite of tryptophan) is 
converted to anthranilic acid and alanine.
1.5. 3. 4. Rat kidney cysteine S-conjugate P-lyase / Glutamine transaminase K
In (1993), Perry et al, reported the amino acid sequence of a rat kidney cytosolic S- 
conjugate p-lyase for the cDNA. The authors showed that the monomer has a Mr of 
47,800 and contains a conserved PLP binding site. Shortly after the report of (Perry et 
a/., 1993). Mosca et al, (1994) reported the deduced amino acid sequence for rat kidney 
kynurenine pyruvate aminotransferase. The enzyme expressed in COS-1 cells exhibited 
both Glutamine transaminase K (GTK) activity (i.e., ability to catalyse the characteristic 
transamination reaction between L-phenylalannine and a-keto-y-methiolbutyrate) and 
kynurenine aminotransferase activity. The amino acid sequence deduced by Mosca et al, 
(1994) for kynurenine pyruvate aminotransferase was identical to that published 
previously by Perry et al, (1993) except for a Val for lie at residue 177 and an Ala for 
Arg at residue 107.
Mosca et al, (1994) assumed that because their expressed enzyme exhibited appreciable 
GTK activity and because the kidney cysteine S-conjugate P-lyase characterized by Perry 
et al, (1993) also possessed GTK activity the three enzymes (i.e., cytGTK, kynurenine 
pyruvate aminotransferase and cytosolic kidney cysteine S-conjugate p-lyase) were 
identical i.e, the same protein entity was able to perform all three reactions. However, the 
situation is more complicated. Certainly, kynurenine aminotransferase possesses 
appreciable cystein S-conjugate p-lyase and GTK activities. However, Abraham and 
Cooper, (1996) resulted in the characterization and cloning of a GTK that is slightly 
smaller than kynurenine pyruvate aminotransferase. The GTK cloned by Abraham and 
Cooper (1996) had appreciable cysteine S-conjugate p-lyase activity and some
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kynurenine pyruvate aminotranferase activity. Evidently, the two enzymes exhibit 
considerable overlap in substrate specificity.
The various reports also highlight the difficulties of working with multifunctional 
enzymes. In particular overlapping specificities may have led to contradictory reports in 
the literature. Perry et al, (1993) stated that the mRNA for kidney cysteine S-conjugate 
p-lyase could only be detected in the kidney cytosol and not in the liver cytosol, yet the 
liver contains appreciable glutamine transaminase (GTE) activity (-30% the specific 
activity of that in the kidney) (Cooper, 1988 and Jones et al, 1988). However GTL is a 
different enzyme. The same group (MacFarlane et al, 1988) reported that cysteine S- 
conjugate p-lyase/GTK is present only in the S3 region of the nephron, whereas Jones et 
al, (1988) reported GTK to be present in the SI, S2, and S3 regions.
Cysteine conjugate p-lyase/GTK/KAT activity is present in cytosol and to a lesser extent 
in mitochondria. With 2mM S- (2-benzothiazolyl)-L- cysteine (BTC), as the substrate 
about two-thirds of the total renal P-lyase activity was present in the cytosolic fraction. 
Rat renal P-lyase was isolated, purified and characterised from kidney cytosol by Stevens 
et al, (1986b) and is a lOOkDa dimer of two 55kDa subunits. The enzyme also has 
phenylalanine a-keto-y-methiolbutyrate transaminase activity. It is thermostable and PLP- 
dependent, with an optimum pH of 8 .8 . Mitochondrial forms of the enzyme, which 
possesses glutamine transaminase K (GTK) activity also were isolated (Lash et al, 1986).
The kinetics of P-lyase activity with cysteine S-conjugates are different in the cytosolic 
and mitochondrial fractions, and the mitochondrial p-lyase enzyme was much more 
sensitive to inhibition by AOAA than the cytosolic one. These results indicated that p- 
lyase activity in the two subcellular fractions is catalysed by distinct enzymes. There is 
some dispute between researchers about the exact location of mitochondrial p-lyase since 
Lash et al, (1986), reported that using either BTC and or DCVC as substrate, p-lyase 
activity appeared to be located in the mitochondrial outer membrane. Mitochondria 
contain four compartments; the inner and outer membrane, the matrix space and the 
intermembrane space. Other studies have reported that 80-85% of glutamine transaminase 
activity in the brain is in the mitochondrial fraction (Cooper, 1988). In the liver however, 
mitochondrial p-lyase activity is in the matrix or intermembrane fraction.
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Abraham et al, (1995) isolated a high molecular weight protein (330kDa) in rat kidney, 
which had weak transaminase activity but did have DCVC-lyase activity. This enzyme 
was immunologically distinct from kidney cytosolic p-lyase/GTK/KAT and could not be 
detected in the brain (Cooper et al, 1993). It can metabolise leukotriene E4 and also 
cysteine conjugates to pyruvate, ammonia and a reactive sulphydryl-containing 
compounds. Abraham et al, (1995), proposed that p-lyase/GTK/KAT is not the major 
cysteine S-conjugate p-lyase activity of rat kidney mitochondria and that the high M.W 
enzyme fulfilled this role. However, this enzyme has little DCVC-and TFEC-lyase 
activity. Subsequently, Abraham and Cooper, (1996) isolated a cDNA encoding a rat 
kidney cytosolic GTK which had both GTK and p-lyase activities and was present as a 
homodimer with each subunit of molecular mass 45.8kDa. This enzyme bears a strong 
sequence similarity to other aminotransferases including 90% homology with that of 
Perry et al, (1993), Mosca et al, (1994). This information would suggest that at least 
two distinct enzymes exist in rat kidney cytosol, both of which have p-lyase/GTK/KAT 
activities. However, our laboratory (P. Goldfarb, personal communication) has found no 
evidence for a second closely-related p-lyase/GTK/KAT mRNA in rat kidney cells or for 
a second closely-related gene in rat genomic DNA.
In a recent study. Commandeur et al, (2000) showed that selenocysteine Se-conjugates 
are also metabolised by highly purified rat renal cysteine conjugate p-lyase/GTK/KAT. 
They used different S-conjugates and Se-conjugates as substrates and demonstrated that 
replacing the sulfur of cysteine S-conjugate by a selenium atom increased significantly 
the p-elimination activity. The specific activities of P-elimination of selenocysteine 
conjugates with n-alkyl-substitutions were 30-50 times higher than that of the 
corresponding cysteine S-conjugates and the Se-phenyl-L-selenocysteine showed 150- 
fold greater specific activity compare to S-phenyl-L-cysteine. This may be due to the 
weaker strength of the C-Se-bond (234 kJ/mol) versus C-S-bonds (272 kJ/mol).
1.5. 3. 5. Cysteine S-conjugate p-lyase / GTK / KAT in the brain
In the CNS, kynureninase metabolises kynurenine to quinolinic acid, a powerful neuro­
excitant, which activates the N-methyl-D-aspartate (NMDA) receptors. When quinolinate 
and certain other kynurenine metabolites were injected intracerebroventricularly in 
rodents, significant behavioural and convulsant effects were noted (Lapin, 1981).
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Therefore, imbalance in the production, transport and catabolism of kynurenine in the 
brain may lead to cerebral damage and may even be involved in the pathogenesis of some 
neurodegenerative and psychiatric diseases. A strong correlation was also found between 
the level of quinolate in cerebrospinal fluid and neurological impairment in human 
immune deficiency virus (HIV) patients (Heyes et al, 1990 and 1991).
Kynurenic acid (KYNA), is a broad-spectrum excitatory amino acid receptor ligand with 
neuroprotective and anticonvulsant effects, and is present in the brain of all mammalian 
species examined to date. The level of KYNA is highest in the human brain, where it 
occurs in micromolar concentration. Moroni et al, (1988), examined the biosynthesis of 
KYNA in cerebral tissues and showed that the human brain contains two enzymes that are 
responsible for the production of KYNA from L-kynurenine. These two kynurenine 
aminotransferases termed KAT 1 and KAT 11 could be physically separated by isoelectric 
focussing on a pH 3-10 ampholine gradient (Okuno et al, 1991). KAT 1, is a dimer 
consisting of two identical subunits of 60kDa and is clearly distinct from both human 
KAT 11 and rat kynurenine-pyruvate aminotransferase (Baran et a l, 1994). Rat brain 
KAT, a single enzyme which is also present in the kidney, has been purified and was 
shown by immunohistochemistry to be localised primarily in astrocytes (Roberts et al, 
1992) and also in medulla and spinal cord of rats (Kapoor et al, 1997). KAT 1 was 
distinguished by a pronounced preference for pyruvate as a co-factor, and have a pH 
optimum of 9.6 and was extensively inhibited by L-glutamine (Guidetti et al, 1997).
Human KAT 11 was active when either pyruvate or 2-oxoglutarate were used as the amino 
acceptor, its pH optimum is 7.4 and was blocked in part, by L-a-aminoadipate which had 
no effect on KAT 1 activity. Evidently, KAT 11 may be responsible for the production of 
KYNA under physiological conditions (Fig 1.9d) whereas, KAT 1 may play a role in the 
pathogenesis of neuropsychiatrie diseases, such as Huntington’s disease, characterised by 
abnormal brain KYNA synthesis and dysfunctional glutamine metabolism. Some studies 
reported that probenecid increases the concentration of KYNA by inhibiting the excretion 
of KYNA from the extracellular fluid and potentiates its effects in the brain in rat and 
mice (Vecsel et al, 1992; Miller et al, 1992; Lou et al, 1994 and Santamaria et al, 
1996).
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Alberati-Giani et al, (1995) isolated the cDNA encoding cytosolic KAT from rat brain 
only to discover that its sequence was identical to that of rat kidney cytosolic p-lyase/ 
GTK (Perry et al., 1993). Both mitochondrial and cytosolic forms of p-lyase are present in 
the human brain and when DCVC is used as a substrate, the only detectable form of p- 
lyase present in rat brain homogenates is identical to rat GTK (Cooper et al, 1993). In 
the rat brain about 80-85% of GTK activity is present in the mitochondrial fraction and 
studies have indicated that there may be two distinct enzymes (Cooper et al, 1993). Both 
the mitochondrial and cytosolic forms of p-lyase have been purified from rat brain and are 
PLP dependent enzymes (Tamburin, 1999; Hodgkin, 1999 and Knyihar-Csillik, 1999).
1.5.4. P-lyase mediated toxicity: Target organ specificity
Although p-lyase is distributed in many tissues and is found in the intestinal micro flora in 
rat, the S3 region (pars recta) of the kidney proximal tubule of rat is the most susceptible 
organ to the nephrotoxicity induced by cysteine conjugates. In man, the main effect of 
cysteine conjugates is neurotoxicity (Schaumburg, 1992), and nephrotoxicity is a minor 
side effect. Factors, which play an important role in organ specific toxicities, are:
(i) Tissue distribution of metabolising enzymes which may activate the
compounds
(ii) Distribution of toxic metabolites amongst the body tissues
(iii) Presence of deactivating enzymes and other defence mechsnisms
I.5.4.I. Nephrotoxicity of p-lyase substrates
The mammalian kidney is a complex organ, both anatomically and fimctionally. In 
addition to the extraction of end products of metabolism, the kidney plays a significant 
role in the regulation of total body homeostasis. It is the predominant organ in the 
regulation of extracellular fluid volume and electrolyte compositions. The kidney is also 
a major site of the formation of hormones that influence systemic metabolic function 
including erythropoietin, 1, 25-dihydroxy vitamin D3, renin and several vasoactive 
prostanoids and kinins. Therefore, toxic insult to the kidney could affect any or all these 
functions. Factors which make kidney particularly susceptible to damage include:
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(i). Concentrating mechanisms'. As water and electrolytes are reabsorbed from the 
glomerular filtrate, the materials remaining (including potential toxicants) in the 
urine may be concentrated. Thus a non-toxic concentration of a chemical in the 
plasma could become toxic in the kidney subsequent to concentration within the 
urine. It should be noted that rat urine is more highly concentrated than human 
urine.
(ii). Renal blood flow: Total blood flow in human, rat and dog ranges from 3 to 5 
ml/min/g of kidney. In a normal human male, renal blood flow is about 2 0 -2 5 %  
of cardiac output and because of this high blood flow, any drug or chemical in the 
systemic circulation will be delivered in relatively high amounts to this organ.
(iii). Xenobiotic metabolism: Many xenobiotic metabolising enzymes are expressed 
in the kidney. Some of these enzymes are glutaminases (Curthoys and Lowry, 
1973), alkaline phosphatase, glutamate dehydrogenase, lactate dehydrogenase and 
glucose-6 -phosphate dehydrogenase (Schmidt et al, 1971), glutamine synthetase 
(Burch et al, 1978), aspartate aminotransferase and alanine aminotransferase 
(Chan et al, 1979), gamma-glutamyl transpeptidase (Shimada et a l, 1982), 
glutathione-S-transferase (Fine et al, 1975), Na-K-ATPase (Katz et al, 1979), D- 
galactosidase, N-acetyl-P-D-glucoseaminidase (LeHir et al, 1980) and glutamine 
transaminase K. Although renal xenobiotic metabolism is quantitatively much 
less than hepatic metabolism, in some specific cases kidney metabolism may play 
an important role in nephrotoxicitiy
(iv). External factors: The kidney is sensitive to external factors that would 
decrease blood pressure or blood volume. Because the kidney is under the 
influence of the sympathetic nervous system, any change in systemic homeostasis 
that would alter sympathetic nerve activity could also influence kidney function.
(v). Kidney architecture: The rat kidney tubule is substantially longer than the 
human tubule due to the greater requirement for water conservation. This makes 
the rat kidney more susceptible than that of man.
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The organ specific toxicity observed with cysteine conjugates has been studied 
extensively in rat. MacFarlene et al, (1989) reported that the nephrotoxicity induced by 
HCBD was specific to the areas of localisation of cysteine conjugate p-lyase enzyme 
protein, as demonstrated using immunohistochemical techniques. The location of cysteine 
conjugate p-lyase was primarily in the S3 or pars recta segment of the proximal tubule. 
This enzyme also is found in both Si and S2 segments of the pars convoluta. The pars 
recta is known to be the site of accumulation of N-acetylated cysteine conjugates which 
are produced via cysteine conjugate p-lyase and subsequent N-acetylation. The 
distribution and specificity of other enzymes such as glutathione transferases, y-glutamyl 
transpeptidases, dipeptidases, acylases, deacylases and other cysteine conjugate p-lyases 
also determine the site of nephrotoxicity together with sulphoxidation reactions, the 
availability of a-keto acids and the transport systems.
Bimer et al, (1993), showed that workers exposed to trichloroethylene (TCE) produced 
appreciable amounts of the two mercapturic acids, N-acetyl-1, 2-DCVC and N-acetyl-2, 
2-DCVC, in their urine. The concentrations of mercapturates present in urine are 
dependent on the balance between acétylation and deacetylation of the cysteine 
conjugates, and the levels of deacetylase in rat and human kidney cytosol were found to 
be comparable. Muti et al, (1992) reported that workers occupationally exposed to the 
dry cleaning fluid, perchloroethylene, had renal changes with diffuse abnormalities 
occurring at the glomerular, proximal and distal tubules level. These abnormalities were 
not comparable with the acute damage observed in rats. Henschler et al, (1995) reported 
an increased incidence of renal cell tumours in workers occupationally exposed to TCE, 
and their results suggested that exposure to high concentration of TCE over prolonged 
periods of time may cause renal tumours in man. In experimental animals, the region of 
kidney, which is the most susceptible to cysteine conjugate toxicity, is the proximal tubule 
and in man this region is where the renal carcinomas arose (Cordon-Cardo et a l, 1989).
1.5.4.2. Neurotoxicity of P-lyase substrates
There is much evidence, which supports the localisation of p-lyase activity in brain tissue. 
Cooper et al, (1993) reported that there is widespread GTK activity in rat brain with the 
highest activity in the choroid plexus.
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In the rat, the areas of brain, which possibly may be most sensitive to quinolinate- 
neurotoxicity, are hippocampus and striatum (Stone, 1993). Any alteration or imbalance 
in kynurenine metabolism in these areas would produce marked effect on brain function, 
leading to several neurological disorders.
Jauch et ah, (1995) examined the level of kynurenic acid, and the activity of KAT I and 
KAT II in 12 regions of the brain of patients which suffer from the late-stage of 
Huntington’s disease. These authors showed that, a selective impairment of kynurenic 
acid biosynthesis in the neostriatum of these patients may possibly be due to a loss of an 
endogenous KAT activator.
Reichert et al, (1976) examined the hypothesis that the neurotoxicity of dichloroacetylene 
(DCA) may be associated with glutathione S-conjugate formation, brain uptake and P- 
lyase biotransformation of dichloroacetylene-derived S-conjugates to toxic metabolites. 
They exposed rabbits to 17, 126, 202 and 307ppm DCA by inhalation. For this reason 
animals were placed in special cages with only the mouth and nose exposed to the 
DC A/air mixture. They reported that DCA is converted to DCVG and DCVC, which can 
cause trigeminal neuropathy in animals and man. Although both DCVG and DCVC 
penetrate into the brain, the data indicated that DCVC but not DCVG was transported by 
the sodium-independent system-L transporters for neutral amino acids. They also reported 
that uptake of the S-labelled-S-conjugates was inhibited by unlabeled DCVC and DCVG 
in a concentration-dependent manner, which may be due to saturation of the carrier 
systems responsible for the transport of DCVG and DCVC across the blood-brain barrier. 
Schaumburg, (1992) reported that workers who were occupationally exposed to 
trichloroethylene, suffered from facial cold sores and trigeminal analgesia, which was 
sometimes accompanied by facial paresis, ptosis, dysarthria, vocal chord paralysis, visual 
loss and dysphagia. Post mortem examination of some patients showed neuronal 
degeneration of brain stem sensory nuclei of the trigeminal nerve and degeneration of 
axons within its tract.
1.6. The mechanism of p-lyase reaction
Cysteine conjugate P-lyase is a pyridoxal phosphate (PLP) dependent enzyme, which can 
cause P-elimination to form pyruvate, ammonia and a sulphur containing thiol.
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The reaction proceeds via an eneamino acid intermediate, which has carbonium ion 
character at the p-carbon (Bild and Morris, 1984), and is responsible for inactivation of 
enzyme. Stevens et al., (1986a) studied the metabolism of DCVC, using LLC-PKi cells 
as a model, and suggested a reaction scheme for p-lyase (Fig 1.10).
They proposed that if  the free amino group of DCVC forms a schiff‘s base with PLP, two 
reactions are possible:
(i). p-elimination, which yields pyruvate, ammonia and a thiol- containing 
compound
(ii). Half-transamination reaction, which leaves the enzyme in its pyridoxamine 
form
The presence of a a-keto acid acceptor for the amino group of pyridoxamine, converts the 
enzyme to a catalytically active form (pyridoxal phosphate) able to catalyse further p- 
elimination reaction. Following half-transamination, the enzyme accumulated in the 
pyridoxamine form, inhibiting further P-elimination, since the cysteine conjugate 
substrate cannot form a Schiff’s base. It has been demonstrated that 65% of DCVC was 
metabolised to its corresponding a-keto acid, (S-1, 2-dichlorovinyl-2-oxo-3- 
mercaptopropionate) of which, 35% is produced by transamination via p-lyase and 30% is 
the product of metabolism by L-a-hydroxy acid oxidase (Stevens et al, 1989). 
Transamination is carried out by PLP-dependent transaminase enzymes, which are 
derived from pyridoxine, during transamination. PLP is converted to pyridoxamine 
phosphate (PMP). As mentioned before, PLP is regenerated by reaction of a a-keto acid 
with the enzyme-PMP complex, giving rise to an enzyme-PLP complex.
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from Stevens et al, 1986a)
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1.6.1. The mechanisms of transamination
Transamination reactions play an important role in the body. One of these reactions is 
glutamine transamination, by the enzyme GTK. By transamination reactions amino acids 
are converted to a-ketoacids, which are toxic to the nervous system. Therefore, 
transamination of glutamine by GTK leads to reamination of these a-ketoacids to related 
amino acids.
Eqa. 1.16
GTK
L -  glutamine + a-ketoacid --------> a-ketoglutaramate + L -  amino acid
Most of the transamination reactions in the body are easily reversible, but of glutamine 
and a-ketoacids is irreversible (Cooper and Meister, 1974). All transaminase enzymes 
are pyridoxal phosphate (PLP) dependent, which is derived from pyridoxine (vitamine 
Bô). During transamination the PLP (active form) is converted to its inactive form 
pyridoxamine phosphate (PMP) (Walsh, 1979). When there is no substrate, the aldehyde 
group of PLP forms a Schiff s base with S-NH2 group of a lysine residue in the active site 
of enzyme. In the presence of amino acids (substrate), S-NH2 is replaced by the a-amino 
group of substrate (Fig 1.11).
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1.7. Mechanisms of toxicity and regeneration in the kidney
Gross examination of a sagital section of the kidney reveals two major anatomic areas, the 
cortex and the medulla (Fig 1.12). The cortex constitutes the major portion of the kidney 
and receives most of the nutrient blood flow to the organ (Goldstein and Schnellmann, 
1998). The nephron is the functional unit of the kidney (Fig 1.13). Each nephron includes 
three portions: the vascular element, the glomerulus and the tubular elements. All 
nephrons have their vascular elements and glomeruli in the cortex. The proximal 
convoluted tubules are localised in the cortex and the pars recta (straight portion) and 
loops of Henele are the medulla of the kidney. Each element of the nephron has specific 
functions and may be influenced by different nephrotoxicants. The cellular response to a 
toxic insult may vary from biochemical aberration to cell death and necrosis. 
Functionally, toxicity may be observed as a spectrum of events from minor alteration in 
transport capability, e.g, polyuria with decreased concentrating capacity, to full renal 
failure with anuria and elevated Blood Urea Nitrogen (BUN). Depending on the 
magnitude of the toxic insult, the changes can be permanent and lethal.
1.7.1. Sites of action of tubular nephrotoxicants
The adult rat kidney contains approximately 30,000 nephrons, whereas the human kidney 
contains about one million. Each nephron consists of renal corpuscle (glomerulus plus 
Bowman’s capsule) and at least 12 morphologically and functionally distinct tubular 
segments. The portion of the kidney, which is most susceptible to nephrotoxicants is the 
proximal tubules. The proximal tubules consist of three segments; the SI (pars 
convoluta), 82 and S3 (pars recta) segments (Tisher and Madsen, 1991). The SI segment 
is the initial portion of the proximal convoluted tubule and the cells of this segment are 
characterised by a tall brush border, abundant mitochondria and a well-developed 
vacuolar lysosomal system. Cells of the S2 segment possess a shorter brush border and 
fewer mitochondria compare to SI. The S3 cells have a well-developed and intermediate­
sized brush border, but fewer and smaller lysosomes and mitochondria than SI and S2. 
The proximal tubule segments also display marked biochemical and physiological 
differences (Goldstein, 1993). The S3 segment is the most sensitive to the toxicity of 
cysteine conjugate metabolites, this might suggest that the cells of S3 segment are 
inherently more sensitive to nephrotoxic cysteine conjugates than the cells of th SI and S2 
segments. Alternatively there may be more production of the toxic species in the
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S3 segment (Jones et al, 1988).
1.7.2. Kidney tubule regeneration
Regeneration can be defined as the process by which an organism reconstitutes parts of 
the body that have been lost or injured. It is perhaps one of the most fascinating and 
complete patterns of tissue response. Although the capacity to regenerate is observed 
throughout the animal kingdom, important variations can be seen in this respect between 
systematic groups, without any clear relationship to evolutionary status. Whereas some 
groups of invertebrates, such as the coelenterates, annelids, fiatworms, echinoderms, and 
crustaceans, exhibit a surprising ability to replace missing parts of the body, this ability is 
considerably restricted in other groups.
In mammals, tissues other than skin and bone also possess repair capability, although it 
varies in extent according to the type of cell involved and other factors, such as 
vascularization. On the one hand, the mucosae of gastrointestinal tract, the respiratory 
tract, and the urinary tract all display excellent repair capacity since, physiologically the 
cells of mucosal surfaces are continuously lost and replaced throughout life. On the other 
hand, the opposite is found in the central nervous system, which cannot replace the loss of 
nerve cells. As a consequence, the repair of toxin-induced injury is relatively site- 
specific, especially when it occurs within internal organs such as the kidney or liver.
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There are examples in humans, and some experimental animal models where extensive 
tubular cell necrosis is associated with failure of renal function. Important biochemical 
abnormalities in acute renal failure include a reduction in the cytosolic concentration of 
ATP and an increase in cytosolic calcium, alteration in the cytoskeleton, generation of 
free radicals and reduced protein synthesis (Weinberg, 1991). However the kidney, in 
contrast to many other organs, possesses a capacity for regeneration after acute ischemic 
and/or toxic injury. This regeneration capacity manifests itself as proliferation and 
migration of young cells along the denuded basal membrane of the injured segment within 
24 hrs of the acute insult (De Broe, 1998). Also the presence of injured cells may actually 
stimulate a proliferative response by other cells. A schematic response to renal injury is 
presented in Figure 1.14.
Recovery fi*om a nephrotoxic injury requires tissue repair and regeneration. Typically 
there is an early and transient increase in DNA synthesis following injury (Hammerman 
and Miller, 1994). A chemical can initiate cell injury by different mechanisms. In some 
cases the chemical may initiate toxicity due to its intrinsic reactivity with cellular 
macromolecules. Some chemicals are metabolised to reactive intermediates that bind to 
cellular macromolecules such as proteins and lipids. Finally some chemicals may initiate 
injury indirectly by inducing oxidative stress, e.g., by increasing the concentrations of 
superoxide anion, hydrogen peroxide and hydroxyl radicals. These can cause lipid 
peroxidation, inactivation of cellular enzymes and DNA strand breaks. Each of these 
mechanisms could lead to cell injury and/or death. Dead cells could be replaced by 
proliferation of non-injured cells and/or non-lethally injured cells that have recovered. 
Non-lethally injured cells that are dysfunctional can die or can subsequently recover 
function and structure. Growth factors are likely play an important role in the proliferative 
response of non-injured cells and even in the recovery of non-lethally injured cells.
Peptide growth factors such as epidermal growth factor (EOF), insulin-like growth factor 
1 (lGF-1) and hepathocyte growth factor (HGF), fibroblast growth factor (FGF) and 
transforming growth factors a  and p (TGF a  and P) which have been implicated in 
proximal tubular regeneration (Hammerman and Miller, 1994; Gheilli et al, 1998 and
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Fig 1.14: Physiological and biochemical responses to a 
nephrotoxic insult (Goldstein and Schnellmann, 1998).
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De Broe, 1998) and are released in response to physiological signals (Mendley and 
Toback, 1990). Physiological signals that release growth factors include the lowering of 
the extra-cellular potassium or sodium concentrations (Walsh-Reitz et al, 1984 and 1986) 
which are common in acute renal failure. As growth factors alter ion and nutrient 
transport and other aspects of cell metabolism, these effector molecules could also 
mediate repair of biochemical and/or sub-cellular injuries and thereby allow an injured 
cell to recover (Toback, 1992). In addition growth factors could stimulate the transition 
of cells from the Go to Gi phase of the cell cycle and possibly speed protein and 
phospholipid synthesis for the formation of brush border and basolateral membranes.
Park et al, (1997) showed that renal tubular regeneration after ischemic injury is coupled 
to the up-regulation and activation of cyclin and cyclin dependent kinases (CDKs). In this 
study they measured the extent of proliferative activity and expression of cyclin and 
CDKs during the regeneration period in the outer medulla of the rat kidney after ischemic 
injury. They also demonstrated that the ratio of proliferating cell nuclear antigen (PCNA) 
immuno-stained nuclei to total nuclei per section of the outer medulla increased after 
ischemic injury.
1.7.3. Apoptosis in the kidney
Apoptosis (programmed cell death) has an important role in the normal function and 
development of the kidney. Apoptosis is a common response to injury in cells exposed to 
modest ischemia or to toxins at concentration below those required to induce metabolic 
collapse and necrosis.
Apoptosis of cells within the kidney during organ development and during regeneration of 
tubules following renal damage ensures proper nephron development and tubular repair 
(Davis and Ryan, 1998). Apoptosis also protects the kidney by eliminating cells 
containing damaged DNA. At any given time, between 3% and 5% of cells in developing 
kidney are apoptotic. It has also been estimated that in the developing kidney, 1 cell dies 
for every 2-4 cells produced by division (Coles et al, 1993). The regeneration process of 
the damaged kidney would not be successful without an increase in apoptosis. During the 
regeneration phase of tubular injury, there is an increase in both cellular proliferation and 
apoptosis. Excess cells produced during regeneration are removed both by desquamation 
into the lumen and by apoptosis (Shimizu and Yamanaka, 1993). Following acute
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necrosis of proximal tubules. There are 2 apoptotic peaks that occur between 1-3 days 
and around 7 days after the injury. By 4 weeks, the level of apoptosis decreases to base 
line levels (Shimizu and Yamanaka, 1993). It is estimated that the entire process of 
apoptosis, fi*om the first structural changes to ingestion by phagocytes, takes ~2 h. In fact, 
the removal of apoptotic cells is so rapid that they are extremely difficult to detect in 
histological sections (Wyllie et al, 1980 and Raff et al, 1993).
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1. 8. Hexachlorobutadiene (HCBD)
1,1,2,3,4,4-Hexachloro 1,3-butadiene, other synonyms; hexachlorobutadiene,
perchlorobutadiene trade names; C46 and Dolon-par) is a by-product of the industrial 
manufacture of certain major chlorinated hydrocarbons.
1.8.1. Agricultural and industrial uses of HCBD
While HCBD is normally viewed as industrial waste and/or an environmental pollutant, it 
has been used in agriculture and industry. In Russia it is used in small quantities as a 
vineyard fumigant against Phylloxera on grapes. It is also used as an agricultural fumigant 
in other coimtries such as; France, Italy, Greece, Spain and Argentina. In industry, it is 
used as solvent for elastomers, as a heat-transfer liquid, a wash liquid for removing of C4 
and higher hydrocarbons and as a fluid for gyroscopes. As a widely distributed 
environmental contaminant (Yang RSH, 1988 and Bemdt et al, 1979). HCBD has been 
reported in domestic and wild animals including sheep, chicken, terns, fish and, also in 
man (Laska e/fl/., 1976).
1.8.2. Physiochemical properties of HCBD (Callahan et al, 1979; Baneijee et al, 1980 
and Ruth, 1986)
Chemical formula: C4CI6
Molecular weight: 260.7
Physical state (25°C): Clear, colourless liquid
Odor: Faint turpentine like odor
Boiling point (at 25mmHg): 210 -  220°C
Melting point: -19 to -22°C
Density (at 20°C): 1.55 - 1.64g/ml
Vapour pressure: 0.15mmHg
Water solubility (at 20°C): Insoluble
Octanol /water partition coefficient: 3.74
Odor Threshold (air): 12mg /m^
Conversion Factor: Ippm = 10.66mg /m^, Img Ivol = .0938ppm
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1.8.3. Environmental fate of HCBD
HCBD is biodegraded in soil aerobic zones but not in anaerobic zones. HCBD is strongly 
adsorbed to organic materials in soil. Its estimated half-lives are, 3-30 days in river water 
and 30-300 days in lake and ground waters. In the atmosphere, HCBD is also degraded by 
photooxidation via addition of hydroxyl radicals to its double bonds. Where HCBD 
reaches the soil surface, evaporation is a significant mechanism of release because of its 
low vapour pressure (O.lSmmHg, at 20°C).
1.8.4. Pharmacokinetics of HCBD
There is little quantitative pharmacokinetic data on HCBD, most available data being 
firom animal studies. HCBD is a highly lipophilic compound and hence can readily cross 
biological membranes. Its oral absorption is dose dependent; at low doses (Img /kg) it is 
absorbed rapidly but at higher doses (50mg /kg) absorption is incomplete. At high doses, 
about 69% and at low doses about 42% of HCBD is excreted unchanged in the feces. The 
renal excretion of HCBD metabolites is 11% of administrated dose (at the high dose), and 
31% at the low dose (Reichert et al., 1985). Like other halogenated hydrocarbons, HCBD 
is metabolised via GSH-conjugate formation. HCBD is initially transported to the liver, 
where it is conjugated with glutathione. This conjugate is excreted in the bile and 
transported intact or as the cysteine conjugate to the kidney (Dekant et al, 1990). There 
the conjugate can be transformed to S-(pentachlorobutadienyl)- cysteine (PCBC), which 
can be converted by a p-lyase to the reactive intermediate tetrachlorobutadienylthioketene 
(Fig 1.15). Alternatively, following N-acetylation in renal tubular cells, mercapturic acid 
is formed and excreted in urine. Other metabolites are also formed via deamination and 
subsequent decarboxylation of the cysteine adduct. HCBD and its metabolites are 
excreted both in the urine and feces (Reichert et al, 1985 and Nash et al, 1984). Bimer 
et al, (1998) reported that HCBD can also be converted to metabolite, N-acetyl-S 
(1,2,3,4,4- pentachloro butadienyl)-L-cysteine sulphoxide (N-AcPCBC-SO), which is 
mediated by cytochrome P4 5 0 3 A4 and is cytotoxic to proximal tubular cells in vitro 
without activation by B-lyase.
Recent studies (Pahler et al, 1997) have indicated that HCBD is capable of binding to 
ct2u-globulin, a sex dependent protein, which is synthesised by the liver of young male 
rats. These findings explained the excretion of this highly lipophilic compound unchanged
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(about 10% over 48h) in the urine. However in another study, Pahler et al, (1999) 
reported that the accumulation of a 2u-globulin has been implicated in the tumorigenicity 
of many non-genotoxic chemicals to the kidney of the male rats. Binding of chemicals to 
ot2u- globulin impaired the renal degradation of a 2u-globulin, resulting in lysosomal 
overload cell death, increased cell proliferation and renal tumour formation. a 2u-globulin 
is a low molecular weight plasma protein (MW 21.4kDa), also called retinal binding 
protein (RBP). The free RBP is rapidly eliminated by glomerular filtration then 
reabsorbed and catabolised by PT cells. In the rat a 2u-globulin is freely filtered and taken 
up by tubules with a low efficiency, so it is poorly reabsorbed and accumulates in PT. As 
the rat becomes older the relative contribution of oc2u-globulin to total protein decreases 
(Stonard et al, 1987).
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1.8.5. Mechanism of HCBD Nephrotoxicity
HCBD is a potent nephrotoxin (Lock et al, 1979), which can cause degeneration, necrosis 
and regeneration in renal tubular epithelial cells (Kociba et al, 1977; Schwetz et al, 
1977; Bemdt et al, 1979; Yang et al, 1989 and Kirby and Bach, 1995). The toxicity of 
HCBD to the kidney is modulated by a probenecid sensitive transport process (Ban and 
Ceaurriz, 1988). Also Hook et al, (1983) reported that the nephrotoxicity of HCBD is 
age, sex and strain related. They dosed the animals with the range of 25-400mg/kg, ip, at 
5ml/kg body weight, and showed that male adult rats are less susceptible than female 
adult or young male rats. 50mg/kg in females produced changes similar to those seen with 
200mg/kg in males. The proximal tubule is the portion of the nephron with greatest 
sensitivity to nephrotoxic effects of chemicals and is also the site of several metabolic 
activities of organic ion accumulation. The main area of the tubule which is damaged by 
HCBD is the S3 or pars recta segment, an area which is rich in p-lyase activity. The 
toxicity of HCBD is due to metabolism to a reactive thiol derivative, which covalently 
binds to macromolecules independently of the dose. This covalent binding also agrees 
well with the organ specific toxicity of HCBD, namely binding is higher in the kidney 
(Yang gr a/., 1989).
The evidence suggests that energy metabolism in mitochondria may be compromised 
upon release of reactive species from cysteine S-conjugates. HCBD decreases ATP levels 
in whole kidney and in the S2 region of kidney tubules of treated rats but ATP levels in 
S3 segment were slightly increased. The finding may be explained by a possible loss of 
fiinctions that require ATP (Kim et al, 1997). In addition, the distribution and specificity 
of other enzymes such as GSH-transferases, y-gt, dipeptidase, acylases, deacylases and 
other cysteine-conjugate P-lyases also determine the site of nephrotoxicity of HCBD 
(Looketal, 1984).
Kociba et al, (1977) dosed rats with 0, 0.2, 2 and 20mg HCBD /kg-day, for up to 2 years. 
They found multiple toxicological effects, including lower body weight gain (more than 
10% depression in both male and female rats), increased mortality, increased kidney 
weights, increased renal tubular hyperplasia, and renal tubular adenomas and 
adenocarcinomas (some of these metastasised to the lungs) in rats exposed to HCBD 
20mg/kg/day for up to 2 years. Less toxicity, but including in renal tubular hyperplasia
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was found in rats ingesting 2 mg/kg-day of HCBD for up to 2 years and no effects were 
seen in rats ingesting 0.2 mg/kg-day for up to 2 years. The toxicological changes in the 
kidney progressed over time and the data as a whole suggest that the renal tumour 
formation resulted from the initial cytotoxicity and tubular regeneration induced by 
exposure to HCBD.
In a further study Reimschuessel et ah, (1990) have shown the effects of HCBD in the 
goldfish kidney. They injected 500mg /kg, ip. as single dose, and demostrated that there 
was extensive vacuolation and necrosis on the epithelial cells of the second and third 
segments of the nephron during the first five days after treatment. In this study they also 
demonstrated the ability of the goldfish kidney to develop new nephrons after HCBD- 
induced nephtrotoxicity.
Kirby and Bach, (1995) reported that HCBD treatment also changed certain urinary 
parameters in the rat, namely an increased urinary volume (10-fold), protein (5-fold), 
glucose (175-fold) and content of brush-border enzymes such as alkaline phosphatase 
(600-fold) and alanine aminopeptidase (10-fold), again indicating proximal tubular 
damage. Most parameters returned to normal levels after single dose HCBD exposure. In 
another study, Stonard et al, (1987) reported that HCBD at single oral dose of 200mg/kg, 
increased urinary excretion of glucose and protein in the rat within 24hr, the peak being 
seen on day 2 for glucose and day 4 for protein.
1.8.6. Neurotoxicity of HCBD
The nervous system has several unique anatomical and physiological features, which 
make it susceptible to the toxicity of those xenobiotics which can cross the blood-brain- 
barrier:
(i) For production of energy, neurons are dependent upon aerobic glycolysis. 
Since neurons have no significant stored energy reserves, they must have a 
constant supply of glucose and oxygen to provide their energy requirements. Thus 
any factors that interrupt the supply of glucose or oxygen, even for a short time, 
may cause damage or even death of neurons.
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(ii) The presence of certain enzymes in the CNS such as p-lyases, glutathione S- 
transferases, some families of cytochrome P450, including CYP lA l and 1A2 
(Morse et al, 1998), IB l (Reider et al, 2000) and also epoxide hydrolase, 
cytochrome P450-linked monooxygenase, NADPH: cytochrome P450 reductase 
and 1-naphthol UDP-glucuronosyl transferase (Ghersi-Ehea et al, 1988), which 
are able to metabolise xenobiotics.
(iii) The nervous system has a high content of lipid especially in myelinated nerve 
fibres, so many lipid soluble toxins can cross the blood-brain-barrier and 
accumulate in the nervous system.
(iv) Neurons of the central nervous system have lost the ability to undergo cell 
regeneration. Therefore any neurons, which are lost due to toxic damage, cannot 
be replaced.
Because HCBD is a highly lipophilic compound, it can cross biological membranes 
including the blood-brain-barrier as the cysteine conjugate, and could undergo a 13- 
elimination reaction by the GTK / KAT / 13-lyase enzyme activity in the brain to produce a 
toxic thiol. Indeed some studies have already suggested that HCBD is also a neurotoxin. 
It has been reported that administration of SOOOppm HCBD for 15 days to rats caused 
some abnormal clinical signs such as lethargy, hunched posture, piloerection, sensitivity 
to light, demyelination and fi*agmentation of femoral nerve fibres, and lack of motor 
coordination (Gradinski et al, 1975; Bemdt and Mehendale, 1979; Harleman and Seinen, 
1979; Jaffe et al, 1983 and Yang et al, 1989). However these findings have been 
neglected until now.
I.8.6.I. Biochemical and Cellular Mechanisms of Neurotoxicity
The biochemical and cellular mechanisms of neurotoxicity according to their toxic actions 
on the nervous system are as follow (Turton and Hooson 1998). Some neurotoxins may 
cause change in more than one of these categories.
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Interference with aerobic metabolism 
Interference with protein synthesis 
Interference with intermediate metabolism 
Change to cellular membranes 
Interference with neurotransmission 
Disturbances of axonal transport 
Damage to non-neuronal cells 
Damage to capillaries 
Damage to choroids plexus
1.8.6.2. The Choroid plexus as a target for toxicity
The word choroid or chorioid is derived from the Greek chorion (skin) which is applied 
generally to vascular membranes or structures. Plexus is derived from a Latin word for a 
twining, and refers to interwoven networks of blood, nerves and lymphatics. So the term 
choroid plexus generally is used to include three histological elements; the ependymal 
covering, the blood vessels and the connective tissue stroma (Netsky and Shuangshoti, 
1970). The choroid plexus is a tuft of capillaries, with a highly vascularised villous 
structure, which is covered by a special double-layered cuboidal epithelium (Fig 1.16). 
These two layers are sealed together where they join by occluding junctions. This 
maintains the integrity of the blood-brain barrier. Choroid plexus exist in all brain 
ventricles and microscopically 3 types of choroid plexus can be distiguished in adult rat 
brain. The lateral ventricle choroid plexus is a thin undulating veil, whereas the choroid 
plexus of the fourth ventricle is highly lobulated and more complex. The third ventricle 
choroid plexus is much smaller in size and has an intermediate appearance (Chodobski et 
al, 1999). The choroid plexus is attached to one side to the wall of the lateral ventricles 
and to the roof of third and fourth ventricles. The other side, which is free, projects into 
the ventricular cavity. The choroid plexus cells are secretory and have access to the blood. 
It is generally accepted that the choroid plexus plays a major role in the production and 
content of cerebrospinal fluid (CSF), although not all CSF is elaborated from it (Dandy 
and Blackfan, 1914 and Milhorat et al, 1971). Because numerous mitochondria are 
present in these cells they are energy-rich. Flexner, (1934) calculated the energy 
requirement of choroid plexus based on oxygen consumption, and found that it is the 
same as in the renal tubules.
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In a further study, Chodobski et al, (1999) indicated that CSF production is under the 
control of a precise neurohormonal regulation of the choroidal blood flow. CSF fills the 
normal spaces in the brain (ventricles) and flows around the outside of the brain and 
spinal cord. The fluid is formed by an active process at a rate that varies considerably 
from species to species but is rather constant when expressed as a fraction of total CSF 
volume or on the basis of plexus weight.
Electron microscope studies on the structure of the choroid plexus have been performed 
by various investigators. Yamadori, (1972) has reported the following results by scanning 
electron microscopy of the choroids plexus in adult rats:
(i) The choroid plexus consists of tortuous capillary blood vessels, an 
epithelial cell layer which covers their surface and connective tissue which 
is not seen from the surface.
(ii) Each epithelial cell has numerous microvilli on its free surface. These villi 
are neither branched nor fused, are variable in shape sometimes with a 
swollen tip. Their thickness is inconstant, even in a single microvillus.
(iii) Clusters of longer protrusions which possibly correspond to groups of 
ciliare scattered on the epithelial surface covered with microvilli.
A cluster cluster which consists of about ten or less cilia is seen in only a 
small proportion of the cells.
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Anatomically there is a difference between the capillaries of the choroid plexus and the 
brain. The wall of the choroidal capillary is fenestrated by pores with membranes, but in 
the brain, capillaries are not fenestrated and are closely invested by glial cells. These 
anatomical differences can explain that why some substances penetrate into the choroid 
plexus, the blood-CSF barrier, but not into the brain (Netsky and Shuangshoti, 1970 ). 
Keep and Jones, (1990) have shown that there is an increase in the number of 
fenestrations in the endothelium of plexus capillaries in rat between the 16* day of 
gestation and 30 days after birth. These fenestrations make choroid plexus capillaries 
more permeable and facilitate the movement of water and small solutes across the 
capillaries
Metabolic studies on the choroid plexus have revealed that it is also rich in enzymes 
which are necessary for active transport. Biochemical analysis of the choroid plexus has 
indicated that the general metabolic activity per unit weight is one third to one half the 
value for the kidney its developmental relative (Fisher and Copenhaver, 1959 reviewed by 
Masuzava and Sato, 1983). Various factors can affect CSF formation and choroid plexus 
function. Keep et al, (1987) showed that 20-day old rats which were fed a diet containing 
20% KCl, had lower body, brain and choroid plexus weights compare to controls and 
enhanced plasma K^ concentrations. In another study, Lindvall-Axelsson et al, (1989) 
investigated the effects of glucocorticoids on the choroid plexus. After 5 days of 
treatment with betamethasone, the CSF production rate in rabbits was reduced by 43%, 
and the transport capacity of the choroid plexus, particularly the N a \ K^ -ATPase activity 
decreased in both rabbits and rats. Faraci et al, (1990) showed that, acetazolamide, a 
carbonic anhydrase inhibitor, (25mg/kg, i.v) decreased production of CSF by 55%, 
despite a 2-fold increase in blood flow to the choroid plexus. Glucose is an essential 
factor, especially for the energy requirement for CSF secretion, so high glucose 
consumption is one of the characteristic features of the choroid plexus (Masuzawa and 
Sato, 1983). Epstein et al, (1977) have reported that intraventricular administration of 
chloera toxin, enhances production of CSF via stimulation of adenylate cyclase, but 
injection of ouabain, a Na K^ -ATPase inhibitor, reduces production of CSF (Welch, 
1963; Yates et al, 1964 and Smith et al, 1974).
The choroid plexus receives adrenergic and cholinergic inervation reaching both the 
secretory epithelium and the vascular smooth muscle cells (Lindvall and Owman, 1981).
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Electric stimulation of the sympathetic nerves decreases the production of CSF about 30% 
(due to (3-receptor stimulation). Blood flow in the choroid plexus is also decreased (due 
to vascular a-receptors). Sympathotectomy increases the formation of CSF 30% above 
control confirming that under normal conditions the choroid plexus is strongly under the 
influence of a sympathetic inhibition. CSF production rate is also reduced by 
cholinomimetic agents, suggesting the presence of muscarinic receptors in the choroid 
plexus.
New methods in receptor autoradiography, immunohistochemistry and molecular biology 
have revealed the presence of many different neuroendocrine effectors or their 
corresponding receptors in the choroid plexus (Nilsson et al, 1992 and Zheng et al, 
(1991). Among the substances present in blood and CSF, serotonin (5-HT), ANP, 
vasopressin and the Insulin-like growth factors (IGFs) have high receptor concentrations 
in the choroid plexus (Nilsson et al,. 1992). Zheng et al,. (1991) found that choroid 
plexus protected the CSF and brain tissue against toxic metals. In rats and rabbits lead, 
cadmium, mercury and arsenic accumulated in the lateral choroid plexus at concentrations 
10-100 fold higher than found in the CSF, brain or blood. The maturation of brain barrier 
systems in foetal, newborn, juvenile and adult rabbits has also been studied (Mitchell et 
al, 1982). They have compared choroid plexus and brain N a \ -ATPase levels in each 
age group, as well as CSF sodium concentration as a measure of the ability of the choroid 
plexus to generate a concentration gradient fi-om blood to CSF.
The choroid plexus is very vulnerable to pathological (ischemia) and chemical damage. 
In a study Johanson et al, (2000), produced a transient forebrain ischemia in adult rats by 
bilateral carotid occlusion and arterial hypotension. They showed that transient forebrain 
ischemia caused substantial damage to epithelial cells of the CP in lateral ventricles such 
as swollen mitochondria, clamped of nuclear chromatin and widespread necrosis. These 
alterations in cellular organelle configuration revealed a severe damage. When transient 
forebrain ischemia was followed by reperfusion, there was moderate to severe damage to 
many regions of the choroidal epithelium. Some cells were disrupted and necrotic but 
some of their neighbours exhibit normal morphology. This different response to ischemia 
is probably due to regional differences in reperfusion or cellular metabolism. Between 
12-24hr after ischemia, they observed a marked restoration in N a \ and water content
76
and also choroidal epithelial cells displayed an overall normal appearance. Because they 
could not find any evidence of mitosis, so they assumed that healthy epithelial cells 
compressed together on the villus or migrated from the choroid plexus stalk to more distal 
regions in order to “fill in gaps” along the basal lamina. In adult rats with exception in the 
stalk region, where the choroid plexus is affixed to the ventricular wall, the choroid 
plexus appeared unable to undergo mitosis so migration or displacement of the choroid 
plexus epithelial cells may help mechanically to reconstruct the epithelial of the villi 
disrupted by ischemia. Several growth factors were upregulated in choroid plexus after 
ischemic insults to the CNS. These growth factors have an important trophic role 
following injury to brain, the ventricular wall or the choroid plexus. These factors 
appeared to mediate the recovery processes by autocrine or paracrine mechanisms via 
their receptors in the choroid plexus.
In another study, Schumacher and Eroschenko, (1985) have demonstrated a chemical- 
induced damage to the choroid plexus in mouse by chlordecon. SEM examination of the 
choroid plexus epithelium after treatment revealed dose-dependent cell alterations such as 
reduction and elimination of cell surface microvilli, increased cytoplasmic vacuolation, 
cellular degeneration and abnormal mitochondria with damaged matrices. Also exposure 
to chlordecone has been shown to cause neurological symptoms in animals and man 
including headache, increased intracranial pressure, papilledema, opsoclonus and body 
tremors.
1.8.7. Reproductive toxicity of HCBD
There are a few reports of HCBD reproductive toxicity in rodents. Saillenfait et ah, 
(1989) reported that exposure of pregnant rats to HCBD by inhalation can cause a 
significant reduction in maternal weight gain and in fetal body weight at 15ppm, but there 
were no embryotoxic or teratogenic effects. Weight reduction and ultrastructural changes 
in the CNS were observed in the offspring of dams treated orally with 8.1 mg / kg HCBD 
from the first day of gestation (Badaeva et al, 1986). Death of newborn offspring was 
observed after a single subcutaneous injection of 20mg/kg to mothers before mating 
(Poteryayeva, 1966).
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1.9. Aims and objectives of this study
From data discussed in this introduction, p-lyase is located in rat brain and therefore it is 
proposed that HCBD maybe a neurotoxin. The neurotoxicity of other halogenated alkenes 
has also been indicated in rabbit and man. It has also been shown that there is rapid 
recovery of the kidney from HCBD toxicity in the young rat. This would suggest that the 
neurotoxicity of HCBD should be investigated properly and that the young male rat might 
be appropriated model animal since it can develop resistance to HCBD nephrotoxicity.
1.9.1. Aims of the experimental work
The initial aim will be to to re-examine the mechanisms of toxicity and regeneration in the 
kidney of the HCBD treated young rat. The CNS of the HCBD treated young rat will then 
be examined for evidence of neurotoxicity. Finally an attempt will be made to 
demonstrate a dose-dependent relationship of HCBD neurotoxicity in the young rat
1.9.2. Overall objectives
Overall I will attempt to determine whether HCBD is a site-specific neurotoxin in the 
young rat. I will also attempt that to correlate site-specificity of toxicity with the 
localisation of cysteine conjugate p-lyase enzyme expression. Finally I will determine 
whether there is relationship between the sites of HCBD toxicity in the young rat and 
those of haloalkene toxicity in man. From this study I hope to provide further evidence to 
assist the risk assessment of HCBD toxicity in man.
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CHAPTER 2: MATERIAL AND METHODS
2.1. Chemicals
All chemicals and suppliers are as follow:
Amersham Pharmacia Biotech, Uppsala, Sweden 
Pharmacia NAP™ 5 Column
Appligen Oncor, Strasburg, France
ApopTag® Direct In Situ hybridisation kit
DAKO, Glustrup, Denmark
AB complex /HRP kit, 
Biotinylated rabbit anti-mouse Ig 
Monoclonal mouse anti-BrdU
BDH Lab Supply, Poole, Dorset, UK
Di-sodium hydrogen orthophosphate, Isopentane, Polysine microscope slides 
Potasium, sodium tartrate. Superfrost plus microscope slides
Becton and Dickinson, Holand, Belgium 
Anti-PCNAIgG
Boehringer Manheim, GmbH, Germany 
Tris buffer
Fischer Scientific International, Leics, UK
Cooper sulphate, DPX liquid montant. Sodium carbonate. Sodium hydroxide. 
Sucrose
Molecular probe, Netherland 
Anti-mouse IgG
Rosch, UK
Unimate 3 GGTIFCC
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Sigma -  Aldrich Ltd, Poole, Dorset, UK
Amediol, BSA protein standard. Bovine Serum Albumin, Diaminobenzidine 
(DAB). Folin-Ciocalteu’s, Goat serum, Hexachlorobutadiene (HCBD), L- 
phenylalanine. Probenecid, a-keto-y-methiol butyrate (a-KMB), Trypsin, Urea 
Nitrogen kit 535-B, Mowiol
2.2. Animal husbandry and treatment
In this project 28-day old male Wistar albino (W/A) rats 70-80 g (Bantin & Kingman, 
UK), were used. Animals were housed in an air-conditioned unit with sawdust 
bedding and were allowed free access to food (Standard rat/mouse diet, BKOOIE) and 
water. A 12 hours light/dark cycle with 20°C and 50% humidity conditions was 
maintained.
2.2.1. Dosing of animals and tissue collection
Upon arrival and after acclimatisation, rats were divided randomly into groups, each 
containing 4 rats. Four groups were placed in the metabolic cages in order to collect 
the 24hr urine. Animals were dosed intraperitoneal (ip) for 1, 2, 3, 4 and 7 days as 
indicated later and examined daily for any effects of treatment on appearance and 
behavior. All animals in each group were killed (24hr after the last dose) by 
anesthesia (pentobarbitone, Sagatal®, stock solution 60mg/ml, O.lml/lOOg body 
weight, ip) and neck dislocation.
Blood samples were taken into anticoagulant tubes by cardiac puncture, all tubes were 
put on a roller mixer, for lOmins, to prevent coagulation. Samples were centrifuged in 
a Beckman J6 for 10 mins, at 1300 xg, plasma transferred to a clean tube and stored at 
-20 °C to measure the concentration of BUN. The packed cell volume was noted as 
an indicator of anemia. Both kidneys were removed, and the right kidney was halved, 
one half immediately fixed in 10% neutral buffered formalin for histopathology 
studies, and the other half, plus the left kidney frozen in liquid nitrogen for subsequent 
enzyme assay and in situ hybridisation. Intact brains were removed, halved, one half 
fixed in formalin and other half frozen in isopentane for enzyme assay. All frozen 
tissues were stored at -80 °C.
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2.3. Fixation, preparation and histological examination of rat kidney 
and brain
All tissues were fixed in 10% neutral buffered formalin at least for one week, cut into 
small pieces and then placed into cassettes for processing on the histokinette tissue 
processor type E7326 (British American optical Co Ltd). In this, the tissues are 
dehydrated to several solutions of formalin, ethanol, xylene and hot wax, to prepare 
them for sectioning.
2.3.1. Sectioning of wax-embedded tissues:
After cooling of the wax blocks, tissues were mounted on the microtome (American 
Optical Corporation), 5p sections cut and placed on the slides by floating the sections 
in warm water. In the case of brain tissue each section (5p) was cut at 500p intervals. 
After cutting, all sections were stained in Haematoxylin and Eosin (H&E). Slides 
were checked to ensure adequate staining of nuclei. If staining was too light, then 
slides were replaced in haematoxylin. If too dark, they were placed into acid alcohol 
for 2  seconds and rewashed in tap water.
2.4. Isolation of kidney subcellular fractions
After defrosting, the left kidney was weighed and placed in ice-cold 0.25M sucrose 
containing lOmM Tris-HCl (pH 7.5) to produce a kidney homogenate of 25% (w/v). 
Kidneys were scissor-minced, homogenised and centrifuged at 144000 xg for 60min 
in a Beckman L7 centrifuge (70.1 X I rotor) to isolate the cytosolic supernatant. The 
cytosolic fraction was stored at -20° C for protein determination and enzyme assay.
2.5. Protein determination
The method of Miller (1951), which is a modification of the Lowry et a l, (1951) 
method was used. A standard curve (Fig 2.1) was generated by using 1ml of bovine 
serum albumin (BSA) as standard at concentrations of 0, 5, 10, 20, 50, 75, 150 and 
200pg/ml. 10-20pl of each sample was diluted to 1ml with Milli Q water. 1ml of 
freshly prepared reagent A (CUSO4 .5 H2O: K^, N a \ tartrate: Na2COs anhydrous in 
0.5M NaOH in the proportion of 1:10:100) and the tubes incubated at room 
temperature for lOmin. 3ml of reagent B (Folin - Ciocalteu reagent which is diluted 
1:10 with MilliQ water) was added to each of the tubes, immediately vortexed and
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incubated at 50° C for lOmins to allow colour to develop. Samples were cooled by 
gently running under the tap and the absorbance determined on a Kontron Uvikon 932 
spectrophotometer at 650nm. Standards were performed in duplicate and samples in 
triplicate.
2.6. Blood Urea Nitrogen (BUN)
The level of BUN was used as an indicator of renal damage. Urea generated from 
protein break down, is eliminated from the body in urine via the kidneys, therefore a 
high concentration of urea in blood indicates kidney damage. The Sigma kit No 535- 
A (Crocker, 1967) was used to determine the concentration of BUN based on the 
production of a pink chromagen as follow:
Eqn. 2.1:
Diacetyl monoxime + Urea  Pink chromage + Hydroxylamine
The intensity of colour produced is directly proportional to the concentration of urea 
in the sample and was measured at 535nm (Uvikon 932 spectrophotometer) as in the 
manufacturer's instructions. To measure BUN concentration, tubes containing 3ml 
BUN acid reagent and 2ml BUN color reagent were prepared. 20pl of the Urea 
Nitrogen Standard Solution (150mg/dl), as standard, at concentrations of 0,15, 30, 45, 
60 and 75mg /dl, to generate a standard curve (Fig 2.2), or 20pl of plasma samples 
were added. All test tubes were placed in boiling water for exactly lOmin. Samples 
were cooled in cold tap water for 3-5mins. Absorbance of standard solutions were 
determined in a Kontron Uvikon 932 spectrophotometer at 535nm, then based on the 
calibration curve, BUN concentration of the plasma samples were measured.
2.7. Glutamine transaminase K (GTK) activity assay
GTK activity in kidney cytosol was assayed according to the method of Cooper and 
Meister, (1985). This assay is based on the transamination reactions between L- 
phenylalanine and an a-ketoacid such as a-keto-y-methiol-butyric (a-KMB) 
producing phenylpyruvate and L-methionine
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Eqn.2.2:
GTK
L-Phenylalanine + a-Keto-y -Methiolbutyric acid ----------------^  Phenylpyruvate + L-Methionine
To assay the activity of GTK, solutions of ammediol buffer (IM, pH 9.0), L- 
phenylalanine (lOOmM) and a-KMB (lOOmM) were prepared and mixed in the ratio 
of (2: 1: 0.5), the ‘GTK reagent’. In tubes, 2.5pl of kidney cytosol was added to 
62.5pl of dH2 0  and mixed. Then 35pl of GTK reagent were added to each sample 
and incubated at 37° C for lOmin. The reaction was terminated by adding of 900pl of 
3.33M NaOH and the absorbance was determined in the Uvikon 932 
spectrophotometer at 322nm. The product of the reaction, phenylpyruvate, absorbs 
strongly at this wavelength. All assays were performed in triplicate. The specific 
activity of the samples were calculated using the following formula:
Ax 1000
S p e c if ic  activ ity  (p m ol /m in  /m g  protein ) =-
6 /  P
A= absorbance at 322nm
s = Molar extinction coefficient of phenylalanine (24000 M Cm’^ )
P = Amount of protein (mg)
2.8. Gamma-Glutamyltransferase (y-gt) Assay
In this assay, the Unimate 3 (y-gt IFCC) reagent was used. The reagent contains L-y- 
glutamyl-3-nitroanilide as the donor substrate and glycylglycine as the acceptor 
substrate. In the presence of these two substrates the following reaction is catalysed
Eqn. 2.3:
y.gt
L-y- glutamyl-3-nitroanilide + glycylglycine ^  L-y- glutamyl-glycylglycine + 
5-amino-2-Nitrobenzoate
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Fig 2.2. Standard calibration curve for BUN using Urea Nitrogen Standard Solution
84
The liberation of yellow coloured 5-amino-2-nitrobenzoate is directly proportional to 
the y-gt activity in the sample and is quantified by measuring the increase of 
absorbance at 405 nm. The reagent is based on the kinetic procedure according to the 
recommendations of the International Federation of Clinical Chemistry. Assays were 
performed on urine samples following desalting (based on manufacturer instruction) 
on Sephadex G25, using Cobas Bio
2.9. TUNEL assay (terminal deoxynucleotidyl transferase-mediated 
dUTP nick end- labeling)
This assay is a convenient method for the rapid identification and quantitation of
apoptotic cells in formalin fixed and paraffin embedded sections. The Apoptag®
Fluorescein Direct In Situ Apoptosis Detection Kit (Appligene Oncor) which
distinguishes apoptosis fi*om necrosis by specifically detecting DNA firagmentation,
was used.
The Oncor ApopTag Direct Kit generates non-isotopic DNA end-extensions in situ. 
Flouroscein-nucleotide residues are added to the DNA by terminal deoxinucleotidyl 
transferase (TdT), an enzyme which catalyses a template independent addition of 
nucleotide triphosphate to the 3’-OH ends of double or single-stranded DNA. When 
the incorporated nucleotides are excited by light of 494nm wavelength, the 
fiouroscein generates an intense signal at 523nm. This mixed molecular biological- 
histochemical system allows for sensitive and specific staining of the very high 
concentrations of 3’-OH ends that are localised in ‘apoptotic bodies’.
The technique relies on the use of exogenous enzymes, such as DNA polymerase I 
and terminal deoxynucleotidyl transferase (TdT), to incorporate labeled nucleotides 
into the 3’-OH released termini of DNA breaks. In general, such techniques are 
termed in situ end labeling (ISEL) and more specifically, in situ nick translation 
(ISNT) when they involve the use of DNA polymerase I, or TdT mediated dUTP nick 
end labeling (TUNEL) when they employ terminal transferase. (Negoesco et al, 
1996).
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In this assay, tissue sections were dewaxed in xylene and rehydrated in decreasing 
concentrations of ethanol (100, 95 and 70%). After washing in dHzO and phosphate 
buffer saline (PBS) all samples were exposed to proteinase K solution (20pg /ml) for 
15min at room temperature. Slides were washed 4x2min in fi-esh dHiO and 
immediately 75pl of equilibrium buffer was applied directly to each tissue and 
covered by a plastic coverslip for l-5min. The coverslips were removed and 54pl of 
the TdT enzyme in reaction buffer was applied to each sample and incubated for Ihr 
in a humid chamber at 37°C. The reaction was stopped by placing the slides in the 
stop-wash solution (1ml stop-wash + 34ml dH2 0 ) in a Coplin jar for lOmin. Finally 
24pl of Oncor Propidium lodide/Antifade was applied, sections were mounted in 
DPX under glass coverslips and assessed by ftouroscent microscope (blue filter) 
(Axiovert 135TV, Zeiss, Germany). All slides were stored at -20 ° C in the dark.
2.10. Proliferating Cell Nuclear Antigen (PCNA) assay
This assay identifies proliferating cells when they are in the “ S ” phase of the cell 
cycle. PCNA, an endogenous cell replication marker of 36kDa, is a part of DNA 
polymerase a, which is vital for DNA replication (Rodrigo et al, 1987). PCNA 
synthesis is started in late Gi and peaks during S phase. Anti-PCNA (Bekton -  
Dickinson, UK) was used as the primary antibody and the goat anti-mouse IgG 
(Molecular Probes, UK) as the secondary antibody. Different dilutions of the primary 
and secondary antibodies were used to determine the best dilution which was 1 : 1 0 0  
of both antibodies. In this assay, antigen retrieval to enhance immuno-histochemical 
staining, by microwave oven heating of tissue sections (Shi et al, 1991) was used. 
Although antigen retrieval is widely used in immunohistochemistry, the method 
originally lacked standardisation. Tacha and Chen, (1994) solved this problem by 
using a calibration method for the microwave and antigen retrieval solution.
To assay PCNA, the method of Shi et al, (1991) was used. In this method, tissue 
sections were dewaxed in xylene, transferred to 100% ethanol and washed in 3% 
H2O2 solution for lOmin at room temperature to block endogenous peroxidase 
activity. Then all slides were placed in plastic Coplin jars containing lOmM citrate 
buffer and heated (190°F) in the microwave for lOmin (2x5min). Slides were 
removed and allowed to cool to room temperature for 20min, washed in PBS and
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blocked with 5% goat serum solution for 20min at room temperature. 80-100pl of 
primary antibody (anti-PCNA IgG) at the ratio of 1:100 in PBS (containing 1% BSA) 
was applied to each slide and incubated in a humid chamber at 4°C overnight. After 
washing the slides (3x2min) in PBS, 80-100pl of secondary antibody (goat anti­
mouse IgG) at the ratio of 1:100 in PBS (containing 1% BSA) was applied to each 
slide and incubated in a humid chamber at room temperature for 30min. Finally the 
slides were rinsed in 3 changes of PBS (2min each), dipped in distilled water and 
mounted with mowiol. Slides were assessed by ftouroscent microscope (green filter) 
(Axiovert 135TV, Zeiss, Germany).
2.11. Bromodeoxyuridine (BrdU) labeling of proliferating cells
5-Bromo-2 ’-deoxyuridine (BrdU) is a brominated analogue of thymidine, which is 
selectively incorporated, in place of thymidine, into cell DNA during the “ S ” phase 
(DNA synthesis) of cell cycle. By labelling with BrdU, DNA synthesis and cell 
proliferation in tissue sections of different body organs including CNS, can be 
identified using monoclonal anti- BrdU antibodies and immunoperoxidase methods 
Qs/ldkry et al, 1993).
In this method, horseradish peroxidase (HRP) an enzyme that specifically reduces 
hydrogen peroxide to produce O2 was used. Diaminobenzidine (DAB), the substrate 
for detection of peroxidase activity, in reaction with O2 produces a brown-black stain 
which is resistant to alcohol. There are two major methods of BrdU administration to 
evaluate cellular proliferation based on BrdU labeling
a. Single BrdU injection: Animals receive a single i.p., injection of BrdU (50- 
lOOmg/kg, rats and 100-200mg/kg, mice) 1 hour prior to killing. This 
method detects the number of cells synthesising DNA during the 1-hour 
window.
b. Continuous dosing with slow releasing BrdU pellets or osmotic mini 
pumps. A pellet and its pump equivalent implanted sub-cutaneously in the 
back of each animal releases BrdU (Ipl/hr) over a period of up to 7 days.
In this study, the first method was used.
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2.11.1. Detection of BrdU labeling
The slides used for BrdU staining were poly-L-lysine coated to ensure that the section 
remained attached to the slide. All sections were dewaxed in xylene and rehydrated 
in ethanol (100, 90 and 70%). To decrease the risk of interference with horse radish 
peroxidase, sections were treated by 3% H2O2 in 70% ethanol, for 30min at room 
temperature. Slides were washed for 5min in running tap water, dipped in distilled 
water and digest in trypsin solution containing calcium chloride for 30min in 37°C. 
Slides again were washed in running tap water for 5min and hydrolysed in 4M HCl 
solution for 15min at 60°C. Slides were washed in tris-buffer-saline (TBS). 80-100 pi 
of first antibody (mouse anti-BrdU) at the ratio of 1:30 (166pl antibody mixed with 
5ml TBS) was applied to each slides and incubated in room temperature for Ihr in a 
slide humid chamber. Slides were washed 2x3min in TBS and biotinylated second 
antibody (rabbit anti-mouse antibody) at the ratio of 1:30 (166pl antibody mixed with 
5ml TBS) was applied to each slides and incubated in room temperature for Ihr slide 
humid chamber. Slides were washed 2x3min in TBS and the complex of avidin and 
biotinylated horseradish peroxidase (HRP) (AB reagent, see appendix) was applied to 
each slide and incubated in room temperature for Ihr slide humid chamber. Finally all 
slides were exposed to diaminobenzidine (DAB) coupling solution for 15-30min and 
mounted with DPX. Slides were assessed by light microscope.
2.12. Statistical analysis
The data were analysed by one-way analysis of variance (ANOVA) followed by 
Bonferroni-Dunn multiple comparison post hoc test (Super ANOVA). Values are 
presented as mean ± SEM. P<0.05 was considered statistically significant.
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CHAPTER 3: NEPHROTOXICITY OF HCBD IN THE YOUNG 
MALE RAT 
3.1. Introduction
As detailed previously, HCBD is a potent nephrotoxin in rodents. The main area of 
the kidney damaged is the S3 (pars recta) segment of the renal proximal tubule, an 
area high in cysteine conjugate p-lyase activity. The data presented below 
demonstrates that the nephrotoxicity of HCBD depends directly on the duration of 
exposure and that regeneration of the kidney tubule can occur.
3.2. Exposure of 28-day male rats to a high dose of HCBD 
(lOOmg/l^)
3.2.1. Dosing of rats with HCBD
After acclimatisation, rats were divided randomly into different groups (each 
containing 4 rats) as follows:
Group 1: Normal saline (0.9%) (1 ml/kg, ip), single dose
Group 2: HCBD (lOOmg /kg, ip), for 1 day
Group 3: HCBD (lOOmg /kg, ip), daily dose for 2 days
Group 4: HCBD (lOOmg /kg, ip) plus probenecid (0.5 mmoles/kg), 0.5 hr before and 
7hr after each dose of HCBD.
All animals in each group were killed on the day after last dose by anaesthesia 
[pentobarbitone (Sagatal®, stock solution 60mg /ml), 0.1ml / lOOg body weight, ip] 
and neck dislocation. Blood samples were taken into anticoagulated tubes by cardiac 
puncture, all tubes were put on a roller mixer for lOmins, to prevent coagulation. 
Samples were spun in a Beckman J6  ultracentriftige for lOmin at 1300 g., plasma 
transferred to a clean tube and stored at -20 °C to measure the concentration of BUN. 
Both kidneys were removed, the right kidney was immediately fixed in 10% neutral 
buffered formalin for histopathology studies, and the left kidney was frozen in liquid 
nitrogen for enzyme assay. All frozen tissues were stored at -80 °C.
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3.2.2. Health and behaviour of treated rats
Some changes occurred in the appearance and behaviour of treated rats such as 
walking on their toes, piloerection and the appearance of dull patchy hair. Also 
treated rats were less active, compared to control ones. These signs may be related to 
abnormalities in the central nervous system. After killing the animals it was noted 
that the liver of the treated group appeared to have a darker colour, was slightly 
larger and contained more lipid. The size of kidneys was also larger in the treated 
group.
3.2.3. Changes in Blood-Urea Nitrogen (BUN)
The level of BUN was used as an indicator of renal damage in treated animals. 
Concentrations of BUN, in the group of rats treated with 100 mg/kg HCBD (Fig 3.1) 
showed that there is significant difference between HCBD treated and the other 
control or HCBD + probenecid groups. This clearly indicates the nephrotoxic effect 
of HCBD and the sparing effect of anion transport inhibitors.
3.2.4. Changes in kidney enzyme activity
In this study the activity of two enzymes, glutamine transaminase K (GTK) and 
gamma-glutamyl transferase (y-gt) were assayed.
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Fig 3.1: Concentration o f BUN in HCBD (lOOmg/kg), saline and probenecid treated  
rats
Rats were treated with HCBD for 1 day and killed 24hr later.
Data shown as mean ± SEM. where n = 4 in each group.
* : p<0.05 compared to control 
**: p<0.01 compared to probenecid 
***: p<0.001 compared to control
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3.2.4.1. Glutamine transaminase K (GTK) activity
3.2.4.1.1. GTK activity in untreated rats
In order to identify the effects of age on the specific activity of the enzyme GTK in 
untreated rats, 5 groups of rats (4 in each group) with different ages, 21, 32, 36, 41 
and 46 day old were used. Data showed that kidney cytosolic GTK specific activity 
is directly dependent on age (Fig 3.2). There is significant differences between 21 
day old and 32 day, 36 day, 41 day and 46 day old which may be due to lower 
activity of this enzyme in 2 1 -day old rats compare to other ones.
3.2.4.1.2. GTK activity in treated animals
The kidney cytosol GTK assay (Fig 3.3) showed that in the 2-day treated group with 
100 mg/kg HCBD there is significant difference between the HCBD and saline 
treated group but not with HCBD plus probenecid group. It was expected that 
because of the substantial damage to the proximal tubules in the HCBD treated rats 
the activity of GTK would be reduced. Surprisingly an increase was observed, which 
may be due to reduced elimination of the enzyme from the proximal tubule because 
of the lack of tubules to produce urine.
3.2.4.2. Gamma-glutamyl transferase (y-gt) activity
y-glutamyltransferase is a serine hydrolase that catalyses the transfer of the D or L- 
glutamyl group from y-glutamyl di- and tripeptides, glutathione or glutathione S- 
conjugates to acceptor amino acids or dipeptides, y-gt activity is present in the bile 
duct, intestinal microvilli, brush-border membrane of the 82  and S3 segments of the 
renal proximal tubules. The kidney has the highest y-gt activity, y.gt specific activity 
in animals treated with lOOmg/kg HCBD for 1 day, was performed with kidney, 
liver, plasma and urine samples. In the kidney homogenate, there was significant 
difference in enzyme activity between control and treated groups (Fig 3.4), however 
in liver homogenate there was no significant difference. It is expected that there 
would be a decrease in activity of the enzyme in the kidney following HCBD 
treatment and a release of the enzyme from the damaged cells into the urine but the 
data obtained showed that there was an increase in enzyme activity.
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Fig 3.2: Age related kidney cytosolic GTK specific activity in untreated m ale rats
Data shown as mean ± SEM. n = 4 
*: p<0.05 compared to 21 day old 
**: p<0.01 compared to 21 day old
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Fig 3.3: Kidney cytosolic GTK specific activity in the HCBD (lOOmg /kg) treated rats.
Animals were dosed daily for 2 days and killed 24hr after the last dose 
Data shown as mean ± SEM. n = 4 
*; p<0.05 compared to control
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In this case I also expected that the enzyme activity would show a significant 
difference between the HCBD treated and control group. In fact the difference was 
not significant (despite the high level elimination of the enzyme in urine) due to 
inter-animal variations (high error bars), and the high amount of excreted protein 
following damage to the tubules. Alternatively it may be due to extensive damage to 
the tubules so the enzyme could not be excreted in urine after being released from the 
damaged cells. The activity of enzyme in the liver also showed an increase between 
the HCBD treated and control group.
In the plasma samples, despite a reduction in the specific activity of enzyme in the 
HCBD treated rats, the difference between the treated and control group was not 
statistically significant (Fig 3.5).
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Fig 3.4: The kidney, liver and urine y.gt specific activity in HCBD (lOOmg/kg) 
treated animals.
Rats were dosed for 1 day and killed 24hr later.
Data shown as mean ± SEM. n = 4 
*: p<0.05 compared to control
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Fig 3.5: Plasma y.gt specific activity in HCBD (lOOmg/kg) treated animals.
Rats were dosed for 1 day and killed 24hr later 
Data shown as mean ± SEM. n = 4
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3.2.5. Histopathology of renal tubular damage (lOOmg/kg)
Light microscopic examination of H&E stained sections of kidneys from HCBD 
treated and HCBD + probenecid treated rats showed extensive damage in the outer 
stripe of the outer medulla (Fig 3.6 and Fig 3.7) in both HCBD exposed groups. In 
addition the corticomedullary junction, some parts of the cortex of the kidney were 
also involved. Because the toxicity of HCBD in the kidney is related to a probenecid 
sensitive transport process, it was expected that probenecid would protect against the 
nephrotoxicity of HCBD. In this experiment probenecid did protect the animals but 
variation between the response of individual animals was observed (Fig 3.8)
3.2.6. Discussion
Injection of a single lOOmg/kg dose of HCBD in the young male rats causes massive 
damage to the S3 segment of the renal proximal tubules which is confirmed by the 
increased concentration of BUN in treated groups. S3 segment is the most sensitive 
area to the toxicity of cysteine conjugates, this suggest that the cells of S3 segment 
are either inherently more sensitive to nephrotoxic cysteine conjugates than the cells 
of SI and S2 segments or that the most of the toxic conjugates are activated in S3 
(Jones et al, 1988).
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Fig 3.6: Representation o f a normal rat kidney
H&E stained sections (xlO).
G: glumerulus 
P: proximal tubule
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Fig 3.7: Effect of a single dose of HCBD (lOOmg /kg) on the young W/A  
rat kidney.
Rats were dose for 1 day and killed 24hr later. Arrows show a typical damage 
in the renal corticomedullary junction.
H&E stained sections (x4)
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Fig 3.8: D ifferent responses of HCBD (100mg/kg) treated anim als in one 
group to the protective effect of probenecid (x4)
A; very mild lesion (arrow)
B; extensive lesion (arrows)
3.3. Exposure of 28-day male rats to repeated low doses (25mg/kg) 
of HCBD
3.3.1. Dosing of rats with HCBD
After acclimatisation, all rats were divided randomly into different groups (each 
containing 4 rats) as follows:
Group 1: Normal saline (1ml /kg, ip), daily dose for 1,2, 3 or 4 days 
Group 2: Probenecid (0.5 mmol /kg, 1ml /kg, ip), daily dose for 2, 3 or 4 days 
Group 3: Probenecid (0.5 mmol/kg), 0.5 hr before and 7hrs after each dose of HCBD 
Group 4: HCBD (25mg /kg, ip), daily dose for 1,2, 3 or 4 days
All animals were killed the day after the last dose. For groups 1 and 4 (4-day treated 
animals) urine samples were collected daily to assay the y-gt activity. The first 
samples were collected one day before dosing and the last samples just before killing 
the animals.
3.3.2. Animal health and behaviour
In the 3- and 4-day HCBD only treated animals, one death was observed in each 
group, one hydronephrotic kidney was found and a reduction in body weight gain in 
rats occurred (Fig 3.9). After 3 days of treatment with HCBD, some changes 
occurred in the appearance and behaviour of rats such as walking on their toes, 
hunched up posture, piloerection and dull patchy hair. The kidney size in the HCBD 
treated groups was larger than control.
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Fig 3.9: Body weight alterations in the HCBD (25mg/kg) treated rats
Animals were weighed on different days before HCBD injection.
(Some data from subsequent long-term studies)
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3.3.3. Changes in Blood Urea Nitrogen level
As shown in Fig 3.10, the level of BUN was elevated in all groups exposed to HCBD 
compare to saline or probenecid alone controls. This indicates that even at 25mg/kg, 
HCBD causes proximal tubule damage in the 28-day old W/A rat. The BUN level 
decreased in the 3- and 4-day exposure groups, indicating that proximal tubule 
regeneration was taking place. The effect of probenecid was variable with some 
sparing effect clear at 2 and 4 days, but not in the 3-day group. This may again be a 
reflection of the inter-animal variation in probenecid effect as observed in the 
lOOmg/kg dosing experiments.
3.3.4. Changes in kidney enzyme acticvity
The activity of two enzymes, glutamine transaminase K (GTK) and y.glutamyl 
transferase (y.gt) were assayed to show the effects of HCBD.
3.3.4.I. Glutamine transaminase K (GTK) activity
The kidney cytosol GTK assay (Fig 3.11) showed that in the 2- and -3-day treated 
groups, despite a reduction in enzyme activity, statistically there was no significant 
difference between the HCBD alone and other treated groups. As the data show, 
probenecid also increases the activity but HCBD+probenecid reduces p-lyase 
activity.
In the 4-day treated groups there was significant difference between HCBD alone 
treated and controls. Again the HCBD+probenecid significantly reduces P-lyase 
activity.
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Fig 3.10: Concentration o f BUN in different groups o f HCBD (25mg/kg) treated rats.
Animals were dosed daily and killed 24hr after the last dose.
Data shown as mean ± SEM. n = 4
*: p<0.05 in the 3 and 4 days compared to saline and probenecid treated 
groups and in the 2-day group compared to the HCBD treatment for 3 and 4 days 
***: p<0.001 compared to saline, probenecid and the HCBD plus probenecid (4 days) 
groups
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Fig 3.11: GTK specific activity in the kidney cytosol o f different groups o f the HCBD  
(25mg/kg) treated rats.
Animals were dose daily and killed 24hr after the last dose.
Data shown as mean ± SEM. n=4
*: p< 0.05 compared to the probenecid control (days 2 and 3) or Saline and probenecid 
control (day 4) groups
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3.3.4.2. y.glutamyl transferase (y.gt) activity
y.gt activity in animals treated with 25mg/kg of HCBD for 1 and 4 days, was 
measured in the kidney and liver homogenates and also in plasma and urine samples 
(Fig 3.12). In the 1-day HCBD (25mg/kg) treated group, like lOOmg/kg, it was 
expected that, there would be a decrease in activity of the enzyme in the kidney 
following HCBD treatment, but the data obtained showed that there was no 
significant difference in enzyme activity from control. The activity of enzyme in the 
liver showed an increase between the HCBD treated and control group (Fig 3.12) 
with substantial inter-animal variation.
As it was expected, y.gt specific activity in the urine samples was increased 
significantly in the HCBD treated rats (Fig 3.13). Also y.gt specific activity in the 
urine samples of the animals treated with HCBD for 4 days showed that after the 
second dose of HCBD, activity of the enzyme in treated rats was significantly 
decreased and eventually returned to normal levels (Fig 3.14). As the data show, 
excretion of y.gt into the urine following exposure to HCBD is dose dependent, the 
lower the dose the higher the excretion. This may he due to lower excretion of 
protein into urine in the low dose treated group because the extent of tubular damage 
was lower in this group, thus giving an apparently higher specific activity.
In the plasma samples, y.gt specific activity showed a significant reduction in the 
HCBD treated group (Fig 3.15). This finding indicates that any increase in the liver 
y.gt is reflected in a decrease in the plasma activity because plasma y.gt activity 
originates from the liver (Pillion 1979).
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Fig 3.12: The kidney and liver y.gt specific activity in the HCBD (25mg/kg) 
treated animals.
Rats were dosed for 1 day and killed 24hr later 
Data shown as mean ± SEM. n = 4
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Fig 3.13: Urinary y.gt specific activity in the HCBD (25mg/kg) treated rats.
Animals were dosed for 1 day and killed 24hr later 
Data shown as mean ± SEM n = 4 
**: p< 0.01 compared to control
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Fig 3.14: Urinary y.gt activity in the HCBD (25mg/kg) treated rats.
Animals were dosed daily for 4 days and killed 24hr after the last dose
Data shown as mean ± SEM. n = 4
***: p< 0.001 compared to day 0, 2, 3 and 4
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Fig 3.15: Plasma y.gt specific activity in the HCBD (25mg/kg) treated rats.
Animals were dosed for 1 day and killed 24hr later 
Data shown as mean ± SEM. n = 4 
*: p< 0.05 compared to control
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3.3.5. Histopathology of renal tubular damage (25mg/kg)
Light microscopic examination of H&E stained sections showed renal proximal 
tubular necrosis at the corticomedullary junction of the kidney in the HCBD treated 
rats. In the 2 day HCBD-treated group the apparent severity of kidney damage is 
greater than 3 and 4 day treated groups (Fig 3.16). Although probenecid could 
decrease the concentration of BUN, it is clear from the histopathology that it did not 
protect the kidney fully (Fig 3.17). In the 3 day exposure group, there was some 
damage at the corticomedullary junction but not as great as for 2 days exposure (Fig
3.18). In this group there was substantial interindividual variation between animals, 
however the protective effect of probenecid was more apparent than at 100mg/kg(Fig
3.19).
The data indicate that the severity of renal tubular damage in the HCBD treated 
groups depends on the duration of exposure. In the 2 day exposure group, there was 
a substantial damage but in the 4 day exposure group the severity of damage was less 
(Fig 3.20). The explanation for this finding is almost certainly that the regeneration 
process commences very rapidly. It is also clear that the regenerated cells are 
resistant to HCBD toxicity. However there was substantial inter-animal variations in 
regeneration and the degree of recovery from the initial HCBD injury. It was also 
found that at this level of HCBD, greater protection was afforded by co-treatment 
with probenecid. However, inter-animal variation was observed again. In the 4-day 
treated group probenecid has protected animals against HCBD better than other 
groups (Fig 3.21).
3.3.6. TUNEL assay (Terminal deoxynucleotidyl transferase-mediated dUTP 
Nick End- labeling)
The TUNEL assay, was performed on kidney sections to detect the presence of 
apoptotic cells. In the 2 and 3 day treated rats some apoptotic cells could be detected 
at the sites of HCBD toxicity (Fig 3.22). No apoptotic cells were found in sections 
from the control or 4 day treated groups.
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Fig 3.16: Effects of HCBD (25mg /kg) on the cortico medullary junction o f the
kidney in the 2 -day treated rats.
Animals were dosed daily for 2 days and killed on day 3. Holes are preparation artifacts.
A; typical damage, arrows indicate damage at the corticomedullary junction (x4)
B; the boxed area in A enlarged (xlO)
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Fig 3.17: Response of rats in the 2 day HCBD + probenecid treated group.
Rats were dosed daily for 2 days and killed On day 3. The extent of the lesion is 
comparable with the HCBD treated group.
Arrows indicate damage at the corticomedullary junction
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Fig 3.18: Effects of HCBD (25mg /kg) on the cortico medullary junction of kidney  
in the 3-day treated rats (x4).
Animals were dosed daily for 3 days and killed on day 4.
A; This animal in the group showed a different lesion compare to others (arrows)
B; a typical lesion (arrows)
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3.19: Response of rats in the HCBD + probenecid (3 days) treated anim als.
The protective effect of probenecid is more apparent than in the 2 day treated group. 
Holes are artifact.
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Fig 3.20: Effects of HCBD (25mg /kg) on the cortico medullary junction o f kidney 
in the 4-day treated rats.
A; This animal showed greater regeneration (arrows) than the others in the group (x4) 
B; Higher power (xlO) view o f an area o f lesion (white arrows) in which substantial 
regeneration is in progress (darker stained cells, black arrow).
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Fig 3.21: Response of rats in the 4 day HCBD + probenecid treated group.
As in the 2 and 3 day treated groups, substantial protection has occurred.
Holes are artifact
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6Fig 3.22: Tunel assay to detect apoptotic nuclei in the kidney o f HCBD (25mg/kg) 
treated rats.
A; Saline-treated control, no strongly fluorescent cells are visible (x20)
B; 2 day HCBD (25mg/kg) treated. The arrow indicates a strongly fluorescent apoptotic 
nucleus (x40)
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3.4. Longer term exposure to low doses of HCBD
Because in the 4 day 25mg/kg treated group regeneration of the kidney proximal 
tubules had occurred, it was decided to dose two further groups of animals for an 
additional 3 days to confirm that the replacement cells were indeed resistant to the 
HCBD toxicity. One group was dosed with the HCBD (25mg/kg) and the other with 
HCBD plus probenecid, as in the previous procedure. All animals were killed on day 
8 .
3.4.1. Animal health and behavior
On day 6 all the HCBD treated rats dragged their rear when walking and showed 
some hyperactivity on day 8. This could have been due to effect on the CNS.
3.4.2. Blood Urea Nitrogen (BUN)
The concentration of BUN in the 7 day HCBD treated group is still significantly 
different from the control and HCBD plus probenecid groups (Fig 3.23). However it 
was substantially less than the BUN level in the 2 day treatment group (Fig 3-24).
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F ig 3 .23: Concentration o f BUN in the 7-day HCBD (25mg/kg) treated rats.
Animals were dosed daily for 7 days and killed 24hr after the last dose.
Data shown as mean ± SEM. n = 4
*: p<0.05 compared to the controls and HCBD+probenecid groups
121
2 5 0
200
_  1 5 0
O)
E
3
CO 100
5 0
I
m
U  S a lin e  
B  P ro b e n e c id
□  HCBD
□  H C B D + prob
m i
3  4
days of exposure
Fig 3.24: Concentration o f BUN in different groups o f HCBD (25mg/kg) 
Treated animals.
Data shown as mean ± SEM. n = 4
*: p< 0.05 compared to the HCBD treatment for 2 days
***: p<0.001 compared to the HCBD treatment for 2 days
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3.4.3. Glutamine transaminase K (GTK) activity
Kidney cytosolic GTK activity was lower in the 7 day HCBD only treated group 
compare to other treated groups (Fig 3.25), which may be due to a low level of 
enzyme in the newly regenerated cells. In the HCBD+ probenecid group the level of 
GTK, while higher than in the HCBD only group is still less than in the saline or 
probenecid control groups. This would indicate that although probenecid afforded 
some protection from HCBD, there was a significant reduction in the kidney GTK 
activity due to proximal tubule cell death and replacement with what appear to be 
immature cells.
3.4.4. Histopathology of renal tubular damage
Light microscopic examination of H&E stained sections showed renal proximal 
tubular regeneration, at the corticomedullary junction in the 7 day HCBD (25mg/kg) 
treated rats (Fig 3.26). Although some very mild damage in the kidney cortex was 
observed, overall the kidney looks quite normal and basophilic. This result clearly 
indicates that following the HCBD-induced loses of cells from the proximal tubules 
and replacement with cells containing reduced levels of cysteine conjugate p-lyase, 
the kidney is resistant to further HCBD toxicity for a substantial period of time. This 
effect was enhanced to some extent by probenecid co-treatment (Fig 3. 27)
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Fig 3.25: GTK specific activity in the kidney cytosol o f the HCBD (25mg/kg) 
treated rats.
Animals were daily dosed for 7 days and killed 24hr after the last dose
Data shown as mean ± SEM. n = 4
*: p< 0.05 compared to saline and probenecid controls
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Fig 3.26: Effect of HCBD (25m g /kg) on rénal proximal tubular cells in the 7day 
treated rats.
Arrows show regenerating tubules 
A;(x4)
B;(xlO)
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Fig 3. 27: Response of rats in the 7 day HCBD plus probenecid treated group (xlO)
Probenecid could highly protect the kidney to HCBD toxicity
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3.4.5. TUNEL and PCNA assays
In TUNEL assay, apoptotic nuclei could not be found in stained sections from the 
kidney of rats treated with HCBD for 7 days. This indicates that no further cell death 
due to p-lyase mediated toxicity is occurring and that the proximal tubule cells are 
near resistant to HCBD toxicity.
The PCNA assay demonstrated an approximately 5-fold increase in the number of 
proximal tubule cells in S-phase compared to the saline treated control rat kidney. 
This finding demonstrates that the regeneration process is still in progress after 7 
days of exposure to HCBD and that new cells are still being produced to repair 
damaged tubules (Fig 3.28). It is also clear from the data that while the replaced 
cells have sufficient filtration capacity to reduce the BUN towards control levels, the 
expression of p-lyase (and perhaps other scavengers) activity is still at a level more 
characteristic of the immature nephron.
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BFig 3.28: PCNA staining in the kidney o f 7 day HCBD (25mg/kg) treated rats
Arrows show fluorescent PCNA in the proximal tubules 
A; Saline control (x20)
B; HCBD treated for 7 days (xlO)
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3.5. Discussion
In addition to confirm the site-specific nephrotoxicity of HCBD at a low dose 
(25mg/kg), the data demonstrated that following death of proximal tubule cells via an 
apoptotic process, a process of regeneration is initiated. However, the replacement 
cells do not display the full spectrum of proximal tubule function, being more 
characteristic of immature, partially differentiated cells. In particular the activity of 
GTK/p-lyase is substantially reduced compare to control, a factor, which probably 
contributes substantially to the resistance of the regenerated tubule to subsequent 
HCBD toxicity.
Cellular factors play an important role in initiating cell proliferation. Growth factors 
produced in the kidney can stimulate resting cells in the Go phase of the cell cycle to 
initiate DNA synthesis and also speed protein and phospholipid synthesis for the 
formation of brush border and basolateral membranes. Also the concentration of 
extracellular Na^ and K’*’ is a parameter that has an important role in cell proliferation 
and the release of renal growth factors. Apparently the effect of low Na^ is faster 
than low and is takes place after 3-5min (Walsh-Reitz et aL, 1986).
The data raises questions in relation to the prolonged exposure of young male rats to 
HCBD;
1. For how long is kidney resistance to HCBD toxicity maintained?
2. Does a return to HCBD toxicity correlate with maturation of replacement cells 
and the expression of normal levels of GTK/p-lyase?
3. Do the behavioral changes in HCBD treated rats, particularly where kidney 
function is being restored, relate to HCBD-induced changes in the CNS, perhaps 
as a result of neurotoxicity?
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CHAPTER 4: NEUROTOXICITY OF HCBD IN THE YOUNG 
MALE RATS 
4.1. Introduction
HCBD and its cysteine-conjugate derivative (Pentachlorobutadienyl)-L-cysteine 
(PCBC), are highly lipophilic compounds, they can cross biological membranes 
including the blood-brain-barrier. There is also much evidence, which demonstrates 
the localisation of p-lyase activity in brain tissue(Okuno et al, 1991; Roberts et al, 
1992; Kapoor et al, 1997). Cooper et al, (1993) reported that there is widespread 
GTK activity in rat brain with the highest activity in the choroid plexus. Thus it is 
possible that PCBC could undergo a B-elimination reaction in the brain, to produce a 
toxic thiol and indeed there are some studies which suggest that HCBD can be 
neurotoxic. It has been reported that administration of 3000ppm HCBD for 15 days 
to rats caused abnormal neurological signs such as; lethargy, hunched posture, 
piloerection, sensitivity to light, demyelination and fragmentation of femoral nerve 
fiber, and lack of motor coordination (Gradinski et al, 1975; Bemdt and Mehendale, 
1979; Harleman and Seinen, 1979; Jaffe et al, 1983 and Yang et al, 1989). In this 
chapter I show that the main area of HCBD damage is the choroid plexus and also 
that the neurotoxicity of HCBD depends directly on the dose and duration of 
exposure.
4.2. GTK activity in the brain of untreated rats
In order to identify the effects of age on the specific activity of the enzyme GTK in 
untreated rats, 5 groups of un-treated rats were sacrificed (4 in each group) with 
different ages (21, 32, 36, 41 and 46-day old). Data presented show that there is a 
significant difference between GTK specific activity in 21-day old and other groups 
(p<0.05) and also the activity is directly dependent on the age, the older the rats the 
higher the activity (Fig 4.1).
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F ig 4.1: Age related GTK specific activity in brain homogenate for untreated rats 
with different ages (21-, 32-, 36-, 41- and 46-day) old.
Data shown as mean ± SEM. n = 4 in each group 
*: p< 0.05 compared to 2 1 -day old group
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4.3. Exposure of the 28-day male rat to HCBD (lOOmg /kg)
Rats were exposed to HCBD at a high dose (as defined by nephrotoxicity) for 1 and 
2 days to determine the extent of toxicity in the CNS
4.3.1. Dosing of rats with HCBD
Upon arrival and after acclimatisation, rats were divided randomly into groups of 4 
as follows:
Group 1: Normal saline (0.9%) (Iml/kg, ip), single dose
Group 2: HCBD (lOOmg /kg, ip), single dose, animals were killed on day 2
Group 3: HCBD (lOOmg /kg, ip), daily dose for 2 days, animals were killed on day 3
All animals in each group were killed by anaesthesia and neck dislocation. Intact 
brains were removed, halved; one half fixed in formalin and the other homogenised 
for enzyme assay. Frozen tissues were stored at -80 °C.
4.3.2. Health and behaviour of treated rats
Changes in the appearance and behavior of treated rats such as piloerection and dull 
patchy hair were observed. Also treated rats were less active, compare to control. All 
these signs may relate to abnormalities in the central nervous system. In this study 
there was 1 death in group 3.
4.3.3. Brain GTK activity in treated rats
Brain GTK specific activity in HCBD (lOOmg /kg) treated animals for two days is 
shown in Fig 4.2. Data shows that there is significant difference between treated and 
control group (p<0 .0 1 ).
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F ig 4.2: Brain GTK specific activity in the HCBD (lOOmg/kg) treated rats.
Rats were dosed for 2 days and killed on day 3 
Data shown as mean ± SEM. n = 4 in each group 
**: p< 0.01 compared to control
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4.3.4. Histopathology of brain tissue damage
5|im sections were cut at 500pm intervals through the brain. Light microscopic 
examination ofH&E staining of the sections were cut in animals treated with HCBD 
for 1 and 2 days (groups 2 and 3) indicates the presence of damage only in the 
choroid plexus. The effect of HCBD is seen even in 1-day treated animals. These 
effects including; dilatation of the lateral and third ventricles (Fig 4.3A and B), 
massive destruction with severe hemorrhage in the choroid plexus of the lateral and 
third ventricles (Fig 4.4 A-C), destruction of the ependymal layer.
In the 2-day treated rats repair activity in the damaged choroid plexus had 
commenced and some cells with darker nuclei were observed (Fig 4.5).
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Fig 4.3: H istopathological examination of the young male W /A rat brain treated  
with lOOmg /kg HCBD by i.p, for 1 day.
Animals were sacrificed on day 2. Stained with H&E.
A; normal third ventricle and choroid plexus (CP) (xlO).
B; HCBD dilated third ventricle with damaged choroid plexus (xlO)
135
BLegend on the next page
136
Fig 4.4: Histopathological exam ination of the young male W/A rat brain treated with 
lOOmg /kg HCBD by i.p, for 1 day.
Animals were sacrificed on day 2. Stained with H&E.
A; lateral ventricle with damaged choroid plexus but normal ependymal layer (mag. x4). 
B; (mag. xlO) and C (mag. x4); severe damage and hemorrhage in the lateral ventricle, 
with massive destruction of ependymal layer. Arrows shown a blood vessel inside the 
ventricle.
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Fig 4.5: Repair activity in the young male W /A rat brain treated with lOOmg /kg  
HCBD by i.p, for 2 days.
Animals were sacrificed on day 3. Stained with H&E 
A; arrow shows a blood vessel (x20)
B ;(x40)
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4.3.5. Bromodeoxyuridine (BrdU) labeling of proliferating cells
DNA synthesis and cell proliferation can be identified by labeling the DNA with 
BrdU. Antibodies against BrdU are used to stain the incorporated BrdU. In Fig 4.6, 
sections of brain, in control (saline plus BrdU) animals which have been labeled by 
Bromodeoxyuridine are shown. This picture showed some regenerating villi, which 
behind that is ependymal layer.
In Fig 4.7, brain sections from HCBD plus BrdU treated animals are shown. Clearly 
the brown staining indicates proliferation repair activity and a mitotic cell can be 
seen in haematoxylin counterstaining.
4.3.6. Discussion
As shown, the choroid plexus is the main area in the brain which is damaged in 
treated animals. The activity of GTK in choroid plexus (15.9 ± 0.1 mU /mg protein) 
is about 5-6 times that of whole brain (Cooper et al, 1993). In the treated rats, the 
GTK activity is significantly decreased, presumably because HCBD has destroyed 
the choroid plexus. This would indicate that the toxicity in the p-lyase mediated and 
that as in the kidney the localised production of toxic thiol radical combined with 
concentrative activity is the mechanistic explanation. It is also of note that as in the 
kidney proximal tubule, there is rapid cellular regeneration to restore function.
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Fig 4.6: BrdU labeling (50mg /kg, for 1 day) of the young male W /A rat brain
Animals were sacrificed on day 2. Staining was with an anti-BrdU anti body to a 
horse-radish peroxidase dye generation system. Arrow indicates the ependymal 
layer where there is little or no proliferation activity observed (x40)
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Fig 4.7: Repair activity in the choroid plexus and ependymal layer following 
HCBD (lOOmg /kg) treatm ent for 1 day.
Animals were sacrificed on day 2. Proliferating cells were labelled with BrdU 
(50mg/kg) and stained with the anti-BrdU/HRP system.
A; arrows indicate area o f BrdU staining (x4)
B; xlO view o f the indicated area 
C; arrow indicates a mitotic cell (x40)
142
4.4. Exposure of 28-day male rat to HCBD (25mg /kg)
The objective of this experiment was to see what happened after exposure of rats to a 
lower dose of HCBD for longer periods.
4.4.1. Dosing of rats with HCBD
Upon arrival and after acclimatisation, all rats were divided randomly in different 
groups (each contains 4 rats) as follows:
Group 1: Normal saline (0.9%) (Iml/kg, ip),
Group 2: HCBD (25mg /kg, ip), daily dose for 2, 3, 4 and 7 days
All animals in each group were killed the day after the last dose by anesthesia and 
neck dislocation. Intact brains were removed, halved; one half fixed in formalin and 
other half was homogenated for enzyme assay. All firozen tissues were stored at -80 
°C.
4.4.2. Health and behaviour of treated rats
In this study 1 death occurred in the 3- and 4-day treated groups. In the 2-day treated 
group it was observed that the brain was oedematous. The brain had filled the skull 
completely and there were some liquid droplets between the dura and the brain 
cortex. After 3 days of treatment with HCBD, changes occurred in the appearance 
and behaviour of rats, e.g., walking on their toes, hunched up posture, piloerection 
and dull patchy hair. Hyperactivity was seen in the 7-day treated rats on day 8 .
4.4.3. Changes in brain Glutamine transaminase K (GTK) activity
Brain GTK specific activity showed no significant difference between treated and 
control group in the 2-, 3- and 4-day treated rats (Fig 4.8). In the 7-day treated rats 
data showed significant difference (p<0.05) between treated and control group (Fig 
4.9).
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Fig 4.8: Brain GTK specific activity in the 2 - ,  3- and 4-day treated rats with 
25mg /kg HCBD.
Animals were dosed daily and killed 24hr after the last dose.
Data shown as mean ± SEM. n = 4
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Fig 4.9: Brain GTK specific activity in the 7-day treated rats w ith 25mg /kg HCBD.
Animals were dosed daily and killed 24hr after the last dose 
Data shown as mean ± SEM. n = 4 
*: p< 0.05 compared to control
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4.4.4. Examination of brain sections by light microscope
Light microscopic examination showed that in the HCBD treated groups of 3-, 4- and 
7-day there was a minor haemorrhage in choroid plexus of the lateral ventricles. Also 
some mitotic and pyknotic figures could be seen in the choroidal cells (Fig 4.10), 
infiltration of ependymal layer (Fig 4.11), vacuolation of the choroidal cells and 
marginal condensation of chromatin (Fig 4.12). In addition, in the low dose treated 
groups changes were observed such as:
a) Disturbance in the architecture of the choroid plexus and detachment of the 
ependyma (Fig 4.13)
b) Hypertrophy of choroidal villi in the lateral ventricles
c) Neuronal cells lining the ventricles were larger than control, and this 
extended to more than two layers
d) Inflammatory cells were presented around the ventricles
e) The channel between ventricles was lined by more than one layer of cells, 
normally is just one layer
f) Moderate hypertrophy of both ventricles
g) Cerebral oedema in the high dose HCBD treated rats compare to low dose 
and control groups. Therefore the size of brain was different in the HCBD 
treated rats (Fig 4.14)
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Fig 4.10: Histopathological examination of the young male W /A rat brain treated  
with 25mg /kg HCBD for 3 days.
Stained with H&E (x20).
White short arrows; minor hemorrahge in the CP.
Black arrows; two mitotic cells.
White long arrows; pyknotic cells
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Fig 4.11: Histopathological exam ination of the young male W/A rat brain treated  
with 25m g /kg HCBD for 4 days.
Stained with H&E. Infiltration of inflammatory cells such as macrophages, polymorphs 
and lymphocytes can be seen (x40)
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Fig 4.12: Histopathological exam ination of the young male W/A rat brain  
treated with 25mg /kg HCBD for 4 days.
Stained with H&E.
White arrows; vacuolated nuclei with the marginal condensation of chromatin 
Black arrows; the ependymal layer (xlOO)
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Fig 4.13: Histopathological examination of the young male W /A rat brain 
treated with 25mg /kg HCBD for 7 days.
Stained with H&E. Disturbance in the normal structure o f  choroid plexus and 
ependymal layer. Choroidal cells look smaller and the ependymal layer has been 
detached which may be due to oedema in the lateral ventricle (x40)
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Fig 4.14: Size of the brains in the different groups of HCBD treated rats.
Data shown as mean ± SEM. n = 4
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4.5. Effect of recovery and re-challenge with HCBD on the brain
In order to determine whether the replacement cells in the choroid plexus retained 
their resistance to HCBD over an extended period, rats which had been treated with 
HCBD at 25mg/kg for 2 days and then allowed to recover for 14 or 21 days prior to 
re-challenge with lOOmg/kg or 25mg/kg HCBD (see 5.2.1) were examined
4.5.1. Extent of CNS glutmine tranaminase K (GTK) to lOOmg/kg re-challenge 
with HCBD
Brain GTK specific activity in the 14 day or 21 day re-challenged groups shows 
significant increase compared to the control group (Fig 4.15). There was no 
significant difference between both HCBD treated groups
4.5.2. Extent of CNS resistance to 25mg/kg re-challenge with HCBD
As can be seen in Fig 4.16 there is no significant difference fi*om control in the level 
of brain GTK specific activity in rats retreated with HCBD after 14 or 21 days 
recovery. This would indicate that at this dose, the regenerated choroid plexus retain 
its resistance to HCBD re-challenge.
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Fig 4.15: Brain GTK specific activity in the 18- and 25-day study.
Rats were dosed daily with HCBD (25mg/kg) for 2 days and then allowed to recover
for 14 or 21 days prior to re-expose to HCBD (lOOmg/kg) on day 17 or 24 respectively.
Animals were killed 1 day later
Data shown as mean ± SEM. n = 4 in each group
**: p< 0.01 compared to control
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Fig 4.16: Brain GTK specific activity in HCBD resistant 28-day old male rats 
re-exposed to HCBD at 25mg/kg.
Animals received an initial dose o f 25mg/kg HCBD for 2 days and then were 
re-challenged with further doses o f  25mg/kg on days 17, 18 or 24, 25.
Data shown as mean ±SEM. n = 4
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4.6. Discussion
Behavioral changes such as tiptoe gait, hunched posture, piloerection, dull patchy 
hair (3 and 4-day treatment) and hyperactivity (7-day treatment) in HCBD treated 
rats, represent that HCBD may cross the blood-brain-barrier and affect the CNS.
The localisation of cysteine conjugate P-lyase activity in brain tissue has been widely 
reported. Cooper et al, (1993) reported that there is substantial GTK activity in rat 
brain, both in mitochondria and cytosol with the highest activity in the choroid 
plexus. Thus the potential for metabolism of cysteine conjugates of halogenated 
alkenes exists. As shown here, effect of HCBD on the activity of GTK in the brain is 
dose dependent. At 25mg /kg, HCBD significantly increased (p<0.05) the brain GTK 
specific activity in the 7-day treated group compare to control group, at lOOmg /kg, 
HCBD significantly (p<0.01) reduced the activity of this enzyme, due to extensive 
damage in choroid plexus. This is demonstrated in the examination of brain sections.
In animals that received 25mg /kg HCBD, minor hemorrhage is seen in the choroid 
plexus of the lateral ventricles, mitotic and pyknotic figures are seen in choroidal 
cells, infiltration of ependymal layer, vacuolation of the central part of choroidal 
cells and condensation of chromatin on margin. At lOOmg /kg however, the severity 
of these effects is much greater. The presence of inflammatory cells around the 
ventricles may also contribute to oedema in the brain and may be an additional 
reason for observed increase in diameter of the brain and decreased staining density 
of cerebral tissue in the HCBD treated groups.
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CHAPTER 5: DEVELOPMENT OF RESISTANCE TO HCBD 
NEPHROTOXICITY IN THE YOUNG MALE RAT
5.1. Introduction
The development of resistance to cellular injury upon repeated exposure to chemicals is 
a well documented toxicological phenomenon. Balazs, (1974) has reported that after 
repeated administration of various chemicals which induce degenerative changes, 
resistance to the toxic effect develops in the target tissue. Such resistance develops only 
after an induced lesion which is not specific to the inducing agent and can extend to 
other agents causing a similar lesion.
The first report of the development of resistance to toxicity in the kidney was reported 
by Suzuki, (cited in Gil y Gil, as quoted by Balazs, 1974) at the beginning of this 
century. He found that a single dose of mercury or uranium salts caused necrosis in the 
proximal convoluted tubules of rabbit kidneys, no further lesions occurred after repeated 
dosing. The similar result also has been reported by Gil y Gil, (1924), (reviewed by 
Balazs, 1974). After few years this phenomenon was confirmed in other species 
(MacNider 1929, reviewed by Balazs, 1974). In 1969, Prescott and Ansari, examined 
the time course of renal tubular changes following daily subcutaneous injections of 
HgCb in rats. They showed that histological examination revealed renal tubular necrosis 
in rats dosed daily with 0.5 mg/kg for 4 days but not in those dosed for 9 days. This 
phenomenon has been observed by Kluwe, (1982a and 1982b), the repeated doses of 
mercuric chloride (HgCb) in rats, which its toxicity pattern is similar to HCBD (both on 
S3 segment), were used. In these studies it was shown that the regenerating tubules had 
an inherent resistance to HgCb injury that the developed resistance of the kidney 
following repeated HgCb treatment was restricted to the pars recta, as is resistant to 
HCBD.
This study has shown that, although the nephrotoxic effects of continuous, daily 
treatment with HCBD are observed during the first two days of exposure, the occurrence
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of the epithelial cell regeneration after 4-7 days of treatment marks the return of tubular 
function to near normal and also the appearance of resistance to the subsequent HCBD 
nephrotoxicity.
5.2. Exposure of HCBD resistant male rats to high dose rechallenge 
with HCBD
In order to determine the duration of HCBD resistance in the kidney of rats exposed to 
25mg/kg of HCBD, 18- and 25-day studies were performed. After an initial 2-day 
exposure, rats were allowed a recovery period of 14 or 21 days before further challenge 
with HCBD at lOOmg/kg.
5.2.1. Dosing of rats with HCBD
After acclimatisation, all rats were divided randomly into different groups (each 
containing 4 rats) as follows:
Group 1: Normal saline (0.1 ml /kg, ip)
Group 2: HCBD (25mg /kg, ip) for 2 days, animals left to recover for 14 days and re­
exposed to HCBD (lOOmg /kg, ip) on day 17. Rats were killed on day 18 
Group 3: HCBD (25mg /kg, ip) as initial dose for 2 days, animals left to recover for 21 
days and re-exposed to HCBD (lOOmg /kg, ip) on day 24. Rats were killed on day 25.
Animals were killed by anaesthesia [pentobarbitone (Sagatal®, stock solution 60mg 
/ml), O.lml/lOOg body weight, ip] and neck dislocation. Both kidneys and the brain were 
removed, the right kidney was immediately fixed in 1 0 % neutral buffered formalin for 
histopathology studies, and the left kidney frozen in liquid nitrogen for enzyme assay. 
The brain was frozen in isopentane (cooled in dry-ice) for enzyme assay. All frozen 
tissues were stored at -80 °C.
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5.2.2. Health and behaviour of treated rats
In the HCBD treated groups, weight loss and reduction in body weight gain were 
observed on the first 2 days of treatment. Animals resumed their weight gain by the day 
7.
5.2.3. Kidney glutamine transaminase K (GTK) specific activity
Kidney cytosolic GTK specific activity is shown in (Fig 5.1). There was significant 
difference between control and treated groups. This reduction in the P-lyase activity 
might be due to low expression of the enzyme in the regenerated cells.
5.2.4. Histopathology of the renal tubules
In the 14 day recovery group, very little kidney damage was observed following re­
challenge with lOOmg/kg HCBD. In one rat a mild inflammatory interstitial fibrosis was 
observed (Fig 5.2) and an occasional mild lesion at the cortico-medullary junction could 
be seen (Fig 5.3). Also regeneration of the lesion site was present. This would suggest 
that even 14 days after dosing with HCBD at 25mg/kg substantial resistance to re­
challenge was present. In the 21-day recovery group, there was substantial damage to 
the S3 segment of the proximal tubule in some animals following re-challenge of 
lOOmg/kg (Fig 5.4). Also in one rat there was evidence of regeneration in the glomeruli. 
This would indicate that the replacement cells of the regenerated proximal tubule had 
now become fully complete for the metabolism of cysteine conjugates. However, there 
was inter-animal variation in the rate of this process.
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Fig 5.1: Kidney cytosolic GTK specific activity in the 18- and 25-day study.
Rats were dosed daily with HCBD (25mg/kg) for 2 days and then allowed to recover
for 14 or 21 days prior to re-expose to HCBD (lOOmg/kg) on day 17 or 24 respectively.
Animals were killed 1 day later
Data shown as mean ± SEM. n = 4 in each group
*: p< 0.05 compare to control
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Fig 5.2: Histopathological exam ination of young m ale W /A rat kidney re-treated  
after 14 days with lOOmg /kg HCBD by i.p, for 1 day
Animals were killed on day 18. Stained with H&E (xlO). Arrows show interstitial 
fibrosis.
à
Fig 5.3: Histopathological examination of young male W /A rat kidney re treated  
after 14 days with lOOmg /kg HCBD hy i.p, for 1 day (xlO)
Animals were sacrificed on day 18. Stained with H&E. A typical medullary ray (arrow)
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Fig 5.4: Histopathological examination o f young male W /A rat kidney re-treated after 
21 days with lOOmg /kg HCBD by i.p, for 1 day.
Animals were killed on day 25. Stained with H&E.
A; very mild lesion (x4)
B; gross lesion and a proliferated glomeruli (arrow) (xlO)
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5.3. Exposure of HCBD resistant rats to low dose re-challenge with 
HCBD
5.3.1. Dosing of rats with HCBD
After acclimatisation, rats were divided randomly into different groups (each containing 
4 rats) as follows:
Group 1: Normal saline (0.1 ml /kg, ip)
Group 2: HCBD (25mg /kg, i.p) for 2 days, animals left to recover for 14 days and re­
exposed to HCBD (25mg /kg, ip) on days 17 and 18. Animals were killed on day 19. 
One rat in this group was not re-exposed to HCBD
Group 3: HCBD (25mg /kg, i.p) for 2 days, animals left to recover for 21 days and re­
exposed to HCBD (25mg /kg, ip) on days 24 and 25. Animals were killed on day 26
Animals were killed by anaesthesia [pentobarbitone (Sagatal®, stock solution 60mg 
/ml), O.lml/lOOg body weight, ip] and neck dislocation. Both kidneys were removed, 
the right kidney was immediately fixed in 1 0 % neutral buffered formalin for 
histopathology studies and the left kidney was frozen in isopentane and liquid nitrogen 
for enzyme assay. Frozen tissues was stored at -80 °C.
5.3.2. Health aud behavior of treated rats
In the HCBD treated groups weight loss and reduction in body weight gain were 
observed on the first 2  days of treatment.
5.3.3. Alteration iu BIood-Urea-Nitrogeu levels
The level of BUN as a marker of kidney damage, showed that in the first exposure to 
HCBD, there was a significant difference between the control and treated groups. But on 
second exposure, there was no significant difference between BUN concentrations of re­
treated and control groups (Fig 5.5). It means that after 14 or 21 days recovery the 
kidney was resistant to subsequent toxic effect of HCBD, therefor BUN returned to the 
normal level.
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5.3.4. Kidney cytosolic glutamine transaminase K (GTK) specific activity
The results of GTK assay on the treated and control groups is seen in Fig 5. 6 . As can be 
seen, the level of GTK in the 2-day treated group is lower than control. In both the 14 
day recovery and the 21 day recovery group, the GTK level was slightly higher compare 
to the 2-day treated and no longer significantly different from untreated control. This 
would indicate that unlike the situation with lOOmg/kg re-challenge, the kidney remains 
relatively resistant to a 25mg/kg re-challenge even 21 days after the initial doses and the 
tubular regeneration. This would confirm the BUN data which also suggests that a 
25mg/kg re-challenge produces little if  any tubular damage.
5.3.5. Histopathology of the reual tubules
Examination of sections from rats re-challenged 14 days after the initial doses of HCBD 
indicates the presence of some minor damage and some regenerating tubules (Figs 5.7 
and 5.8). In the group re-challenged after 21 days recovery there is slightly more damage 
(Fig 5.9) but not as severe as for re-challenge of lOOmg/kg HCBD. This would confirm 
the previous data which suggest that following repair of the initial HCBD induced 
damage, the kidney remains relatively resistant to HCBD re-challenge for a considerable 
period of time.
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Fig 5.5: Blood urea nitrogen levels in HCBD resistant 28-day old male rats 
re-exposed to HCBD at 25mg/kg.
Animals received an initial dose o f 25mg/kg HCBD for 2 days and then were re­
challenged with further doses o f 25mg/kg on days 17, 18 or 24, 25. Plasma blood 
urea nitrogen levels were normal. Data shown as mean ±SEM. n = 4 
**: p< 0.01 compared to exposure group
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Fig 5.6: Kidney cytosolic GTK specific activity in HCBD resistant 28-day old 
male rats re-exposed to HCBD at 25mg/kg.
Animals received an initial dose o f  25mg/kg HCBD for 2 days and then were re­
challenged with further doses o f  25mg/kg on days 17, 18 or 24, 25.
Data shown as mean ±SEM. n = 4
*: p< 0.05 compared to HCBD 2 day only
**: p< 0.01 compared to control
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Fig 5.7: Histopathological examination o f young male W /A rat kidney treated only 
with 2 initial doses o f HCBD (25mg /kg) and killed on day 19.
Stained with H&E (xlO)
G
Legend on the next page
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Fig 5.8: Histopathological exam ination of young male W /A rat kidney re treated  
with HCBD.
Animals received an initial dose of 25mg/kg HCBD for 2 days and then were 
re-challenged with further doses of 25mg/kg on days 17 and 18 and killed on day 19. 
Stained with H&E.
G; glumerulus
A; very mild lesion (arrow) (x4)
B; some damage in the inner cortex (arrow head) (xlO)
C; tubules with some debris inside (arrow) in cortico-medullary junction (xlO)
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Fig 5.9: Histopathological exam ination of young male W/A rat kidney re-treated  
with HCBD.
Animals received an initial dose of 25mg/kg HCBD for 2 days and then were re- challenged 
with further doses of 25mg/kg on days 24 and 25 and killed on day 26. Stained with H&E. 
G: glumerulus
A; minor damage (arrow ) and regenerating tubules after damage (xlO)
B; a rare lesion in the cortex (xlO)
C; typical regenerating tubules (arrow) (x40)
D; the same as C, but further into the inner cortex, minor damaged (arrow) and regenerating 
tubules (arrow head) (x40)
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5.3.6. Proliferating cell nuclear antigen (PCNA) assay
Examination of kidney sections by PCNA staining confirms that after 14 days recovery, 
there is some minor damage caused by re-challenge with 25mg/kg HCBD and that the 
replacement cells are able to engage in regenerative activity (Fig 5.10).
5.3.7. Discussion
The results of the experiment using a low dose (25mg/kg) of HCBD to re-challenge 
HCBD resistant rats indicates that the kidney remains relatively insensitive to this dose 
even 21 days after the initial damage. However, some damage and regeneration can be 
seen again, suggesting that the replacement cells have regained some of their ability to 
metabolise cysteine conjugates. It is also evident that the replacement cells are able 
themselves to provide ftirther regeneration if required. In many ways the slow 
development of full functionality in the kidney, compared to untreated rats, mimics the 
normal post-natal development process in which kidney GTK/p-lyase activity only 
increase substantially on response to post-natal hormonal stimuli.
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Fig 5.10: Staining of a formalin fixed section of kidney for PCNA (14 day recovery).
Rats were treated for 2 days with HCBD 25mg/kg/day and then allowed to recover for 
14 days. They were then re-challenge with 2 further doses of HCBD at 25mg/kg/day. 
Rats were killed on day 19. PCNA containing nuclei in dividing cells are stained with 
fluorescent (x20)
171
CHAPTER 6: DISCUSSION AND CONCLUSION 
6.1. Introduction
The trifunctional enzyme GTK/KAT/cysteine conjugate p-lyase, has been found in 
bacteria (Larsen and Larson, 1983; Tomisawa et al, 1984; Larsen, 1985 and Larsen and 
Stevens, 1986), helminthes (Adcock et ah, 1999 and 2000) in the mammalian kidney 
(Stevens et al., 1986b; Lash et al, 1986 and 1990; Abraham et al, (1995), liver (Tateishi 
et al, 1978 and Tomisawa et al, 1986) and in the brain (Moroni et al, 1988; Okuno et 
al, 1991; Roberts et al, 1992; Cooper et al, 1993) of rats and other mammals including 
man. This enzyme mediates phase three metabolism of the cysteine conjugates of some 
chemicals such as halogenated xenobotics. In this study, hexachlorobutadiene (HCBD), a 
lipohpilic halogenated alkene whose metabolism is via glutathione conjugation, was used 
to extend knowledge on its nephrotoxicity in young rats and also to examine whether this 
compound can produce neurotoxicity as alluded to in some reports (Gradinski et al, 
1975; Bemdt and Mehendale, 1979; Harleman and Seinen, 1979; Jaffe et al, 1983; Yang 
et al, 1989).
6.2. Nephrotoxicity of HCBD
The mammalian kidney is a complex organ. Its main structural unit, the nephron, 
consists of several cell types each displaying different morphological, biochemical and 
functional properties. Because of this heterogeneity, exposure of the kidney, both in vivo 
and in vitro, to different nephrotoxins leads to different patterns of cellular injury. Since 
the kidney receives 25% of the cardiac output, renal cells, particularly the consentrative 
epithelial cells of the proximal tubules, are extremely prone to toxic damage.
Studies on rodents have shown that HCBD is a potent age, sex and strain related 
nephrotoxin (Lock and Ishmael, 1979). Hook et al, (1983) have reported that adult male 
rats are less susceptible than adult female or young male rats to toxicity of HCBD, and 
that a dose of 50mg /kg HCBD in adult female rats produces the same effect as 200mg 
/kg in adult male rats.
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In this study, concentration of blood urea nitrogen (BUN) was used as an indicator of 
kidney damage. Although this parameter has been used by others (Lock and Ishmael, 
1985; Ban and de Ceaurriz, 1988) some investigators believed that concentration of BUN 
may not be a good marker of kidney damage, and they believed that site specific marker 
should be used. Trevisan et al, (1999) used the activity of glutaminase synthetase (GS) 
in urine as a sensitive marker for damage in the S3 segment of the kidney tubule and N- 
acetyl-P-D-glucosaminidase (NAG) for Si and S2 segment injury into the proximal 
tubule. Also the level of BUN is age related, the younger the age the higher the level of 
BUN (Hook et al, 1983). In my study the concentration of BUN in young rats with both 
doses of HCBD showed similar levels, so in the young rat, the dose of HCBD apparently 
had no significant effect on the level of BUN.
The level of BUN, in different groups of treated rats showed that only in the 2-day (25mg 
/kg) treated group was there a significant difference between treated and control as 
probenesid protected groups. In the 3- and 4-day treated animals there was no significant 
difference between HCBD treated and other groups and BUN returned to nearly normal 
level after 7 days treatment.
In the 18-day study with low dose re-treatment, the level of BUN is exactly the same as 
the control group which means that kidney fimction is apparently normal. In the 25-day 
study with low dose retreatment, the concentration of BUN is slightly (but not 
significantly) higher than control group. Apparently the kidney had regained its 
susceptibility to HCBD toxicity. In fact the data showed that, after daily exposure for 4 
days the kidney was no longer sensitive to ftirther doses of HCBD. This was confirmed 
by histopathological examination.
The activity of two enzymes, glutamine transaminase K (GTK) and y.glutamyl 
transferase (y.gt) were assayed to examine the effects of HCBD. The effect of HCBD on 
kidney GTK specific activity is apparently dose dependent. With the low dose (25mg 
/kg) although the kidney cytosolic GTK specific activity is decreased slightly by HCBD 
in all groups, however, there was no significant difference except in the 4- and 7-day
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treated animals where there was significant difference between the HCBD and 
probenecid treated groups (p< 0.05). With the high dose (lOOmg /kg), the activity of this 
enzyme showed an increase which is significantly different from the saline treated group. 
It means that although HCBD extensively damaged the pars recta (S3) segment of the 
kidney, rich in p-lyase, and I expected that the activity of this enzyme to be reduced, but 
the level of this enzyme was still enough high to do P-elimination reaction in the assay. 
This result is agreed well with Kim et al., (1997) which used HCBD 200mg/kg and 
reported that the specific activity of cytosolic GTK in the kidney homogenate is increased 
which is due to increase in the synthesis of cytosolic GTK after acute exposure to PCBC.
In the long term study, 18- and 25-day, re-treatment of animals with lOOmg/kg of HCBD 
(after two initial 25mg/kg doses), reduces the kidney GTK activity in both treated groups 
compare to control (p<0.05). Re-treatment of animals with 25mg/kg, resulted in a 
significant (p<0.01) decrease in GTK activity in the 18-day group, while there was no 
significant difference into 25-day study group. This might be due to low expression of p- 
lyase in the regenerated proximal tubule cells or possibly to lower expression of GTK/p- 
lyase in surviving undamaged cells following the initial exposure to HCBD.
y.glutamyl transferase (y.gt), is a membrane-bound enzyme, which is present in the brush- 
border membrane of the S 2  and S 3  segments of the renal proximal tubules. This enzyme 
is often eliminated in urine following damage to proximal tubules. Again, if  the level of 
this enzyme is markedly reduced due to cellular damage, so resistance of kidney to 
further doses of HCBD may related to this phenomenon.
The effect of HCBD on y.gt specific activity was dose dependent. In animals treated with 
low dose, there was a dramatic increase in y.gt elimination in the 24hr-urine samples, but 
after second dose the elimination of y.gt was reduced to the same level as the control 
group. It is interesting that, even though a substantial amount of y.gt is eliminated from 
the kidneys following damage the level of this enzyme is still high in the kidney and there 
is no significant difference in kidney homogenates enzyme levels between treated and 
control groups.
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Overall HCBD has no significant effect on total kidney and liver y.gt specific activity in 
the young male rat, so the acquired resistance of the kidney to repeated doses of HCBD, 
cannot be related to any changes in the level of this enzyme in kidney or liver and other 
mechanisms such as reduction of proximal tubular GTK/p-lyase or other enzymes 
/transporters must be responsible.
Histopathological examination of the kidney sections showed that the effects of HCBD 
on the renal proximal tubule is dose-dependent. As expected, the main area of the kidney 
damaged was the straight portion of the proximal tubules (pars recta or S3 segment), rich 
in GTK/p-lyase (Ishmael et al, 1982 and 1984; Lock et al, 1984; Ishmael and Lock, 
1986; Jones et al, 1988). In this study I showed by TUNEL assay that one mechanism of 
cell death is apoptosis.
The high doses of HCBD (lOOmg /kg) also cause damage to parts of renal cortex (Si and 
S2 segments) as well. What is also interesting and I have to emphasis this, is that in 
almost all treated groups there is interindividual variation between animals in response to 
HCBD and particularly to HCBD plus probenecid treatment.
In the 25mg/kg 2-and 3-day treatment groups, the kidney showed necrosis at the 
corticomedullary junction, which appeared as a strip in this area. This necrosis is typical 
of HCBD damage in the kidney. In these two groups probenecid could not protect 
animals properly although it decreased the level of BUN specially in the 2-day treated 
group.
Since in the 3-day exposure experiment changes in the behavior and appearance of 
animals and also some effects in the H&E stained brain sections (e.g. minor hemorrhage 
in the choroid plexus) were observed, animals were treated for longer to give more 
chance for HCBD to cross the blood-brain barrier. In this group I observed the same 
behavioral changes, as in the 3-day study, but the kidney showed a different appearance 
fi*om previously. In this group the renal proximal tubules had regenerated and showed a
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basophilic appearance. This finding agrees with the report of Toback, (1992) and 
Trevisan e /<2/., (1999).
Prescott, (1966) has shown that, under normal conditions, nearly 2x10^ tubular epithelial 
cells (about one cell per human nephron) are lost into the urine each day. So some 
regenerative /replacement capacity is required under normal circumstances to replace the 
lost cells and to maintain structural integrity in the kidney. Growth factors produced in 
the kidney must initiate such cell proliferation. These factors stimulate resting cells in the 
Go phase of cell cycle to initiate DNA synthesis and subsequently to undergo mitosis. 
The concentration of extracellular Na^ and is also a parameter that has an important 
role in cell proliferation and the release of renal growth factors. Walsh-Reitz and Toback 
(1984) have shown that a reduction in extracellular K"*” concentration from 5.4mM 
(normal) to 3.2mM, induced accelerated tubular growth. The growth stimulation appears 
after one hour. Walsh-Reitz et al., (1986) have shown that cell replication is also 
stimulated in the kidney when the Na"^  concentration is reduced from 155mM (normal) to 
130mM. This activity appeared after 3-5min. The question is that whether HCBD has 
any effect on the release of renal growth factors perhaps by causing changes in the Na"^  
/K^ balance remains to be investigated.
In animals treated for 7 days, it was observed that the kidney appeared to have returned to 
normal but had become resistant to further doses of HCBD. This finding also agrees with 
previous studies using other nephrotoxins (Prescott and Ansari, 1969; Kluwe, 1982a, 
1982b and Toback, 1992). In these studies daily injection of 0.5 mg/kg HgCb for 4 days 
produced renal tubular necrosis which was not present in the rats dosed for 9 days. The 
regenerated tubules also had inherent resistance to HgCb injury. In this study staining 
for PCNA, a method of cellular proliferation was used to demonstrate the mechanism of 
tubular regeneration following HCBD treatment.
In order to define the length of the regained for the kidney to resume its susceptibility to 
HCBD, 18- and 25- day studies with both low (25mg/kg) and high (lOOmg/kg) doses of 
HCBD (following two initial doses of 25mg/kg) were performed. In the 18-day study
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histopathological examination of the kidneys in animals of this group and also animals in 
the 25-day study, which received 2 further doses of HCBD, showed that the severity of 
damage to kidneys is much less than in the 2-day treated animals, a clear indication that 
the tubular cells were still resistant to the low dose of HCBD. Concentration of BUN in 
these two groups also confirmed these results. In animals re-exposed to the high dose of 
HCBD, the data shown that the susceptibility to HCBD was starting to return.
The mechanisms by which the proximal tubular cells become resistant to HCBD are not 
fully understood but could include:
1. Decreased vulnerability due to immaturity of the regenerated cells (all specific kidney 
functions decreased).
2. Lower GTK/ p-lyase expression in undamaged cells following the initial exposure to 
HCBD
3. Low expression of GTK/p-lyase in the new replacement cells due to their immaturity.
4. Effects of HCBD on drug metabolism in the liver.
5. Decreased proximal tubule concentrative mechanisms
6. Following half transamination, the enzyme in surviving cells accumulates in the 
pyridoxamine phosphate (inactive) form leading to inhibition of further P-elimination, 
i.e. pyruvate is not produced to reactivate the enzyme (Kim et al, 1997). Thus, no 
further P-elimination takes place.
While the data would point towards reduced expression of GTK/p-lyase in the 
regenerated proximal tubule, changes in other enzymes or transport systems cannot be 
ruled out. Plant et al, 1997 have shown that level of GTK/p-lyase changes during 
development of the brain and kidney and that GTK/p-lyase gene expression may be 
hormonally driven during a relatively narrow developmental window. In this situation it 
would not be surprising if  there was a significant time lag before replacement cells 
developed full functionality.
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6.3. Neurotoxicity of HCBD
As mentioned before, one of the main purposes of this project was to find other target 
organs for the toxicity of HCBD particularly as the neurotoxicity of halogenated alkenes 
such as dichloroacetylene (DCA) in rabbits has been reported (Reichert et al, 1976). In 
rats there has been suggestive evidence of HCBD neurotoxicity (Gradinski et a l, 1975; 
Bemdt and Mehendale, 1979; Harleman and Seinen, 1979; Jaffe et a l, 1983 and Yang et 
a l, 1989) and neurotoxic effects of trichloroethylene (TCA) in man has been reported 
(Schaumburg, 1992).
In this study I found that the area of brain in young rats which is sensitive to toxic effects 
of HCBD at lOOmg/kg is the choroid plexus of the lateral and third ventricles. This 
sensitivity may be related to;
a) The different anatomical stmcture of choroid plexus capillaries. The wall of the 
choroidal capillary is fenestrated by pores with membranes whereas generally in the 
brain, capillaries are not fenestrated and are closely invested with glial cells. 
Therefore, the choroid plexus capillaries are more vulnerable to the penetration by 
chemicals (Netsky and Shuangshoti, 1970).
b) The highest specific activity of the enzyme GTK/p-lyase in the choroid plexus 
(Cooper et al, 1993) and other enzymes such as y.gt and dipeptidase (Patel et a l, 
1993) which can metabolise HCBD to its related cysteine conjugate are also present.
In this study, GTK activity in the whole brain was significantly reduced after the high 
dose of HCBD which is predictable because of the massive damage to choroid plexus. 
But with low dose of HCBD, GTK activity was significantly increased just in the 7-day 
treated group compare to control which can be due to induction of this enzyme with low 
repeated doses of HCBD.
I have also observed that the size of the brain in rats, treated with HCBD at lOOmg /kg, is 
bigger than control and low dose treated animals. In a study (Palm et al, 1995) has
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shown that any damage to choroid plexus leads to significant increases in the Na"^  (85%) 
and water (22%) content of brain leading to transient oedema.
In the 2-day treated animals with high dose, I have also found evidence of choroid plexus 
recovery and regeneration. BrdU labeling of proliferated cell confirmed this. The 
mechanisms of choroid plexus recovery have been studied after a transient forebrain 
ischemia (Johanson et al, (2000). They induced ischemia using bilateral carotid 
occlusion which caused substantial damage to choroid plexus epithelial cells of the lateral 
ventricles. Following injury, three kind of cells were found; normal cells, sub-lethally 
injured cells and damaged cells. They also proposed that sub-lethally injured cells may 
be rescued by growth factors and restore the choroid plexus. Epithelial cells of 
mammalian choroid plexus are synthesise and secrete many growth factors and other 
peptides that have trophic effects following injury to the brain ventricular system 
(Valentino et al, 1988; Bohannon et al, 1988; Wanaka et al, 1990; Vega et al, 1992 
and Esser et al, 1998). Thus, while the brain cannot restore damage to neurons it has the 
ability to regenerate damaged non-neuronal cells such as the choroid plexus.
6.4. Conclusion
In this study, both high and low doses of HCBD caused massive damage and 
necrosis in the renal cortico-medullary junction (pars recta) of the young male 
W/A rat. One of the mechanisms of cell death in the proximal tubule was 
apoptosis. After 4 consecutive daily doses of HCBD, the kidney became resistant 
to further doses and regeneration of the proximal tubule was observed.
Histopathological examination of H&E stained brain sections showed that the 
choroid plexus in the lateral and third ventricles, was the main area of the brain 
which is sensitive to the high dose (lOOmg /kg) of HCBD. Thus HCBD is also a 
CNS neurotoxin in the young male W/A rat.
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APPENDIX
BUFFERS, SOLUTIONS AND REAGENTS
ABC solution / HRP kit
1 drop solution A 
1 drop solution B 
5ml Tris buffer saline (TBS)
Make up at least 30min before use
Ammediol buffer (IM)
2.1 g, 2 -  amino - 2-methyl - 1 ,3 -  propanediol - HCl 
10 ml distilled water
Adjust to pH 9.0 by concentrated HCl, make up to 20ml by distilled water 
Citrate Buffer
Stock A (4.2g Citric acid in 200ml ddH20)
Stock B (14.7g Na citrate in 500ml ddH20)
18ml Stock A 
82ml Stock B
Make up to 1000ml with ddH20 
Adjust pH to 6.0
Diaminobenzidine (DAB) coupling solution
1 DAB tablet (lOmg)
1 Urea H2O2 tablet ( )
15ml Tris buffer saline (TBS)
Make up just before use
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Goat serum blocking solution
5% goat serum in PBS containing 1% bovine serum albumin (BSA
GTK reagent
2ml, IM Amediol buffer
1ml, lOOmM L-phenylalanine (16.5mg/ml)
0.5ml, lOOmM a-KMB (17mg/ml)
Homogenization solution
0.25M sucrose containing lOmM Tris-HCl, pH 7.5
Hydrochloric acid (4M)
136ml HCl (stock solution 36%)
264ml distilled water
Hydrogen peroxide blocking solution
3ml H2O2 (fresh stock 30%)
300ml, 70% Ethanol 
Make up just before use
Mouse anti-BrdU Ab
166pl anti-BrdU Antibody 
5ml, Tris buffer saline 
Make up just before use
Phsophate Buffer Saline (PBS)
Dissolve 1 PBS tablet in 100ml distilled water 
Autoclave to sterile
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Proteinase K  solution (20|Jig /ml)
6 mg / 300ml dH2 0  (stock solution lOmg /ml)
Rabbit anti-mouse Ab (BrdU labeling)
16pl Rabbit anti-mouse Antibody 
5ml, Tris buffer saline 
Make up just before use
Solution A (protein determination)
1ml 5% (w /v) CUSO4 . 5 H2O 
10ml 1% (w /v) K, Na tartrate
100ml 10% (w /v) Na2COs anhydrous (prepared in 0.5M NaOH) 
Solution B (protein determination)
Folin -  Ciocalteu reagent, diluted at the ratio of 1:10 in Milli Q water
Tris Buffer Saline (TBS)
1000ml, O.lMTris (12.1g/l)
800ml, O.IM HCl [(8.4ml /1, stock solution 37%)}
Adjust to pH 7.6
Dilute 1:10 with normal saline
Trypsin digest solution
400mg Trypsin
400mg Calcium chloride anhydrous 
Add 400ml distilled water 
Adjust pH to 7.8 (critical) with 0. IM NaOH 
Make up just before use
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